Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RELY trial)

DUPLICATE-RELY

October 9, 2020

NCT04593043

1. RCT Details

1.1 Title

Dabigatran versus Warfarin in Patients with Atrial Fibrillation (RELY trial)

1.2 Intended aim(s)

To compare the risk of stroke or systemic embolism in atrial fibrillation (AF) patients with dabigatran versus warfarin use.

1.3 Primary endpoint for replication

The primary outcome of the study was stroke and systemic embolism.

1.3.1 Required power for primary endpoint and noninferiority margin (if applicable)

Assuming a 2-year recruitment period and at least 1 year of follow-up and a primary event rate of 1.6% per year, it was determined that at least 15,000 patients would be needed to achieve a minimum of 450 events. The study would have approximately 84% power to conclude noninferiority of dabigatran over warfarin at alpha of 0.025 (1-sided) level.

1.4 Secondary endpoint for replication (assay sensitivity) and RCT finding

Major bleeding; RR = 0.93 (95% CI 0.81-1.07)

1.5 <u>Trial estimate</u>

RR = 0.66 (95% CI 0.53-0.82) comparing 150mg dabigatran vs warfarin (Connolly et al., 2009)

2. Person responsible for implementation of replication in Aetion

Hemin Lee, MD, MPH and Ajinkya Pawar, PhD implemented the study design in the Aetion Evidence Platform. They are not responsible for the validity of the design and analytic choices. All implementation steps are recorded and the implementation history is archived in the platform.

3. Data Source(s)


United/Optum, MarketScan, Medicare

4. Study Design Diagram

The study design diagram visualizes key aspects of the longitudinal study design for expedited review.

Figure 1.

Design Diagram – RE-LY TRIAL REPLICATION



5. Cohort Identification

5.1 Cohort Summary

This study will involve a new user, parallel group, propensity score-matched, retrospective cohort study design comparing dabigatran (150mg) to warfarin users. The patients will be required to have continuous enrollment during a baseline period of 180 days before initiation of dabigatran or warfarin (index date). We will restrict the analyses to patients with a diagnosis of AF with risk factors for stroke or systemic embolism in the 12 months prior to drug initiation.

5.2 Important steps for cohort formation

New users (defined as no use in 180 days prior to index date) of an exposure and a comparator drug will be identified.

5.2.1 Eligible cohort entry dates

Market availability of dabigatran in the U.S. for non-valvular atrial fibrillation started on October 19, 2010

- For Medicare: October 19, 2010 December 31, 2017 (end of available data)
- For Marketscan: October 19, 2010 December 31, 2018 (end of available data)
- For Optum: October 19, 2010 December 31, 2019 (end of available data)

5.2.2 Specify <u>inclusion/exclusion</u> criteria for cohort entry and define the index date

Inclusion and exclusion criteria were adapted from the trial as closely as possible. Definitions for all inclusion/exclusion are provided in **Appendix A** and are summarized in the flowcharts below.

5.3 Flowchart of the study cohort assembly

For dabigatran 150mg vs. warfarin

Optum		Truven		Medicare	
Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients	Less Excluded Patients	Remaining Patients

All patients		77,673,639		200,203,908		6,886,908
Did not meet cohort entry criteria	-76,847,731	825,908	-199,014,982	1,188,926	-2,335,930	4,550,978
Excluded due to insufficient enrollment	-80,642	745,266	-107,905	1,081,021	-1,565,261	2,985,717
Excluded due to prior use of referent	-564,968	180,298	-751,832	329,189	-2,241,426	744,291
Excluded due to prior use of exposure	-44,640	135,658	-71,891	257,298	-196,688	547,603
Excluded because patient qualified in >1 exposure category	-5	135,653	-9	257,289	-24	547,579
Excluded based on Dabigatran (dose other than 150mg)	-306	135,347	-534	256,755	-2,557	545,022
Excluded based on Age	0	135,347	0	256,755	-162	544,860
Excluded based on Gender	0	135,347	0	256,755	0	544,860
Excluded based on Inclusion 1a or 1b or 1 c - Atrial fibrillation	-71,189	64,158	-135,349	121,406	-220,602	324,258
Excluded based on Inclusion 2a-2e History of Stroke, TIA, Systemic embolism / EF<40% / NYHA 2 or higher / Age >75 / Age 65+RF	-11,313	52,845	-17,737	103,669	-24,940	299,318
Excluded based on Inclusion 3 - Age >= 18	-1	52,844	-1	103,668	0	299,318
Excluded based on Exclusion 1 - History of heart valve disorders	-17,688	35,156	-5,687	97,981	-94,948	204,370
Excluded based on Exclusion 2a - Severe/disabling stroke	-576	34,580	-1,111	96,870	-3,090	201,280
Excluded based on Exclusion 2b - Any stroke	-960	33,620	-1,391	95,479	-3,948	197,332
Excluded based on Exclusion 3a - Major Surgery	-1,091	32,529	-2,526	92,953	-6,491	190,841
Excluded based on Exclusion 3c - Intracranial hemorrhage - Inpatient	-51	32,478	-331	92,622	-595	190,246
Excluded based on Exclusion 3d - Gastrointestinal hemorrhage	-4,848	27,630	-1,601	91,021	-5,353	184,893
Excluded based on Exclusion 3e - Symptomatic or endoscopically documented gastroduodenal ulcer disease	-121	27,509	-714	90,307	-3,148	181,745
Excluded based on Exclusion 3f - Hemorrhagic disorder or bleeding diathesis	-257	27,252	-756	89,551	-1,787	179,958
Excluded based on Exclusion 3i - Uncontrolled hypertension	-51	27,201	-400	89,151	-804	179,154
Excluded based on Exclusion 7 - Severe renal impairment	-1,301	25,900	-4,674	84,477	-12,016	167,138
Excluded based on Exclusion 8 - Active infective endocarditis	0	25,900	-7	84,470	-8	167,130
Excluded based on Exclusion 9 - Active liver disease	-36	25,864	-248	84,222	-608	166,522

Effectiveness research with Real World Data to support FDA's regulatory decision making

Excluded based on Exclusion 10 - Pregnancy	0	25,864	-2	84,220	-1	166,521
Excluded based on Exclusion 11 - Anemia and Thrombocytopenia	-191	25,673	-1,227	82,993	-2,797	163,724
Excluded based on Exclusion 14 - Alcohol abuse or dependence	-28	25,645	-103	82,890	-138	163,586
Excluded based on Exclusion 14 - Drug abuse or dependence	-22	25,623	-47	82,843	-111	163,475
Excluded based on Exclusion 14 - CCI (180 days)	-7	25,616	-47	82,796	-1,939	161,536
Final cohort		25,616		82,796		161,536

^{*} Medicare database includes all patients using a novel oral anticoagulant and a subset of patients using warfarin during 2011-2017.

6. Variables

6.1 Exposure-related variables:

Study drug:

The study exposure of interest is initiation of dabigatran. Initiation will be defined by no use of dabigatran or a comparator in the prior 6 months before treatment initiation (washout period).

Comparator agents-

- Initiators of dabigatran (150mg) will be compared to initiators of-
 - Warfarin

6.2 Covariates:

- Age
- Sex
- Combined Comorbidity Index (CCI), measured over the baseline covariate assessment period, defined as 180 days prior to and including index date

Covariates listed above represent only a small subset of covariates that will ultimately be controlled for in the design and analysis. We use the covariates above only for initial feasibility analyses to judge whether there is likely to be sufficient overlap between treatment groups to proceed with the study. Remaining covariates are defined only after the study has passed the

initial feasibility analysis and the initial power assessment and are listed in Table 1 (Appendix B).

6.3 Outcome variables and study follow-up:

6.3.1 Outcome variables

Primary Effectiveness outcomes of interest: (definitions provided in **Appendix A**):

- **Primary Outcome:** Stroke (hemorrhagic, ischemic) and systemic embolism
- Secondary outcomes: Individual components
 - Hospital admission for stroke (principal diagnosis position)
 - Hospital admission for systemic embolism (principal diagnosis position)

Control outcomes of interest (control outcomes only serve to assess aspects of study validity but are not further interpreted):

1. Major bleeding

6.3.2 Study follow-up

Both as-treated (AT) and intention-to-treat (ITT) analyses will be conducted with treatment defined as the index drug on the day of cohort entry. Because adherence in the real-world databases is expected to be much worse than in the trial, the AT analysis is the **primary** analysis, as it targets the relative hazard of outcomes on treatment.

For the AT analyses, the follow-up will start the day after initiation of apixaban and comparator and will continue until the earliest date of the following events:

- The first occurrence of the outcome of interest, unless otherwise specified for selected outcomes,
- The date of end of continuous registration in the database,
- End of the study period,
- Measured death event occurs,
- Nursing home admission

- Nursing home admissions are considered a censoring event because the data sources utilized typically provide little to no data on a patient, particularly on drug utilization, after admission. We will utilize this as an exclusion reason for cohorts for the same reason.
- The date of drug discontinuation, defined as the date of the last continuous treatment episode of the index drug (dabigatran and comparator) plus a defined grace period (i.e., 10 days after the end of the last prescription's days' supply in main analyses).
- The date of augmentation or switching from exposure to comparator or vice versa or augmentation/switching to any other NOAC (e.g. switching from dabigatran or warfarin to apixaban would be a censoring event);
 - o A dosage change on the index treatment does not fulfill this criterion
 - o An added treatment that is not part of the exposure or comparator group does not fulfill this criterion
- Dispensing of a fibrinolytic agent

For the intention-to-treat (ITT) analyses, the censoring based on the augmentation/switching and treatment discontinuation will be replaced with a maximum allowed follow-up time of 365 days.

7. Initial Feasibility Analysis

Aetion report name:

For dabigatran vs. warfarin

Optum- https://bwh-dope.aetion.com/projects/details/707/results/59579/result/0 Marketscan- https://bwh-dope.aetion.com/projects/details/708/results/59601/result/0 Medicare- https://bwh-dope.aetion.com/projects/details/709/results/59602/result/0

Date conducted: 10/5/20 (Medicare 10/6/20)

Complete Aetion feasibility analysis using age, sex, and CCI as the only covariates and the primary endpoint (Section 6.3.1) as the outcome. No measures of association will be computed nor will incidence rates stratified by treatment group.

- Report patient characteristics by treatment group
- Report summary parameters of study population
- Report median follow-up time by treatment group

• Report reasons for censoring in the overall study population

8. Initial Power Assessment

Aetion report name:

For dabigatran vs. warfarin

Optum- https://bwh-dope.aetion.com/projects/details/707/results/53772/result/0
Marketscan- https://bwh-dope.aetion.com/projects/details/709/results/53771/result/0
Medicare- https://bwh-dope.aetion.com/projects/details/709/results/53770/result/0

Date conducted: 05/11/2020

In order to complete the initial power analysis, the dummy outcome of a 90-day gap in database enrollment will be used. This outcome is used to ensure that no information on the comparative risks of the outcomes of interest are available at this stage. Complete a 1:1 PS-matched comparative analysis using this outcome. PS should include only 3 covariates: age, sex, and combined comorbidity index. Power calculations are based on the formulas from Chow et al. (2008).

- Stop analyses until feasibility and power are reviewed by primary investigators and FDA. Reviewers evaluate the results of the analyses described above in Sections 7 and 8, including numbers of patients, patient characteristics, follow-up time, and reasons for censoring by treatment group, as well as overall rates of outcomes and study power. These parameters are re-evaluated and reported in the subsequent sections, after incorporating feedback and refining the protocol.
- Stop analyses until feasibility and power are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:	Jessica Franklin	Date reviewed:	6/3/20
Reviewed by FDA:	Ken Quinto	Date reviewed:	6/30/20
Reasons for stopping			
analysis (if required):			

9. Balance Assessment

Aetion report links:

Optum: https://bwh-dope.aetion.com/projects/details/707/results/59580/result/0
Marketscan: https://bwh-dope.aetion.com/projects/details/708/results/59603/result/0
Medicare: https://bwh-dope.aetion.com/projects/details/709/results/59604/result/0

Date conducted: 10/5/20 (Medicare 10/6/20)

After review of initial feasibility and power analyses, complete creation of the remaining covariates (see Table 1 below for list of covariates). Again, using the dummy outcome of a 90-day gap in database enrollment, complete a 1:1 PS-matched analysis. The PS should include the complete list of covariates (excluding laboratory values, which are missing in some patients).

• Provide plot of PS distributions stratified by treatment group.

Note- Please refer to **Appendix B**.

• Report covariate balance after matching.

Note- For Table 1, please refer to Appendix B.

• Report reasons for censoring by treatment group.

	Overall	Referent	Exposure
Dummy Outcome	0 (0.00%)	0 (0.00%)	0 (0.00%)
Death	657 (0.84%)	369 (0.94%)	288 (0.74%)
Start of an additional exposure	2,760 (3.53%)	1,189 (3.04%)	1,571 (4.02%)
End of index exposure	62,039 (79.39%)	31,190 (79.83%)	30,849 (78.96%)
Specified date reached (Dec 17/Dec 18/Dec 19)	2,483 (3.18%)	1,281 (3.28%)	1,202 (3.08%)
End of patient enrollment	4,128 (5.28%)	1,938 (4.96%)	2,190 (5.61%)
Switch to other NOACs (for censoring) + nursing home admission	6,073 (7.77%)	3,103 (7.94%)	2,970 (7.60%)

• Report follow-up time by treatment group.

Effectiveness research with Real World Data to support FDA's regulatory decision making

Median Follow-Up Time (Days) [IQR]				
Patient Group Optum Truven Medicare				
Overall Patient Population	98 [38-191]	98 [38-193]	98 [38-202]	
Referent	98 [43-192]	98 [43-178]	98 [42-196]	
Exposure	98 [38-190]	98 [38-220]	98 [38-211]	

• Report overall risk of the primary outcome.

	Optum	Marketscan	Medicare	Pooled
Risk per 1,000 patients	4.57	5.20	6.04	5.64

10. Final Power Assessment

Date conducted:

- Re-calculate power in the appropriate excel table, using the revised number of matched patients from the PS-match in Section 9. All other parameters in the table should be the same as in Section 8. If the study is to be implemented in more than one database, copy and paste excel sheet to report power for each database separately and for the pooled analysis that uses data from all databases together. Power calculations are based on the formulas from Chow et al. (2008).
 - For dabigatran 150mg vs. warfarin
 - o Pooled

Superiority Analysis		Non-inferiority Analysis	
Number of patients matched	78,140	Number of patients matched	78,140
Reference	39,070	Reference	39,070
Exposed	39,070	Exposed	39,070
Risk per 1,000 patients	5.64	Risk per 1,000 patients	5.64
Desired HR from RCT	0.66	Assumed HR from RCT	1
Alpha (2-sided)	0.05	Alpha (2-sided)	0.05
		Non-inferiority margin	1.46
Number of events expected	440.7096	Number of events expected	440.7096
Power	0.991836251	Power	0.977906369

o Optum

Superiority Analysis		Non-inferiority Analysis	
Number of patients matched	5,580	Number of patients matched	5,580
Reference	2,790	Reference	2,790
Exposed	2,790	Exposed	2,790
Risk per 1,000 patients	4.57	Risk per 1,000 patients	4.57
Desired HR from RCT	0.66	Assumed HR from RCT	1
Alpha (2-sided)	0.05	Alpha (2-sided)	0.05
		Non-inferiority margin	1.46
Number of events expected	25.5006	Number of events expected	25.5006
Power	0.182503488	Power	0.157581463

MarketScan

Superiority Analysis		Non-inferiority Analysis	
Number of patients matched	27,920	Number of patients matched	27,920
Reference	13,960	Reference	13,960
Exposed	13,960	Exposed	13,960
Risk per 1,000 patients	5.20	Risk per 1,000 patients	5.20
Desired HR from RCT	0.66	Assumed HR from RCT	1
Alpha (2-sided)	0.05	Alpha (2-sided)	0.05
		Non-inferiority margin	1.46
Number of events expected	145.184	Number of events expected	145.184
Power	0.70656205	Power	0.625504572

o Medicare

Superiority Analysis		Non-inferiority Analysis	
Number of patients matched	44,640	Number of patients matched	44,640
Reference	22,320	Reference	22,320
Exposed	22,320	Exposed	22,320
Risk per 1,000 patients	6.04	Risk per 1,000 patients	6.04
Desired HR from RCT	0.66	Assumed HR from RCT	1
Alpha (2-sided)	0.05	Alpha (2-sided)	0.05
		Non-inferiority margin	1.46
Number of events expected	269.6256	Number of events expected	269.6256
Power	0.926676361	Power	0.874319968

• Stop analyses until balance and final power assessment are reviewed by primary investigators, FDA, and assigned members of advisory board.

Reviewed by PI:	Jessica Franklin	Date reviewed:	9/8/20
Reviewed by FDA:	Ken Quinto	Date reviewed:	9/29/20
Reasons for stopping			
analysis (if required):			

11. Study Confidence and Concerns

<u>Deadline for voting on study confidence and listing concerns:</u>

Date votes and concerns are summarized:

- If final feasibility and power analyses are reviewed and approved, proceed to the remaining protocol steps.
- All study team and advisory board members that review this protocol should at this stage provide their level of confidence for the success of the RWD study in the <u>Google Form</u>. This form also provides space for reviewers to list any concerns that they feel may contribute to a failure to replicate the findings of the RCT, including differences in study populations, poor measurement of study

variables, or residual confounding. All responses will be kept confidential and individual-level results will only be shared with the individual respondent.

• After the deadline for voting has passed, provide the distribution of responses and summarize all concerns here.

12. Register study protocol on clinicalTrials.gov

Date conducted:

• Register the study on <u>clinicalTrials.gov</u> and upload this document.

13. Comparative Analyses

Aetion report name:

Date conducted:

- 13.1 For primary analysis:
- 13.2 For sensitivity analyses:

14. Requested Results

14.1 <u>Table 1: Baseline characteristics before and after adjustment</u>

Variable	Before adjus	tment		After adjustment			
	Referent	Exposure	Std. diff.	Referent	Exposure	Std. diff.	
Number of patients			-			-	
Age categories							

14.2 <u>Table 2: Follow-up time</u>

Patient Group	Median Follow-Up Time (Days) [IQR]
Overall Patient Population	
Referent	
Exposure	

14.3 <u>Table 3: Censoring events</u>

	Overall	Referent	Exposure
Outcome			
Death			
Start of an additional exposure			
End of index exposure			
Specified date reached			
End of patient data			
End of patient enrollment			

14.4 <u>Table 4: Results from primary analyses;</u>

Analysis	No. exposed events	No. referent events	Exposed rate	Referent rate	HR (95% CI)
Crude					
Analysis 1					
Analysis 2					

HR, Hazard Ratio; Cl, Confidence Interval.

14.5 <u>Table 5: Results from secondary analyses;</u>

Effectiveness research with Real World Data to support FDA's regulatory decision making

15. References

Chow S, Shao J, Wang H. 2008. *Sample Size Calculations in Clinical Research*. 2nd Ed. Chapman & Hall/CRC Biostatistics Series. **page** 177

Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139-51.

#	RE-LY trial definitions	Implementation in routine care	References/Rationale	Color coding
-	ILE ET GIAI GENNIAONS	I imprementation in routine care	Please see the following Google Drive for further details or any missing	
			information:	Criteria
	Trial details- Primary approval; U	intended Control laborations	https://drive.google.com/open?id=1WD618wrywYjEaXzfLTcuK-VCcnb6b-	Citteria
-	That details- Primary approval; O	intended 3 With laber change	ICD-10 codes are not listed in this document because of excel cell size	
			limitations and excessive number of ICD-10 codes. Full ICD-10 code lists	
			will be available in the above Google Drive Folder (link above). ICD-9 to ICD-	
			10 code conversions were completed using a SAS macro that implements forward/backward mapping based on the CMS ICD-9 to ICD-10 mapping:	Adequate mapping in claims
			https://www.nber.org/data/icd9-icd-10-cm-and-pcs-crosswalk-general-	
_	EXPOSURE vs. C		equivalence-mapping.html	
-	Fixed doses of dabigatran (110 mg or 150 mg twice daily) vs. adjusted-dose warfarin	Dabigatran (110mg or 150mg twice daily) vs adjusted-dose warfarin		Intermediate mapping in claims
	PRIMARY OF	JTCOME		Poor mapping or cannot be measured in claims
		Measured 1 day after drug initiation in diagnosis position and care setting specified below.		
			For stroke:	
		For stroke: Primary diagnosis position in inpatient care setting	PPV of 85% or higher for ischemic stroke	
		430.xx Subarachnoid hemorrhage (SAH)	PPV ranging from 80% to 98% for hemorrhagic stroke →[Andrade SE, Harrold LR, Tjia J, et al. A systematic review of validated	
		431.xx Intracerebral hemorrhage (ICH)	methods for identifying cerebrovascular accident or transient ischemic	
	The primary outcome is a composite of stroke (including hemorrhagic) and systemic embolism event	433.x1 Occlusion and stenosis of precerebral arteries with cerebral infarction 434.xx (excluding 434.x0) Occlusion and stenosis of cerebral arteries with cerebral infarction	attack using administrative data. Pharmacoepidemiology and Drug Safety 2012;21 Suppl 1:100-28.]	Can't be measured in claims but not important
	The phillary ductome is a composite of stroke (including hemorinagic) and systemic embolishi event	436.x Acute, but ill-defined cerebrovascular events	→[Tirschwell DL, Longstreth WT, Jr. Validating administrative data in stroke	for the analysis
			research. Stroke; a journal of cerebral circulation 2002;33:2465-70.] → [Roumie CL. Mitchel E. Gideon PS. Varas-Lorenzo C. Castellsague J. Griffin	
1		Systemic embolism (Arterial embolism and thrombosis): Primary diagnosis position in inpatient care setting	MR. Validation of ICD-9 codes with a high positive predictive value for	
		ICD-9: 444.xx	incident strokes resulting in hospitalization using Medicaid health data.	
		ICD-10: I74.x	Pharmacoepidemiology and drug safety 2008;17:20-6.]	
	INCLUSION (1 AF documented as follows: (1a or 1b or 1c)	CRITERIA CONTROLLA CONTROL		4
	TAN accumented as follows: (18 of 18 of 16)	Measured 4 weeks prior to and including day of drug initiation in any diagnosis position and any care setting		1
1	There is ECG documented AF on the day of screening or randomization	Atrial fibrillation ICD-9 diagnosis: 427.31		
		ICD-10 diagnosis: I48.0x, I48.1x, I48.2x, I48.9x		
		Measured 12 months prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient		
		care setting		
1	The patient has had a symptomatic episode of paroxysmal or persistent AF documented by 12-lead ECG within 6 m before	Atrial fibrillation		
	randomization	ICD-9 diagnosis: 427.31		
		ICD-10 diagnosis: I48.0x, I48.1x, I48.2x, I48.9x		
	There is documentation of symptomatic or asymptomatic paroxysmal or persistent AF on 2 separate occasions, at least 1 day	>2 Diagnoses separated by 1 day to 30 days, measured 12 months prior to and including day of drug initiation in any		1
	apart, one of which is within 6 m before randomization.	diagnosis position and inpatient or outpatient care setting		
1	In this case, AF may be documented by 12 lead ECG, rhythm strip, pacemaker/ICD electrogram, or Holter ECG. The duration of	A CALPIANA CA		
	AF should be at least 30 s. Electrograms (not marker channels or mode switch episodes) from pacemakers and defibrillators can be used to document	Atrial fibrillation ICD-9 diagnosis: 427.31		
	only 1 episode of paroxysmal or persistent AF	ICD-10 diagnosis: I48.0x, I48.1x, I48.2x, I48.9x		
	2 In addition to documented AF, patients must have one of the following: (2a or 2b or 2c or 2d or 2e)			4
		Measured any time prior to and including day of drug initiation in any diagnosis position and inpatient care setting		
		Any stroke		
		ICD-9 diagnosis: 430.xx, 431.xx, 433.xx, 434.xx, 436.xx		
,	a • History of previous stroke, TIA, or systemic embolism	Systemic embolism		
		ICD-9 diagnosis: 444.xx (arterial embolism) ICD-10 diagnosis: I74.x arterial embolism and thrombosis		
		ICLP-10 diagnosis. 174.x at tendi embolism and thrombosis		
		<u>TIA</u>		
		ICD-9 diagnosis: 435.xx (Transient cerebral ischemia)		
		Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient care setting		1
	Ejection fraction <40% documented by echocardiogram, radionuclide or contrast angiogram	Heart failure. systolic		
2	in the last 6 m	ICD-9 diagnosis: 428.2x, 428.4x		
		ICD-10 diagnosis: I50.2x, I50.4x		
		Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient care setting		
		inveasured 100 days prior to and including day of drug initiation in any diagnosis position and inpatient care setting		
2	c • Symptomatic heart failure, New York Heart Association class 2 or higher in the last 6 m	Congestive heart failure		
		ICD-9 diagnosis: 428.x, 398.91, 402.01, 402.11, 402.91, 404.01, 404.11, 404.91, 404.03, 404.13, 404.93		
		ICD-10 diagnosis: ISO.1, ISO.2x, ISO.3x, ISO.4x, ISO.8x, ISO.9, IO9.81, I11.0, I13.0, I13.2		1
2	d • Age ≥75 y	Measured on the day of drug initiation		
		Age ≥75		

2e •	Age ≥65 y and one of the following:	Measured on the day of drug initiation	
	<u> </u>	Age ≥65 +	
	– Diabetes mellitus on treatment	Measured any time prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting Diabetes mellitus ICD-9 diagnosis: 250.x1, 250.x3, 250.x0, 250.x2 ICD-10 diagnosis: 250.x1, 250.x3, 250.x0, 250.x2 ICD-10 diagnosis: E10.x, E11.x AND At least one of the following drug prescriptions from 0 to 30 days after diagnosis*: Bolus Insulin insulin human regular, Insulin Aspart, Insulin Glulisine, Insulin Issup, Insulin Aspart/Insulin Aspart Protamine, Insulin Ispro/Insulin Ispro Protamine, insulin,pork purified Basal Insulin: Insulin human isophane (NPH), Insulin human regular/ Insulin human isophane (NPH), Insulin Detemir, Insulin Glargine, Insulin Degludec, Insulin zinc human rec, Insulin zinc extend human rec, Insulin inph human recom/insulin regular human rec, Insulin inph human recom/insulin regular human rec Metformin DDPa inhibitors: Alogliptin, Linagliptin, Saxagliptin, Sitagliptin Sulfonylureas Acetohexamide, Chlorpropamide, tolazamide, tolbutamide, Gliptzide, Glyburide, Glimepiride Meglitinide derivatives Repaglinide, Nateglinide Alpha-glucosidae inhibitors Acarbose, Miglitol Thiazolidinediones (TZDs) Rosiglitazone, Pieglitazone Glucagonilke peptide—1 (GEN-1) agonists Exensitide, Liraglutide, Lixisenatide, Albiglutide, Dulaglutide, semaglutide SGLT2 inhibitors Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin Pramlintide	
	- Documented coronary artery disease (any of: prior myocardial infarction, positive stress test, positive nuclear perfusion study, prior CABG surgery or PCI, angiogram showing ≥75% stenosis in a major coronary artery	Measured any time prior to and including day of drug initiation in diagnosis position and care setting specified below: Acute MI (Inpatient, any position): (ICD-9 diagnosis: 410.xx Old MI (Inpatient, any position): (ICD-9 diagnosis: 412.xx Angina pectoris (Inpatient, any position): (ICD-9 diagnosis: 413.xx Angina pectoris (Inpatient, any position): (ICD-9 diagnosis: 413.xx LICD-9 diagnosis: 413.xx LICD-10 diagnosis: 141.xx ICD-10 diagnosis: 141.xx	
	- Hypertension requiring medical treatment	Measured any time prior to and including day of drug initiation** in any diagnosis position and inpatient or outpatient care setting Hypertension ICD-9 diagnosis: 401.x – 405.x AND At least one drug prescriptions from 0 to 14 days after diagnosis*: ACE inhibitor Benazepril, captopril, enalapril, fosinopril, lisinopril, mexipril, perindopril, quinapril, ramipril, trandolapril ARB Azilsartan, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan Beta blocker Acebutolol, atenolol, betavolol, bisoprolol, carecolol, careveliol, esmolol, labetalol, metoprolol tartrate, metoprolol succinate, propranolol, pentutolol, pindolol, nadolol, nebivolol, sotalol, timdol Calcium channel blocker Diltiazem, mibefradil, verapamil, amlodipine, clevidipine, bepridil, felodipine, isradipine, nicidolipine Other hypertension drugs Doxazosin, eplerenone, prazosin, terazosin, clonidine, guanabenz, guanadrel, guanethidine, guanfacine, hydralazine, methyldopa, metyrosine, reserpine, minoxidil, aliskiren, apraclonidine	
3 /	Age >18 y at entry	Measured on the day of drug initiation Age > 18	
		N/A	,
	Written, informed consent	N/A	

_			1
1	History of heart valve disorders (ie, prosthetic valve or hemodynamically relevant valve disease)	Measured anytime prior to and including day of drug initiation in any diagnosis position and inpatient care setting 394.x (diseases of mitral valve), 395.x (diseases of antiral valve), 395.x (diseases of other endocardial structures), 398.9x (other and unspecified rheumatic heart diseases) V42.2 (heart valve replaced by transplant), V43.3 (heart valve replaced by a mechanical device/prosthesis) V62.2 (heart valve replaced by transplant), V43.3 (heart valve replaced by a mechanical device/prosthesis) V62.0 (heart valve replaced by a mechanical device/prosthesis) V62.0 (heart valve replaced by transplant), V63.3 (heart valve replaced by a mechanical device/prosthesis) V62.0 (heart valve valve) V63.3 (heart valve valve) V64.3 (heart valve) V64.3 (heart valve valve) V64.3 (heart	
2	Severe, disabling stroke within the previous 6 months or Any stroke within the previous 14 days	1) Disabling stroke effects Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting ICD-9 diagnosis: 438.xx (Late effects of cerebrovascular disease) ICD-10 diagnosis: 69 (Sequelae of cerebrovascular disease) ICD-10 diagnosis: 273.6 (Limitation of activities due to disability) -OR- 2) Any stroke: Measured 14 days prior to and including day of drug initiation in primary diagnosis position and inpatient care setting ICD-9 diagnosis: 430.xx, 431.xx, 433.xx, 434.xx, 436.xx	
3	Conditions associated with an increased risk of bleeding:		
3a	• Major surgery in the previous month	Measured 30 days prior to and including day of drug initiation in any procedure position and inpatient or outpatient care setting- (10-9 procedure codes: Major surgery selected from codes range 34.x-84.x 30-34 Operations On The Respiratory System 35-39 Operations On The Cardiovascular System 40-41 Operations On The Digestive System 42-54 Operations On The Digestive System 55-59 Operations On The Mula Genital Organs 65-71 Operations On The Female Genital Organs 75-79 Obstertical Procedures 76-84 Operations On The Musculoskeletal System	
3b	Planned surgery or intervention in the next 3 m	N/A	
3с	• History of intracranial, intraocular, spinal, retroperitoneal or atraumatic intra-articular bleeding	Measured anytime prior to and including day of drug initiation in any diagnosis position and inpatient care setting Intracranial hemorrhage: (Intracoular hemorrhage: 379.23 vitreous hemorrhage, H43.1x 432.8 H43.1x H43.1x	

_			
		Measured 365 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting:	
		ICD-9 diagnosis: 578.x Gastrointestinal hemorrhage	
3d	Gastrointestinal hemorrhage within the past year	ICD-10 diagnosis: K92.2: Gastrointestinal hemorrhage, unspecified acute hemorrhagic gastritis (K29.01) peptic ulcer with hemorrhage (K25.4 - excluding K25.9 - K26.x - excluding K26.9 - K27.x-K28.x) gastritis and duodenitis with hemorrhage (K29.x) diverticular disease with hemorrhage (K37.x) anglodysplasia of stomach with hemorrhage (K31.811)	
		CPT/HCPCS: 0W3P8ZZ - (ICD10) Control Bleeding in Gastrointestinal Tract, Via Natural or Artificial Opening Endoscopic 43255 - (ICPCS) Esophagogastroduodenoscopy, flexible, transoral; with control of bleeding, any method / Upper gastrointestinal endoscopy including esophagus, stomach, and either the duodenum and/or jejunum as appropriate; with control of bleeding, any method 44.43 - (ICD9) ENDOSCOPIC CONTROL OF GASTRIC OR DUODENAL BLEEDING	
		Measured 30 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting:	
3е	Symptomatic or endoscopically documented gastroduodenal ulcer disease in the previous 30 days	ICD-9 diagnosis: Disease of esophagus: 530.1x-530.4x, 530.8x, 530.9x Gastric ulcer: 531.x Duodenal ulcer: 532.x Peptic ulcer: 533.x Acute gastritis: 535.0x Other specified gastritis: 535.4x Unspecified gastritis: 535.6x Duodenitis: 535.6x	
		ICD-10 diagnosis: Peptic ulcer, site unspecified K27.x K25.9 - Gastric ulcer, unspecified as acute or chronic, without hemorrhage or perforation K26.9 Duodenal ulcer, unspecified as acute or chronic, without hemorrhage or perforation	
		Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting	
3f	Hemorrhagic disorder or bleeding diathesis	Bleeding diathesis: ICD-9 diagnosis: 286 x. Coagulation defects 287 x Purpura and other hemorrhagic conditions	
		ICD-10 diagnosis: D65.x Disseminated intravascular coagulation [defibrination syndrome] D66.x Hereditary factor VIII deficiency D67.x Hereditary factor K deficiency D68.x Other coagulation defects D69.x Purpura and other hemorrhagic conditions	
3g	Need for anticoagulant treatment of disorders other than Atrial fibrillation	N/A	
3h	Fibrinolytic agents within 48 h of study entry	We will censor the patients upon initiating these drugs after cohort entry: Fibrinolytic agent: Alteplase, reteplase, tenecteplase, streptokinase, urkinase	
		Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting	
3i	Uncontrolled hypertension (systolic blood pressure >180 mm Hg and/ or diastolic blood pressure >100 mm Hg)	Malignant hypertension: ICD-9 diagnosis: 401.0x (no ICD-10) Hypertensive urgency/ Hypertensive crisis: ICD-10 diagnosis: If5x (no ICD-9)	
3i	Recent malignancy or radiation therapy (56 m) and not expected to survive 3 y	ICD-10 diagnosis: 116.X (no ICD-9)	
4	Contraindication to warfarin treatment	N/A	
5	Reversible causes of atrial fibrillation (eg, cardiac surgery, pulmonary embolism, untreated hyperthyroidism). Plan to perform a pulmonary vein ablation or surgery for cure of the AF	N/A N/A	
	The second secon	Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting	
7	Severe renal impairment (estimated creatinine clearance s30 mL/min)	CKD stage 4/5/ESRD ICD-9 diagnosis: 585.4x, 585.5x, 585.6x ICD-10 diagnosis: N18.4x, N18.5x, N18.6x	
		<u>Dialysis/ Renal transplant</u> Codes are in the sheet "Dialysis and Renal Transplant"	

_			
		Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting	
8	Active infective endocarditis	Infective endocarditis ICD-9 diagnosis: 42.1x ICD-10 diagnosis: 133 x	
9	Active liver disease, including but not limited to:	Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting Acute Liver Disease: ICD-9 diagnosis: 070.xx, 570.xx- 573.xx, 576.8x, 782.4x, 789.5x ICD-10 diagnosis: 815.x, B16.x, B17.x, K76.x, R17.x, R18.x, K72.00, K76.2	
		ICD-9 procedure codes: 39.1x, 42.91	
	Persistent ALT, AST, Alk Phos > 2× ULN	N/A	
	Known active hepatitis C (positive HCV RNA)	N/A	
	Active hepatitis B (HBs antigen +, anti HBc IgM+)	N/A	
9d	Active hepatitis A	N/A	
10	Women who are pregnant or of childbearing potential who refuse to use a medically acceptable form of contraception throughout the study	Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting Codes are in the sheet "Pregnancy"	
11	Anemia (hemoglobin level < 100g/L) or thrombocytopenia (platelet count <100 × 109/L)	Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting Anemia (non-deficiency/neoplastic/chemotherapy/hemorrhagic assoicated) ICD-9 diagnosis: 282.x, 283.x, 284.x, 285.x ICD-10 diagnosis: D55 - D62, D63.0 Thrombocytopenia: ICD-9 diagnosis: 287.3x, 287.4x, 287.5x ICD-10 diagnosis: 287.3x, 287.4x, 287.5x ICD-10 diagnosis: D69.3x, D69.4x, D69.5x, D69.6x	
12	Patients who have developed transaminase elevations upon exposure to ximelagatran.	N/A	
13	Patients who have received an investigational drug in the past 30 d	N/A	
14	Patients considered unreliable by the investigator or have a life expectancy less than the expected duration of the trial because of concomitant disease, or has any condition which in the opinion of the investigator, would not allow safe participation in the study (eg, drug addiction, alcohol abuse)	Measured 180 days prior to and including day of drug initiation in any diagnosis position and inpatient or outpatient care setting CCI >=10 (life expectancy less than the expected duration of the trial) -OR- Alcohol abuse or dependence ICD-9 diagnosis: 291.xx, 303.xx, 305.xx, 571.0x, 571.1x, 571.2x, 571.3x, 357.5x, 425.5x, E860.0x (CMS has not released mapping for new ICD10 for this code), V11.3x ICD-10 diagnosis: F10.x, F70.x, G62.1, I42.6, 099.31x Drug abuse or dependence 292.xx, 304.xx, 305.2x.305.9x, 548.3x 965.0x, 967.xx, 969.4x-969.6x, 969.72-969.79, 970.81 ICD-10 diagnosis: F11.x, F12.x, F13.x, F14.x, F15.x, F16.x, F18.x, F19.x, G62.0, 099.32x	
15	Any known hypersensitivity to galactose if the warfarin used contains galactose.	N/A	

<u>Trial ID</u>	pNDA22
Trial Name (with web links)	<u>RE-LY</u>
<u>NCT</u>	NCT00262600
Therapeutic Area	Cardiology/Vascular Diseases
Brand Name	<u>Pradaxa</u>
Generic Name	dabigatran etexilate mesylate
Sponsor	Boehringer Ingelheim
<u>Year</u>	2010
pNDA Indication	For the risk reduction of stroke and embolism due to atrial fibrillation
Measurable endpoint	primary composite endpoint of stroke and systemic embolism
Trial finding	Rates of the primary outcome were 1.69% per year in the warfarin group, as compared with 1.53% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.91; 95% confidence interval [CI], 0.74 to 1.11; P<0.001 for noninferiority) and 1.11% per year in the group that received 150 mg of dabigatran (relative risk, 0.66; 95% CI, 0.53 to 0.82; P<0.001 for superiority).
Blinding	fixed doses of dabigatran — 110 mg or 150 mg twice daily —each administered in a blinded manner, and adjusted-dose warfarin in an unblinded fashion
No. of Patients	18,113
Comparator	Active

72.3 HIGH FORCEPS OPERATION

Pregnancy Diagnosis codes 650 NORMAL DELIVERY 660 OBSTRUCTED LABOR 661 ABNORMALITY OF FORCES OF LABOR 662 LONG LABOR 663 UMBILICAL CORD COMPLICATIONS DURING LABOR AND DELIVERY 664 TRAUMA TO PERINEUM AND VULVA DURING DELIVERY 665 OTHER OBSTETRICAL TRAUMA 667 RETAINED PLACENTA OR MEMBRANES WITHOUT HEMORRHAGE 668 COMPLICATIONS OF THE ADMINISTRATION OF ANESTHETIC OR OTHER SEDATION IN LABOR AND DELIVERY 669.94 UNSPECIFIED COMPLICATION OF LABOR AND DELIVERY POSTPARTUM CONDITION OR COMPLICATION V24 POSTPARTUM CARE AND EXAMINATION V24.0 POSTPARTUM CARE AND EXAMINATION IMMEDIATELY AFTER DELIVERY V24.1 POSTPARTUM CARE AND EXAMINATION OF LACTATING MOTHER V24.2 ROUTINE POSTPARTUM FOLLOW V27 OUTCOME OF DELIVERY V27.0 MOTHER WITH SINGLE LIVEBORN V27.1 MOTHER WITH SINGLE STILLBORN+A2:J81 V27.2 MOTHER WITH TWINS BOTH LIVEBORN V27.3 MOTHER WITH TWINS ONE LIVEBORN AND ONE STILLBORN V27.4 MOTHER WITH TWINS BOTH STILLBORN V27.5 MOTHER WITH OTHER MULTIPLE BIRTH ALL LIVEBORN V27.6 MOTHER WITH OTHER MULTIPLE BIRTH SOME LIVEBORN V27.7 MOTHER WITH OTHER MULTIPLE BIRTH ALL STILLBORN V27.9 MOTHER WITH UNSPECIFIED OUTCOME OF DELIVERY Procedure codes 72.0 LOW FORCEPS OPERATION 72.1 LOW FORCEPS OPERATION WITH EPISIOTOMY 72.2 MID FORCEPS OPERATION 72.21 MID FORCEPS OPERATION WITH EPISIOTOMY 72.29 OTHER MID FORCEPS OPERATION

- 72.31 HIGH FORCEPS OPERATION WITH EPISIOTOMY
- 72.39 OTHER HIGH FORCEPS OPERATION
- 72.4 FORCEPS ROTATION OF FETAL HEAD
- 72.5 BREECH EXTRACTION
- 72.51 PARTIAL BREECH EXTRACTION WITH FORCEPS TO AFTERCOMING HEAD
- 72.52 OTHER PARTIAL BREECH EXTRACTION
- 72.53 TOTAL BREECH EXTRACTION WITH FORCEPS TO AFTERCOMING HEAD
- 72.54 OTHER TOTAL BREECH EXTRACTION
- 72.6 FORCEPS APPLICATION TO AFTERCOMING HEAD
- 72.7 VACUUM EXTRACTION
- 72.71 VACUUM EXTRACTION WITH EPISIOTOMY
- 72.79 OTHER VACUUM EXTRACTION
- 72.8 OTHER SPECIFIED INSTRUMENTAL DELIVERY
- 72.9 UNSPECIFIED INSTRUMENTAL DELIVERY
- 73.0 ARTIFICIAL RUPTURE OF MEMBRANES
- 73.01 INDUCTION OF LABOR BY ARTIFICIAL RUPTURE OF MEMBRANES
- 73.09 OTHER ARTIFICIAL RUPTURE OF MEMBRANES
- 73.1 OTHER SURGICAL INDUCTION OF LABOR
- 73.2 INTERNAL AND COMBINED VERSION AND EXTRACTION
- 73.21 INTERNAL AND COMBINED VERSION WITHOUT EXTRACTION
- 73.22 INTERNAL AND COMBINED VERSION WITH EXTRACTION
- 73.3 FAILED FORCEPS
- 73.4 MEDICAL INDUCTION OF LABOR
- 73.5 MANUALLY ASSISTED DELIVERY
- 73.51 MANUAL ROTATION OF FETAL HEAD
- 73.59 OTHER MANUALLY ASSISTED DELIVERY
- 73.6 EPISIOTOMY
- 73.8 OPERATIONS ON FETUS TO FACILITATE DELIVERY
- 73.9 OTHER OPERATIONS ASSISTING DELIVERY
- 73.91 EXTERNAL VERSION ASSISTING DELIVERY
- 73.92 REPLACEMENT OF PROLAPSED UMBILICAL CORD
- 73.93 INCISION OF CERVIX TO ASSIST DELIVERY
- 73.94 PUBIOTOMY TO ASSIST DELIVERY
- 73.99 OTHER OPERATIONS ASSISTING DELIVERY
- 74.0 CLASSICAL CESAREAN SECTION

- 74.1 LOW CERVICAL CESAREAN SECTION
- 74.2 EXTRAPERITONEAL CESAREAN SECTION
- 74.3 REMOVAL OF EXTRATUBAL ECTOPIC PREGNANCY
- 74.4 CESAREAN SECTION OF OTHER SPECIFIED TYPE
- 74.9 CESAREAN SECTION OF UNSPECIFIED TYPE
- 74.91 HYSTEROTOMY TO TERMINATE PREGNANCY
- 74.99 OTHER CESAREAN SECTION OF UNSPECIFIED TYPE
- 75.4 MANUAL REMOVAL OF RETAINED PLACENTA
- 75.5 REPAIR OF CURRENT OBSTETRIC LACERATION OF UTERUS
- 75.6 REPAIR OF OTHER CURRENT OBSTETRIC LACERATION
- 75.7 MANUAL EXPLORATION OF UTERINE CAVITY, POSTPARTUM
- 75.9 OTHER OBSTETRIC OPERATIONS

Dialysis codes

ESRD, defined as 2 codes (either inpatient or outpatient), separated by at least 30 days

Codes include:

- ICD9 prox codes:

39.95, Hemodialysis

54.98, Peritoneal dialysis

- ICD9 dx codes:

585.5x, Chronic kidney disease, Stage V (for ESRD with no mention of dialysis)

585.6x, End stage renal disease (for ESRD with dialysis)

V56.0x, encounter for dialysis NOS

V56.8x, encounter for peritoneal dialysis

V45.1x, renal dialysis status

- CPT4 codes:

90957, 90960, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 4 or more face-to-face physician visits per month

90958, 90961, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 2-3 face-to-face physician visits per month

90959, 90962, ESRD related services monthly, for patients 12-19 and 20 years of age and older; with 1 face-to-face physician visit per month

90920, 90921, ESRD related services per full month; for patients 12-19 and twenty years of age and over

90924, 90925, ESRD related services (less than full month), per day; for patients 12-19 and twenty years of age and over

90935, Hemodialysis procedure with single physician evaluation

90937, Hemodialysis procedure requiring repeated evaluation(s) with or without substantial revision of dialysis prescription

90945, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies), with single physician evaluation

90947, Dialysis procedure other than hemodialysis (eg, peritoneal dialysis, hemofiltration, or other continuous renal replacement therapies) requiring repeated physician evaluations, with or without substantial revision of dialysis prescription

90965, 90966, ESRD related services for home dialysis per full month, for patients 12-19 and 20 years of age and older

90969, 90970, ESRD related services for dialysis less than a full month of service, per day; for patients 12-19 and 20 years of age and older

90989 Dialysis training natient including helner where annlicable any mode completed course

20202, Diarysis training, patient, meraanig neiper where appheasie, any mode, compieted coarse

90993, Dialysis training, patient, including helper where applicable, any mode, course not completed, per training session

90999, Unlisted dialysis procedure, inpatient or outpatient

99512, Home visit for hemodialysis

- HCPCS codes:

G0257, Unscheduled or emergency dialysis treatment for ESRD patient in a hospital outpatient dept. that is not certified as an ESRD facility

G0314, G0317, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age an over to include monitoring for the adequacy of nutrition, etc. w/4 or more physician visit per month

G0315, G0318, ESRD related services during the course of treatment, for patients 12-19 and 20yrs of age and over to include monitoring for the adequacy of nutrition, etc. w/2 or 3 physician visit per month

G0316, G0319, ESRD related services during the course of treatment, for patients 12-19 and 20 yrs of age and over to include monitoring for the adequacy of nutrition, etc. w/1 physician visit per month

G0322, G0323, ESRD related services for home dialysis patients per full month: for patients 12-19 and 20 yrs of age and over to include monitoring for adequacy of nutrition and etc.

G0326, G0327, ESRD related services for home dialysis (less than full month), per day; for patients 12-19 and 20 yrs of age and over

S9335, Home therapy, hemodialysis; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing services coded separately), per diem

S9339, Home therapy, peritoneal dialysis, administrative services, care coordination and all necessary supplies and equipment, per diem

OR

Kidney transplant, defined as either 1 inpatient or 1 outpatient code

Codes include:

-ICD9 dx codes:

V42.0x, Kidney transplant status

996.81 Complications of transplanted kidney

-ICD9 prox codes:

55.6x, Transplant of kidney (Exclude 55.61)

- CPT4 codes:

50360, Renal allotransplantation, implantation, graft, w/o donor & recipient nephrectomy

50365, Renal allotransplantation, implantation, graft, w/donor & recipient nephrectomy

Documented Coronary Artery Disease

```
ICD10: Coronary Bypass -
```

```
02.10083, 02.1008x, 02.1009x, 02.100Ax, 02.100Jx, 02.100Kx, 02.100Zx, 02.10483, 02.10488, 02.10489,
02.1048x, 02.1049x, 02.1049x, 02.104Ax, 02.104Jx, 02.104Kx, 02.104Zx, 02.1108x, 02.1109x, 02.110Ax,
02.110Jx, 02.110Kx, 02.110Zx, 02.1148x, 02.1149x, 02.114Ax, 02.114Jx, 02.114Kx, 02.114Zx, 02.1208x,
02.1209x, 02.120Ax, 02.120Jx, 02.120Kx, 02.120Zx, 02.1248x, 02.1249x, 02.124Ax, 02.124Jx, 02.124Kx,
02.124Zx, 02.1308x, 02.1309x, 02.130Ax, 02.130Jx, 02.130Kx, 02.130Zx, 02.1348x, 02.1349x, 02.134Ax,
02.134x, 02.134Kx, 02.134Zx, 02.1K0Zx, 02.1K4Zx, 02.1L08X, 02.1L09x, 02.1L0Ax, 02.1L0Jx, 02.1L0Kx, 02.1l0Zx,
02.1L0Zx, 02.1L48X, 02.1L49x, 02.1L4xx, 02.7004x, 02.7006x, 02.7007x, 02.700Dx, 02.700Ex, 02.700Fx,
02.700Gx, 02.700Tx, 02.700Zx, 02.703xx, 02.704xx, 02.7104x, 02.7105x, 02.7106x, 02.7107x, 02.710Dx,
02.710Ex, 02.710Fx, 02.710Gx, 02.710Tx, 02.710Zx, 02.7134x, 02.7135x, 02.7136x, 02.7137x, 02.713Dx,
02.713Ex, 02.713Fx, 02.713Gx, 02.713Tx, 02.713Zx, 02.7144x, 02.7145x, 02.7146x, 02.7147x, 02.714Dx,
02.714Ex, 02.714Fx, 02.714Gx, 02.714Tx, 02.714Zx, 02.7204x, 02.72056, 02.72066, 02.7206Z, 02.72076,
02.7207Z, 02.720Dx, 02.720Ex, 02.720Fx, 02.720Tx, 02.720Zx, 02.7234x, 02.7235x, 02.7236x, 02.7237x,
02.7237x, 02.723Dx, 02.723Ex, 02.723Fx, 02.723Gx, 02.723Tx, 02.723Tx, 02.723Zx, 02.723Zx, 02.7244x,
02.7245x, 02.7246x, 02.7247x, 02.724Dx, 02.724Ex, 02.724Fx, 02.724Gx, 02.724Tx, 02.7304x, 02.7304x,
02.7305x, 02.7306x, 02.7307x, 02.730Dx, 02.730Ex, 02.730Fx, 02.730Gx, 02.730Tx, 02.730Zx, 02.7334x,
02.7335x, 02.7336x, 02.7337x, 02.733Dx, 02.733Ex, 02.733Fx, 02.733Gx, 02.733Tx, 02.733Zx, 02.7344x,
02.7345x, 02.7346x, 02.7347x, 02.734Dx, 02.734Ex, 02.734Fx, 02.734Gx, 02.734Tx, 02.734Zx, 02.C00Zx,
02.C03Zx, 02.C04Zx, 02.C10Zx, 02.C13Zx, 02.C14Zx, 02.C20Zx, 02.C23Zx, 02.C24Zx, 02.C30Zx, 02.C33Zx, 02.C34Zx
```

Stenting:

Inpatient CPT-4:

92980, 92981, 92928-92929, 92933-92934

OR-

Inpatient ICD-9 Procedure:

36.06

36.07

Inpatient ICD-10 Procedure:

02.7004x, 02.7005x, 02.7006x, 02.7007x, 02.700Dx, 02.700Ex, 02.700Fx, 02.700Gx, 02.700Tx, 02.700Zx, 02.7034x, 02.7035x, 02.7036x, 02.7037x, 02.703Dx, 02.703Ex, 02.703Fx, 02.703Gx, 02.703Tx, 02.703Zx, 02.7044x, 02.7045x, 02.7046x, 02.7047x, 02.704Dx, 02.704Ex, 02.704Fx, 02.704Gx, 02.704Tx, 02.704Zx, 02.7104x, 02.7105x, 02.7106x, 02.7107x, 02.710Dx, 02.710Ex, 02.710Fx, 02.710Gx, 02.710Tx, 02.710Zx,

02.71346, 02.7134Z, 02.71356, 02.7135Z, 02.71366, 02.7136Z, 02.7137G, 02.7137Z, 02.713D6, 02.713DZ, 02.713E6, 02.713EZ, 02.713F6, 02.713F2, 02.713G6, 02.713G2, 02.713T6, 02.713T2, 02.713Z6, 02.713Z2, 02.71446, 02.71447, 02.71456, 02.71457, 02.71466, 02.71467, 02.71476, 02.71477, 02.71406, 02.71407, 02.714E6, 02.714EZ, 02.714F6, 02.714FZ, 02.714G6, 02.714GZ, 02.714T6, 02.714TZ, 02.714ZZ, 02.72046, 02.7204z, 02.72056, 02.7205z, 02.72066, 02.7206z, 02.72076, 02.7207z, 02.720D6, 02.720Dz, 02.720E6, 02.720EZ, 02.720F6, 02.720FZ, 02.720G6, 02.720GZ, 02.720T6, 02.720TZ, 02.720Z6, 02.720ZZ, 02.72346, 02.7234Z, 02.72356, 02.7235Z, 02.72366, 02.7236Z, 02.7237Z, 02.7237Z, 02.723DG, 02.723DZ, 02.723EG, 02.723EZ, 02.723F6, 02.723FZ, 02.723G6, 02.723GZ, 02.723T6, 02.723TZ, 02.723Z6, 02.723ZZ, 02.72446, 02.7244Z, 02.72456, 02.7245Z, 02.72466, 02.7246Z, 02.7247G, 02.7247Z, 02.724DG, 02.724DZ, 02.724EG, 02.724EZ, 02.724F6, 02.724FZ, 02.724G6, 02.724T6, 02.724TZ, 02.724Z6, 02.724ZZ, 02.73046, 02.7304Z, 02.73056, 02.7305Z, 02.73066, 02.7306Z, 02.73076, 02.7307Z, 02.730D6, 02.730DZ, 02.730E6, 02.730EZ, 02.730F6, 02.730FZ, 02.730G6, 02.730GZ, 02.730T6, 02.730TZ, 02.730TZ, 02.730Z6, 02.730ZZ, 02.73346, 02.7334Z, 02.73356, 02.7335Z, 02.73366, 02.7336Z, 02.73376, 02.73376, 02.7337Z, 02.733DG, 02.733DZ, 02.733E6, 02.733EZ, 02.733F6, 02.733FZ, 02.733G6, 02.733GZ, 02.733T6, 02.733TZ, 02.733Z6, 02.733ZZ, 02.733ZZ, 02.73446, 02.7344Z, 02.73456, 02.7345Z, 02.73466, 02.73476, 02.7347Z, 02.34D6, 02.734DZ, 02.734E6, 02.734EZ, 02.734F6, 02.734FZ, 02.734G6, 02.734GZ, 02.734T6, 02.734TZ, 02.734Z6, 02.734ZZ, 02.C00Z6, 02.C03Z6, 02.C03ZZ, 02.C04Z6, 02.C10Z6, 02.C13Z6, 02.C13ZZ, 02.C14Z6, 02.C20Z6, 02.C23Z6, 02.C23ZZ, 02.C24Z6, 02.C30Z6, 02.C33ZZ, 02.C34Z6

Appendix B: Dabigatran vs Warfarin




Table 1: Dabigatran vs Warfarin

					Unmatched							
L	Optur	n I	I	MarketS	ican		Medicare				POOLED	
Variable	WARFARIN	Dabigatran 150mg	St. Diff.	Reference - warfarin los	ure - Dabigatran 150mg	St. Diff.	Reference - warfarin D	abigatran 150mg	St. Diff.	Reference - warfarin	Exposure - Dabigatran 150mg	St. Dif
Number of patients	22,665	2,936		67,790	14,929		136,087	25,230		226,542	43,095	
Age	•	,			,			.,			.,	
mean (sd)	77.97 (6.21)	74.91 (7.65)	0.44	78.02 (9.20)	74.13 (9.67)	0.41	79.43 (7.37)	76.93 (6.88)	0.35	78.86 (7.86)	75.82 (8.01)	0.38
median [IQR]	79.00 [76.00, 82.00]	77.00 [70.00, 80.00]	0.29	79.00 [74.00, 84.00]	76.00 [68.00, 81.00]	0.32	79.00 [75.00, 84.00] 7.	00 [73 00 81 00]	0.28	79.00 (7.86)	76.65 (8.01)	0.30
Age categories without zero category	75.00 [70.00, 02.00]	77.00 [70.00,00.00]	0.23	7 5.00 [7 4.00, 04.00]	70.00 [00.00,01.00]	0.52	75.00 [75.00, 04.00]	00 [/ 5.00, 01.00]	0.20	75.00 (7.00)	70.03 (0.01)	0.50
18 - 54; n (%)	128 (0.6%)	54 (1.8%)	-0.11	1.319 (1.9%)	586 (3.9%)	-0.12	586 (0.4%)	123 (0.5%)	-0.01	2.033 (0.9%)	763 (1.8%)	-0.08
55 - 64; n (%)	573 (2.5%)	198 (6.7%)	-0.20	4,878 (7.2%)	1,917 (12.8%)	-0.19	1,594 (1.2%)	351 (1.4%)	-0.02	7,045 (3.1%)	2,466 (5.7%)	-0.13
65 - 74; n (%)	3,335 (14.7%)	705 (24.0%)	-0.24	11,624 (17.1%)	3,645 (24.4%)	-0.18	26,002 (19.1%)	7,382 (29.3%)	-0.24	40,961 (18.1%)	11,732 (27.2%)	-0.22
>=75; n (%)	18,629 (82.2%)	1,979 (67.4%)	0.35	49,969 (73.7%)	8,781 (58.8%)	0.32	107,905 (79.3%)	17,374 (68.9%)	0.24	176,503 (77.9%)	28,134 (65.3%)	0.28
Gender without zero category- United	10,023 (02.270)	1,575 (07.476)	0.55	45,505 (75.770)	0,701 (50.070)	0.52	107,505 (75.5%)	17,374 (00.370)	0.24	170,303 (77.370)	20,234 (03.370)	0.20
Males; n (%)	12,791 (56.4%)	1,776 (60.5%)	-0.08	36,708 (54.1%)	8,819 (59.1%)	-0.10	72,765 (53.5%)	14,393 (57.0%)	-0.07	122,264 (54.0%)	24,988 (58.0%)	-0.08
Females; n (%)	9,874 (43.6%)	1,160 (39.5%)	0.08	31,082 (45.9%)	6,110 (40.9%)	0.10	63,322 (46.5%)	10,837 (43.0%)	0.07	104,278 (46.0%)	18,107 (42.0%)	0.08
Race	.,. , ,	,,		. , ,	., ., ,			,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		., ., .,	-, - , - ,	
White; n (%)							127,987 (94.0%)	23.447 (92.9%)		127.987 (94.0%)	23,447 (92.9%)	0.00
Black: n (%)							3,795 (2.8%)	714 (2.8%)		3,795 (2.8%)	714 (2.8%)	0.00
Asian; n (%)							1,217 (0.9%)	344 (1.4%)		1,217 (0.9%)	344 (1.4%)	0.00
Hispanic; n (%)							1,169 (0.9%)	245 (1.0%)		1,169 (0.9%)	245 (1.0%)	0.00
North American Native; n (%)							428 (0.3%)	70 (0.3%)		428 (0.3%)	70 (0.3%)	0.00
Other/Unknown: n (%)							1,491 (1.1%)	410 (1.6%)		1,491 (1.1%)	410 (1.6%)	0.00
Region without zero category- United v3 (lumping							1,471 (1.1/0)	-10 (1.0/0)		2,771 (1.1/0)	410 (1.070)	0.00
missing&other category with West)												
Northeast; n (%)	2,860 (12.6%)	428 (14.6%)	-0.06	15,592 (23.0%)	3,464 (23.2%)	0.00	27,525 (20.2%)	4,871 (19.3%)	0.02	45,977 (20.3%)	8,763 (20.3%)	0.00
South; n (%)	5,965 (26.3%)	1,026 (34.9%)	-0.19	21,981 (32.4%)	3,920 (26.3%)	0.13	44,598 (32.8%)	10,023 (39.7%)	-0.14	72,544 (32.0%)	14,969 (34.7%)	-0.06
Midwest; n (%)	4,585 (20.2%)	473 (16.1%)	0.11	18,724 (27.6%)	5,249 (35.2%)	-0.16	38,803 (28.5%)	5,759 (22.8%)	0.13	62,112 (27.4%)	11,481 (26.6%)	0.02
West; n (%)	9,255 (40.8%)	1,009 (34.4%)	0.13	11,263 (16.6%)	2,233 (15.0%)	0.04	25,161 (18.5%)	4,577 (18.1%)	0.01	45,679 (20.2%)	7,819 (18.1%)	0.05
Unknown+missing; n (%)	N/A	N/A	#VALUE!	230 (0.3%)	63 (0.4%)	-0.02	N/A	N/A	#VALUE!	230 (0.3%)	63 (0.4%)	-0.02
CV Covariates												
Ischemic heart disease; n (%)	5,796 (25.6%)	854 (29.1%)	-0.08	22,356 (33.0%)	5,213 (34.9%)	-0.04	37,673 (27.7%)	8,145 (32.3%)	-0.10	65,825 (29.1%)	14,212 (33.0%)	-0.08
Acute MI; n (%)	192 (0.8%)	19 (0.6%)	0.02	1,721 (2.5%)	411 (2.8%)	-0.02	1,928 (1.4%)	380 (1.5%)	-0.01	3841 (1.7%)	810 (1.9%)	-0.02
ACS/unstable angina; n (%)	196 (0.9%)	30 (1.0%)	-0.01	1.436 (2.1%)	412 (2.8%)	-0.05	1.896 (1.4%)	456 (1.8%)	-0.03	3528 (1.6%)	898 (2.1%)	-0.04
Old MI; n (%)	654 (2.9%)	72 (2.5%)	0.02	2,040 (3.0%)	506 (3.4%)	-0.02	4,824 (3.5%)	1.089 (4.3%)	-0.04	7518 (3.3%)	1667 (3.9%)	-0.03
Stable angina; n (%)	557 (2.5%)	99 (3.4%)	-0.05	2,157 (3.2%)	612 (4.1%)	-0.05	3,376 (2.5%)	966 (3.8%)	-0.07	6,090 (2.7%)	1,677 (3.9%)	-0.07
Coronary atherosclerosis and other forms of chronic	337 (2.370)	33 (3.4%)	-0.03	2,137 (3.270)	012 (4.170)	-0.03	3,370 (2.370)	300 (3.8%)	-0.07	0,030 (2.770)	1,077 (3.570)	-0.07
ischemic heart disease: n (%)	5,348 (23.6%)	808 (27.5%)	-0.09	20,511 (30.3%)	4,710 (31.5%)	-0.03	34,808 (25.6%)	7,439 (29.5%)	-0.09	60,667 (26.8%)	12,957 (30.1%)	-0.07
Other atherosclerosis with ICD10 v2 Copy; n (%)	291 (1.3%)	50 (1.7%)	-0.03	1,283 (1.9%)	237 (1.6%)	0.02	1,625 (1.2%)	346 (1.4%)	-0.02	3199 (1.4%)	633 (1.5%)	-0.01
Previous cardiac procedure (CABG or PTCA or Stent)	231 (1.370)	30 (1.770)	-0.03	1,203 (1.570)	237 (1.070)	0.02	1,023 (1.270)	340 (1.470)	-0.02	3133 (1.470)	033 (1.370)	-0.01
v4; n (%)	19 (0.1%)	7 (0.2%)	-0.03	712 (1.1%)	161 (1.1%)	0.00	893 (0.7%)	154 (0.6%)	0.01	1624 (0.7%)	322 (0.7%)	0.00
History of CABG or PTCA; n (%)	1,022 (4.5%)	146 (5.0%)	-0.02	2,582 (3.8%)	672 (4.5%)	-0.04	8,074 (5.9%)	2,028 (8.0%)	-0.08	11,678 (5.2%)	2,846 (6.6%)	-0.06
Any stroke; n (%)	1,585 (7.0%)	271 (9.2%)	-0.08	5,866 (8.7%)	1,426 (9.6%)	-0.03	8,312 (6.1%)	1,840 (7.3%)	-0.05	15,763 (7.0%)	3,537 (8.2%)	-0.05
Ischemic stroke (w and w/o mention of cerebral	1,565 (7.070)	271 (3.270)	-0.00	3,000 (0.770)	1,420 (3.0%)	-0.03	0,512 (0.170)	1,040 (7.570)	-0.03	13,703 (7.070)	3,337 (0.270)	-0.03
infarction); n (%)	1,579 (7.0%)	270 (9.2%)	-0.08	5,843 (8.6%)	1,421 (9.5%)	-0.03	8,268 (6.1%)	1,832 (7.3%)	-0.05	15,690 (6.9%)	3,523 (8.2%)	-0.05
Hemorrhagic stroke; n (%)	12 (0.1%)	3 (0.1%)	0.00	41 (0.1%)	8 (0.1%)	0.00	56 (0.0%)	9 (0.0%)	#DIV/0!	109 (0.0%)	20 (0.0%)	#DIV/0
TIA; n (%)	627 (2.8%)	151 (5.1%)	-0.12	2,260 (3.3%)	759 (5.1%)	-0.09	3,166 (2.3%)	811 (3.2%)	-0.06	6053 (2.7%)	1721 (4.0%)	-0.07
Other cerebrovascular disease; n (%)	386 (1.7%)	54 (1.8%)	-0.01	1,417 (2.1%)	315 (2.1%)	0.00	2.122 (1.6%)	433 (1.7%)	-0.01	3925 (1.7%)	802 (1.9%)	-0.02
Late effects of cerebrovascular disease; n (%)	110 (0.5%)	10 (0.3%)	0.03	77 (0.1%)	19 (0.1%)	0.00	511 (0.4%)	69 (0.3%)	0.02	698 (0.3%)	98 (0.2%)	0.02
Cerebrovascular procedure; n (%)	2 (0.0%)	0 (0.0%)	#DIV/0!	73 (0.1%)	25 (0.2%)	-0.03	91 (0.1%)	21 (0.1%)	0.00	166 (0.1%)	46 (0.1%)	0.00
Heart failure (CHF): n (%)	3,108 (13.7%)	335 (11.4%)	0.07	15,297 (22.6%)	3,232 (21.6%)	0.02	17,205 (12.6%)	2.846 (11.3%)	0.04	35,610 (15.7%)	6.413 (14.9%)	0.02
Peripheral Vascular Disease (PVD) or PVD Surgery v2;	3,100 (13.770)	555 (11.470)	0.07	13,237 (22.070)	3,232 (21.070)	0.02	17,203 (12.070)	2,040 (11.370)	0.04	33,010 (13.770)	0,413 (14.570)	0.02
n (%)	1,790 (7.9%)	210 (7.2%)	0.03	5.549 (8.2%)	974 (6.5%)	0.07	8,046 (5.9%)	1,363 (5.4%)	0.02	15,385 (6.8%)	2.547 (5.9%)	0.04
Atrial fibrillation; n (%)	21,440 (94.6%)	2,786 (94.9%)	-0.01	61,508 (90.7%)	14,189 (95.0%)	-0.17	121,089 (89.0%)	21,872 (86.7%)	0.02	204,037 (90.1%)	38,847 (90.1%)	0.00
Other cardiac dysrhythmia; n (%)	10.235 (45.2%)	1,233 (42.0%)	0.01	18.823 (27.8%)	4.688 (31.4%)	-0.17	47,883 (35.2%)	8.912 (35.3%)	0.00	76.941 (34.0%)	14.833 (34.4%)	-0.01
Cardiac conduction disorders; n (%)	1,169 (5.2%)	1,233 (42.0%)	-0.04	3,958 (5.8%)	953 (6.4%)	-0.08	6,776 (5.0%)	1,425 (5.6%)	-0.03	11903 (5.3%)	2561 (5.9%)	-0.03
Other CVD; n (%)	2,744 (12.1%)	358 (12.2%)	0.04	18,692 (27.6%)	4,297 (28.8%)	-0.03	14,045 (10.3%)	2,647 (10.5%)	-0.03	35,481 (15.7%)	7,302 (16.9%)	-0.03
Diabetes-related complications	2,, 77 (12.1/0)	550 (12.2/0)	0.00	10,032 (27.070)	-,237 (20.070)	-0.03	1-,043 (10.3/0)	2,047 (10.370)	-0.01	55,401 (15.770)	.,302 (10.3/0)	-0.03
·	211 /1 40/1	41 (1.4%)	0.00	052/1 20/1	105/1 20/1	0.00	1 242 /1 00/1	229 (0.9%)	0.01	2 505 /1 10/1	ACC /1 10/\	0.00
Diabetic retinopathy; n (%) Diabetes with other ophthalmic manifestations; n	311 (1.4%)	41 (1.476)	0.00	852 (1.3%)	196 (1.3%)	0.00	1,343 (1.0%)	223 (U.976)	0.01	2,506 (1.1%)	466 (1.1%)	0.00
(%)	24 (0.1%)	2 (0.1%)	0.00	710 (1.0%)	130 (0.9%)	0.01	866 (0.6%)	162 (0.6%)	0.00	1600 (0.7%)	294 (0.7%)	0.00
(%) Retinal detachment, vitreous hemorrhage,	24 (0.1%)	2 (0.170)	0.00	/10(1.0%)	130 (0.3%)	0.01	000 (0.0%)	102 (0.070)	0.00	1000 (0.7%)	234 (U.7 %)	0.00
vitrectomy; n (%)	41 (0.2%)	7 (0.2%)	0.00	157 (0.2%)	35 (0.2%)	0.00	214 (0.2%)	40 (0.2%)	0.00	412 (0.2%)	82 (0.2%)	0.00
	23 (0.1%)	2 (0.1%)	0.00	137 (0.2%)	34 (0.2%)	0.00	199 (0.1%)	35 (0.1%)	0.00	349 (0.2%)	71 (0.2%)	0.00
Retinal laser coagulation therapy; n (%) Occurrence of Diabetic Neuropathy v2 Copy; n (%)	1,095 (4.8%)	116 (4.0%)	0.00	2,494 (3.7%)	485 (3.2%)	0.00	3,720 (2.7%)	626 (2.5%)	0.00	7309 (3.2%)	1227 (2.8%)	0.00
	1,095 (4.8%)	110 (4.0%)	0.04	2,494 (5.7%)	483 (3.2%)	0.03	3,720 (2.7%)	UZU (Z.370)	0.01	/309 (3.2%)	1221 (2.8%)	0.02
Occurrence of diabetic nephropathy V3 with ICD10 Copy; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	#VALUE!	000 (0.0%)	#VALUE
Hypoglycemia v2; n (%)	148 (0.7%)	19 (0.6%)	#DIV/0! 0.01	780 (1.2%)	138 (0.9%)	0.03	1.333 (1.0%)	221 (0.9%)	#DIV/0! 0.01	2261 (1.0%)	378 (0.9%)	#VALUE!
Hypoglycemia v2; n (%) Hyperglycemia: n (%)	148 (0.7%) 775 (3.4%)	19 (0.6%)	-0.03	1,082 (1.6%)	303 (2.0%)	-0.03	1,333 (1.0%) 5,641 (4.1%)	1,169 (4.6%)	-0.02	7498 (3.3%)	378 (0.9%) 1586 (3.7%)	-0.02
	//5 (3.4%)	114 (5.9%)	-0.03	1,082 (1.6%)	303 (2.0%)	-0.03	5,641 (4.1%)	1,109 (4.6%)	-0.02	/498 (3.3%)	1586 (3./%)	-0.02
Disorders of fluid electrolyte and acid-base balance; n (%)	797 (3.5%)	111 (3.8%)	-0.02	4,181 (6.2%)	939 (6.3%)	0.00	5,781 (4.2%)	1.199 (4.8%)	-0.03	10759 (4.7%)	2249 (5.2%)	-0.02
()	(, . ,	(0.0,-)	0.02			0.00		-, (,			(,-)	0.02
Diabetic ketoacidosis; n (%)	12 (0.1%)	2 (0.1%)	0.00	65 (0.1%)	9 (0.1%)	0.00	107 (0.1%)	23 (0.1%)	0.00	184 (0.1%)	34 (0.1%)	0.00
Hyperosmolar hyperglycemic nonketotic syndrome	47 /0 40/1	1 (0.00/)	0.04	40 (0.40/)	7 (0.00/)	0.04	01 (0 10/)	24 (0.10/)	0.00	457/0.40/	22 /0 40/	0.00
(HONK); n (%)	17 (0.1%)	1 (0.0%)	0.04	49 (0.1%)	7 (0.0%)	0.04	91 (0.1%)	24 (0.1%)	0.00	157 (0.1%)	32 (0.1%)	0.00
Diabetes with peripheral circulatory disorders with	EEA/2 400	40 /4 C0/1	0.06	1 375 /4 00/1	220 /4 (0/)	0.02	2 (04/2 00/)	422 (4 70/)	0.02	AE 33 /3 00/3	730/4 700	0.02
ICD-10 v2 Copy; n (%) Diabetic Foot: n (%)	554 (2.4%) 413 (1.8%)	48 (1.6%) 39 (1.3%)	0.06	1,275 (1.9%) 1,743 (2.6%)	239 (1.6%) 268 (1.8%)	0.02	2,694 (2.0%) 3.207 (2.4%)	433 (1.7%) 457 (1.8%)	0.02	4523 (2.0%) 5363 (2.4%)	720 (1.7%) 764 (1.8%)	0.02
Gangrene v2; n (%)	19 (0.1%)	1 (0.0%)	0.04	103 (0.2%)	16 (0.1%)	0.03	108 (0.1%)	12 (0.0%)	0.04	230 (0.1%)	29 (0.1%)	0.00

Lower extremity amputation; n (%)	55 (0.2%)	8 (0.3%)	-0.02	131 (0.2%)	29 (0.2%)	0.00	277 (0.2%)	39 (0.2%)	0.00	463 (0.2%)	076 (0.2%)	0.00
Osteomyelitis; n (%)	40 (0.2%)	4 (0.1%)	0.03	274 (0.4%)	50 (0.3%)	0.02	404 (0.3%)	52 (0.2%)	0.02	718 (0.3%)	106 (0.2%)	0.02
Skin infections v2; n (%)	1,050 (4.6%)	137 (4.7%)	0.00	4,516 (6.7%)	784 (5.3%)	0.06	7,183 (5.3%)	1,151 (4.6%)	0.03	12749 (5.6%)	2072 (4.8%)	0.04
Erectile dysfunction; n (%)	343 (1.5%)	69 (2.4%)	-0.07	726 (1.1%)	237 (1.6%)	-0.04	904 (0.7%)	232 (0.9%)	-0.02	1973 (0.9%)	538 (1.2%)	-0.03
Diabetes with unspecified complication; n (%) Diabetes mellitus without mention of complications;	187 (0.8%)	20 (0.7%)	0.01	519 (0.8%)	101 (0.7%)	0.01	764 (0.6%)	139 (0.6%)	0.00	1470 (0.6%)	260 (0.6%)	0.00
n (%)	5,754 (25.4%)	833 (28.4%)	-0.07	16,310 (24.1%)	3,721 (24.9%)	-0.02	34,888 (25.6%)	6,813 (27.0%)	-0.03	56,952 (25.1%)	11,367 (26.4%)	-0.03
Hypertension: 1 inpatient or 2 outpatient claims within 365 days; n (%)	16,322 (72.0%)	2,239 (76.3%)	-0.10	42,997 (63.4%)	9,870 (66.1%)	-0.06	108,842 (80.0%)	21,120 (83.7%)	-0.10	168,161 (74.2%)	33,229 (77.1%)	-0.07
Hyperlipidemia v2; n (%)	11,780 (52.0%)	1,804 (61.4%)	-0.19	25,573 (37.7%)	6,296 (42.2%)	-0.09	59,674 (43.8%)	12,723 (50.4%)	-0.13	97,027 (42.8%)	20,823 (48.3%)	-0.11
Edema; n (%)	1,814 (8.0%)	243 (8.3%)	-0.01	5,614 (8.3%)	1,040 (7.0%)	0.05	8,853 (6.5%)	1,425 (5.6%)	0.04	16281 (7.2%)	2708 (6.3%)	0.04
Renal Dysfunction (non-diabetic) v2; n (%)	7 (0.0%)	1 (0.0%)	#DIV/0!	50 (0.1%)	6 (0.0%)	0.04	33 (0.0%)	3 (0.0%)	#DIV/0!	#VALUE!	010 (0.0%)	#VALUE!
Occurrence of acute renal disease v2; n (%)	2 (0.0%)	1 (0.0%)	#DIV/0!	46 (0.1%)	6 (0.0%)	0.04	23 (0.0%)	3 (0.0%)	#DIV/0!	71 (0.0%)	10 (0.0%)	#DIV/0!
Occurrence of chronic renal insufficiency; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	1 (0.0%)	0 (0.0%)	#DIV/0!	#VALUE!	000 (0.0%)	#VALUE!
Chronic kidney disease v2; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	#VALUE!	000 (0.0%)	#VALUE!
CKD Stage 3-4; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	#VALUE!	000 (0.0%)	#VALUE!
Occurrence of hypertensive nephropathy; n (%) Occurrence of miscellaneous renal insufficiency v2; n	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	#VALUE!	000 (0.0%)	#VALUE!
(%)	1 (0.0%)	0 (0.0%)	#DIV/0!	4 (0.0%)	0 (0.0%)	#DIV/0!	6 (0.0%)	0 (0.0%)	#DIV/0!	#VALUE!	000 (0.0%)	#VALUE!
Glaucoma or cataracts v2; n (%)	5,118 (22.6%)	675 (23.0%)	-0.01	15,190 (22.4%)	3,243 (21.7%)	0.02	1,139 (0.8%)	160 (0.6%)	0.02	21,447 (9.5%)	4,078 (9.5%)	0.00
Cellulitis or abscess of toe; n (%)	191 (0.8%)	17 (0.6%)	0.02	500 (0.7%)	93 (0.6%)	0.01	2,821 (2.1%)	399 (1.6%)	0.04	3512 (1.6%)	509 (1.2%)	0.03
Foot ulcer; n (%)	422 (1.9%)	40 (1.4%)	0.04	1,801 (2.7%)	271 (1.8%)	0.06	128 (0.1%)	27 (0.1%)	0.00	2351 (1.0%)	338 (0.8%)	0.02
Bladder stones; n (%)	26 (0.1%)	5 (0.2%)	-0.03	78 (0.1%)	28 (0.2%)	-0.03	1,422 (1.0%)	293 (1.2%)	-0.02	1526 (0.7%)	326 (0.8%)	-0.01
Kidney stones; n (%)	171 (0.8%)	33 (1.1%)	-0.03	813 (1.2%)	228 (1.5%)	-0.03	12,492 (9.2%)	2,078 (8.2%)	0.04	13476 (5.9%)	2339 (5.4%)	0.02
Urinary tract infections (UTIs); n (%)	1,630 (7.2%)	185 (6.3%)	0.04	5,324 (7.9%)	927 (6.2%)	0.07	40,989 (30.1%)	8,320 (33.0%)	-0.06	47,943 (21.2%)	9,432 (21.9%)	-0.02
Dipstick urinalysis; n (%)	5,873 (25.9%)	901 (30.7%)	-0.11	13,373 (19.7%)	3,156 (21.1%)	-0.03	14,042 (10.3%)	2,978 (11.8%)	-0.05	33,288 (14.7%)	7,035 (16.3%)	-0.04
Non-dipstick urinalysis; n (%)	2,541 (11.2%)	355 (12.1%)	-0.03	3,103 (4.6%)	801 (5.4%)	-0.04	5,152 (3.8%)	1,026 (4.1%)	-0.02	10,796 (4.8%)	2,182 (5.1%)	-0.01
Urine function test; n (%)	687 (3.0%)	102 (3.5%)	-0.03	2,778 (4.1%)	638 (4.3%)	-0.01	2,169 (1.6%)	447 (1.8%)	-0.02	5634 (2.5%)	1187 (2.8%)	-0.02
Cytology; n (%)	250 (1.1%)	38 (1.3%)	-0.02	1,664 (2.5%)	358 (2.4%)	0.01	2,833 (2.1%)	519 (2.1%)	0.00	4747 (2.1%)	915 (2.1%)	0.00
Cystoscopy; n (%)	380 (1.7%)	48 (1.6%)	0.01	1,732 (2.6%)	378 (2.5%)	0.01	#REF!	#REF!	#REF!	#REF!	#REF!	#REF!
Other Covariates												
Liver disease; n (%)	84 (0.4%)	14 (0.5%)	-0.01	343 (0.5%)	98 (0.7%)	-0.03	443 (0.3%)	100 (0.4%)	-0.02	870 (0.4%)	212 (0.5%)	-0.01
Osteoarthritis; n (%)	3,538 (15.6%)	497 (16.9%)	-0.04	10,558 (15.6%)	2,139 (14.3%)	0.04	21,641 (15.9%)	3,936 (15.6%)	0.01	35737 (15.8%)	6572 (15.3%)	0.01
Other arthritis, arthropathies and musculoskeletal												
pain; n (%)	7,087 (31.3%)	897 (30.6%)	0.02	23,692 (34.9%)	4,746 (31.8%)	0.07	41,341 (30.4%)	7,342 (29.1%)	0.03	72120 (31.8%)	12985 (30.1%)	0.04
Dorsopathies; n (%)	3,877 (17.1%)	535 (18.2%)	-0.03	12,398 (18.3%)	2,723 (18.2%)	0.00	22,378 (16.4%)	4,307 (17.1%)	-0.02	38653 (17.1%)	7565 (17.6%)	-0.01
Fractures; n (%)	627 (2.8%)	65 (2.2%)	0.04	3,305 (4.9%)	496 (3.3%)	0.08	5,148 (3.8%)	760 (3.0%)	0.04	9080 (4.0%)	1321 (3.1%)	0.05
Falls v2; n (%)	688 (3.0%) 1.758 (7.8%)	67 (2.3%) 188 (6.4%)	0.04 0.05	1,133 (1.7%) 5,295 (7.8%)	149 (1.0%) 1.008 (6.8%)	0.06 0.04	2,111 (1.6%) 10,526 (7.7%)	262 (1.0%) 1.911 (7.6%)	0.05 0.00	3932 (1.7%) 17579 (7.8%)	478 (1.1%) 3107 (7.2%)	0.05 0.02
Osteoporosis; n (%) Hyperthyroidism; n (%)	1,758 (7.8%)	23 (0.8%)	-0.01	494 (0.7%)	1,008 (6.8%)	0.04	1,000 (0.7%)	248 (1.0%)	-0.03	1657 (0.7%)	375 (0.9%)	-0.02
Hypothyroidism v2; n (%)	3,397 (15.0%)	425 (14.5%)	0.01	7,128 (10.5%)	1,551 (10.4%)	0.00	15,444 (11.3%)	3,025 (12.0%)	-0.03	25969 (11.5%)	5001 (11.6%)	0.02
Other disorders of thyroid gland V2; n (%)	505 (2.2%)	74 (2.5%)	-0.02	1,546 (2.3%)	387 (2.6%)	-0.02	2,907 (2.1%)	676 (2.7%)	-0.02	4958 (2.2%)	1137 (2.6%)	-0.03
Depression; n (%)	1,103 (4.9%)	144 (4.9%)	0.00	3,463 (5.1%)	728 (4.9%)	0.02	6,172 (4.5%)	1,217 (4.8%)	-0.04	10738 (4.7%)	2089 (4.8%)	0.03
Anxiety; n (%)	973 (4.3%)	154 (5.2%)	-0.04	2,440 (3.6%)	592 (4.0%)	-0.02	5.217 (3.8%)	1,082 (4.3%)	-0.03	8630 (3.8%)	1828 (4.2%)	-0.02
Sleep Disorder; n (%)	1,509 (6.7%)	291 (9.9%)	-0.12	6,461 (9.5%)	1,761 (11.8%)	-0.07	7,241 (5.3%)	1,661 (6.6%)	-0.05	15211 (6.7%)	3713 (8.6%)	-0.07
Dementia; n (%)	1,070 (4.7%)	113 (3.8%)	0.04	3,564 (5.3%)	483 (3.2%)	0.10	6,660 (4.9%)	919 (3.6%)	0.06	11294 (5.0%)	1515 (3.5%)	0.07
Delirium; n (%)	85 (0.4%)	16 (0.5%)	-0.01	960 (1.4%)	124 (0.8%)	0.06	1.006 (0.7%)	154 (0.6%)	0.01	2051 (0.9%)	294 (0.7%)	0.02
Psychosis; n (%)	119 (0.5%)	13 (0.4%)	0.01	772 (1.1%)	104 (0.7%)	0.04	944 (0.7%)	177 (0.7%)	0.00	1835 (0.8%)	294 (0.7%)	0.01
Obesity; n (%)	1,627 (7.2%)	283 (9.6%)	-0.09	3,572 (5.3%)	1,075 (7.2%)	-0.08	9,935 (7.3%)	2,313 (9.2%)	-0.07	15134 (6.7%)	3671 (8.5%)	-0.07
Overweight; n (%)	619 (2.7%)	83 (2.8%)	-0.01	498 (0.7%)	96 (0.6%)	0.01	2,324 (1.7%)	441 (1.7%)	0.00	3441 (1.5%)	620 (1.4%)	0.01
Smoking; n (%)	1,391 (6.1%)	228 (7.8%)	-0.07	2,660 (3.9%)	831 (5.6%)	-0.08	14,879 (10.9%)	3,432 (13.6%)	-0.08	18930 (8.4%)	4491 (10.4%)	-0.07
Alcohol abuse or dependence; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Drug abuse or dependence; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
COPD; n (%)	2,521 (11.1%)	302 (10.3%)	0.03	9,289 (13.7%)	1,896 (12.7%)	0.03	12,605 (9.3%)	2,316 (9.2%)	0.00	24415 (10.8%)	4514 (10.5%)	0.01
Asthma; n (%)	928 (4.1%)	134 (4.6%)	-0.02	3,235 (4.8%)	799 (5.4%)	-0.03	4,679 (3.4%)	1,016 (4.0%)	-0.03	8842 (3.9%)	1949 (4.5%)	-0.03
Obstructive sleep apnea; n (%)	1,465 (6.5%)	273 (9.3%)	-0.10	5,202 (7.7%)	1,465 (9.8%)	-0.07	5,922 (4.4%)	1,420 (5.6%)	-0.06	12589 (5.6%)	3158 (7.3%)	-0.07
Pneumonia; n (%)	479 (2.1%)	46 (1.6%)	0.04	4,419 (6.5%)	880 (5.9%)	0.02	4,846 (3.6%)	865 (3.4%)	0.01	9744 (4.3%)	1791 (4.2%)	0.00
Imaging; n (%)	3 (0.0%)	1 (0.0%)	#DIV/0!	115 (0.2%)	18 (0.1%)	0.03	2,821 (2.1%)	399 (1.6%)	0.04	2939 (1.3%)	418 (1.0%)	0.03
Other Medications	7 527 (22 70)	997 (34.0%)	-0.01	23.436 (34.6%)	5 240 (25 20()	-0.01	47.332 (34.8%)	8.768 (34.8%)	0.00	70405 (24.50/)	15014 (34.8%)	0.00
Use of ACE inhibitors; n (%) Use of ARBs: n (%)	7,637 (33.7%) 4.045 (17.8%)	997 (34.0%) 571 (19.4%)	-0.01 -0.04	23,436 (34.6%) 14,719 (21.7%)	5,249 (35.2%) 3,547 (23.8%)	-0.01	47,332 (34.8%) 26.443 (19.4%)	8,768 (34.8%) 5.734 (22.7%)	-0.08	78405 (34.6%) 45207 (20.0%)	15014 (34.8%) 9852 (22.9%)	-0.07
Use of Loop Diuretics - United: n (%)	4,045 (17.8%) 4,781 (21.1%)	482 (16.4%)	-0.04 0.12	21,128 (31.2%)	3,432 (23.0%)	0.05	26,443 (19.4%) 34,289 (25.2%)	5,734 (22.7%) 4,812 (19.1%)	-0.08 0.15	45207 (20.0%) 60198 (26.6%)	8726 (20.2%)	0.15
Use of other diuretics- United; n (%)	4,781 (21.1%) 859 (3.8%)	91 (3.1%)	0.12	4.266 (6.3%)	730 (4.9%)	0.06	6,138 (4.5%)	860 (3.4%)	0.06	11263 (5.0%)	1681 (3.9%)	0.15
Use of nitrates-United; n (%)	1,267 (5.6%)	146 (5.0%)	0.03	6.398 (9.4%)	1,249 (8.4%)	0.04	10.986 (8.1%)	1.964 (7.8%)	0.01	18651 (8.2%)	3359 (7.8%)	0.01
Use of other hypertension drugs; n (%)	1,739 (7.7%)	228 (7.8%)	0.00	5.200 (7.7%)	1,037 (6.9%)	0.03	9.777 (7.2%)	1.817 (7.2%)	0.00	16716 (7.4%)	3082 (7.2%)	0.01
Use of digoxin- United: n (%)	3,142 (13.9%)	318 (10.8%)	0.09	13,308 (19.6%)	2,168 (14.5%)	0.14	20,843 (15.3%)	2,997 (11.9%)	0.10	37293 (16.5%)	5483 (12.7%)	0.11
Use of Anti-arrhythmics: n (%)	2,154 (9.5%)	459 (15.6%)	-0.18	9,822 (14.5%)	3,029 (20.3%)	-0.15	15,578 (11.4%)	4,366 (17.3%)	-0.17	27554 (12.2%)	7854 (18.2%)	-0.17
Use of COPD/asthma meds-United; n (%)	3,022 (13.3%)	435 (14.8%)	-0.04	12,353 (18.2%)	2,900 (19.4%)	-0.13	20,518 (15.1%)	4,170 (16.5%)	-0.04	35893 (15.8%)	7505 (17.4%)	-0.04
Use of statins; n (%)	12,189 (53.8%)	1,579 (53.8%)	0.00	37,940 (56.0%)	8,310 (55.7%)	0.01	74,659 (54.9%)	14,235 (56.4%)	-0.03	124788 (55.1%)	24124 (56.0%)	-0.02
Use of other lipid-lowering drugs; n (%)	1,345 (5.9%)	221 (7.5%)	-0.06	6,440 (9.5%)	1,567 (10.5%)	-0.03	9,683 (7.1%)	2,038 (8.1%)	-0.04	17468 (7.7%)	3826 (8.9%)	-0.04
Use of antiplatelet agents; n (%)	1,466 (6.5%)	282 (9.6%)	-0.11	8,223 (12.1%)	2,505 (16.8%)	-0.13	12,346 (9.1%)	3,435 (13.6%)	-0.14	22035 (9.7%)	6222 (14.4%)	-0.14
Use of heparin and other low-molecular weight					, ,							
heparins; n (%)	501 (2.2%)	11 (0.4%)	0.16	29 (0.0%)	2 (0.0%)	#DIV/0!	5,084 (3.7%)	125 (0.5%)	0.22	5614 (2.5%)	138 (0.3%)	0.19
Use of NSAIDs; n (%)	1,606 (7.1%)	290 (9.9%)	-0.10	5,269 (7.8%)	1,572 (10.5%)	-0.09	11,395 (8.4%)	3,015 (12.0%)	-0.12	18270 (8.1%)	4877 (11.3%)	-0.11
Use of oral corticosteroids; n (%)	3,335 (14.7%)	475 (16.2%)	-0.04	12,514 (18.5%)	2,819 (18.9%)	-0.01	23,765 (17.5%)	4,688 (18.6%)	-0.03	39614 (17.5%)	7982 (18.5%)	-0.03
Use of bisphosphonate (United); n (%)	961 (4.2%)	109 (3.7%)	0.03	3,457 (5.1%)	681 (4.6%)	0.02	5,374 (3.9%)	1,024 (4.1%)	-0.01	9792 (4.3%)	1814 (4.2%)	0.00
Use of opioids- United; n (%)	4,335 (19.1%)	569 (19.4%)	-0.01	16,765 (24.7%)	3,550 (23.8%)	0.02	30,560 (22.5%)	5,619 (22.3%)	0.00	51660 (22.8%)	9738 (22.6%)	0.00
Use of antidepressants; n (%)	3,538 (15.6%)	473 (16.1%)	-0.01	12,223 (18.0%)	2,578 (17.3%)	0.02	24,350 (17.9%)	4,457 (17.7%)	0.01	40111 (17.7%)	7508 (17.4%)	0.01

								//				
Use of antipsychotics; n (%)	225 (1.0%)	25 (0.9%)	0.01	1,128 (1.7%)	168 (1.1%)	0.05	2,318 (1.7%)	392 (1.6%)	0.01	3671 (1.6%)	585 (1.4%)	0.02
Use of anticonvulsants; n (%)	2,045 (9.0%)	248 (8.4%)	0.02	6,508 (9.6%)	1,262 (8.5%)	0.04	13,821 (10.2%)	2,344 (9.3%)	0.03	22374 (9.9%)	3854 (8.9%)	0.03
Use of lithium- United; n (%)	16 (0.1%)	3 (0.1%)	0.00	46 (0.1%)	14 (0.1%)	0.00	57 (0.0%)	23 (0.1%)	-0.04	119 (0.1%)	40 (0.1%)	0.00
Use of Benzos- United; n (%)	1,463 (6.5%)	205 (7.0%)	-0.02	8,662 (12.8%)	1,940 (13.0%)	-0.01	10,944 (8.0%)	1,679 (6.7%)	0.05	21069 (9.3%)	3824 (8.9%)	0.01
Use of anxiolytics/hypnotics- United; n (%)	937 (4.1%)	184 (6.3%)	-0.10	4,377 (6.5%)	1,073 (7.2%)	-0.03	7,226 (5.3%)	1,699 (6.7%)	-0.06	12540 (5.5%)	2956 (6.9%)	-0.06
Use of dementia meds- United; n (%)	840 (3.7%)	98 (3.3%)	0.02	3,200 (4.7%)	474 (3.2%)	0.08	6,279 (4.6%)	927 (3.7%)	0.05	10319 (4.6%)	1499 (3.5%)	0.06
Use of antiparkinsonian meds- United; n (%)	492 (2.2%)	43 (1.5%)	0.05	1,880 (2.8%)	371 (2.5%)	0.02	3,833 (2.8%)	682 (2.7%)	0.01	6205 (2.7%)	1096 (2.5%)	0.01
Any use of pramlintide; n (%)	2 (0.0%)	0 (0.0%)	#DIV/0!	19 (0.0%)	8 (0.1%)	-0.04	11 (0.0%)	1 (0.0%)	#DIV/0!	32 (0.0%)	9 (0.0%)	#DIV/0!
Any use of 1st generation sulfonylureas; n (%)	1 (0.0%)	0 (0.0%)	#DIV/0!	19 (0.0%)	5 (0.0%)	#DIV/0!	10 (0.0%)	4 (0.0%)	#DIV/0!	30 (0.0%)	9 (0.0%)	0.00
Entresto (sacubitril/valsartan); n (%)	21 (0.1%)	3 (0.1%)	0.00	18 (0.0%)	2 (0.0%)	#DIV/0!	30 (0.0%)	7 (0.0%)	#DIV/0!	69 (0.0%)	12 (0.0%)	0.00
Labs										90,455	17,865	
Lab values- HbA1c (%) v3; n (%)	2,340 (10.3%)	328 (11.2%)	-0.03	682 (1.0%)	109 (0.7%)	0.03	N/A	N/A	#VALUE!	3,022 (3.3%)	437 (2.4%)	0.05
Lab values- HbA1c (%) (within 3 months) v3; n (%)	1,502 (6.6%)	212 (7.2%)	-0.02	480 (0.7%)	69 (0.5%)	0.03	N/A	N/A	#VALUE!	1,982 (2.2%)	281 (1.6%)	0.04
Lab values- HbA1c (%) (within 6 months) v3; n (%)	2,340 (10.3%)	328 (11.2%)	-0.03	682 (1.0%)	109 (0.7%)	0.03	N/A	N/A	#VALUE!	3,022 (3.3%)	437 (2.4%)	0.05
Lab values- BNP; n (%)	227 (1.0%)	28 (1.0%)	0.00	45 (0.1%)	17 (0.1%)	0.00	N/A	N/A	#VALUE!	272 (0.3%)	045 (0.3%)	0.00
Lab values- BNP (within 3 months); n (%)	165 (0.7%)	24 (0.8%)	-0.01	36 (0.1%)	14 (0.1%)	0.00	N/A	N/A	#VALUE!	201 (0.2%)	038 (0.2%)	0.00
Lab values- BNP (within 6 months); n (%)	227 (1.0%)	28 (1.0%)	0.00	45 (0.1%)	17 (0.1%)	0.00	N/A	N/A	#VALUE!	272 (0.3%)	045 (0.3%)	0.00
Lab values- BUN (mg/dl); n (%)	4,553 (20.1%)	704 (24.0%)	-0.09	559 (0.8%)	166 (1.1%)	-0.03	N/A	N/A	#VALUE!	5,112 (5.7%)	870 (4.9%)	0.04
Lab values- BUN (mg/dl) (within 3 months); n (%)	3,091 (13.6%)	479 (16.3%)	-0.08	387 (0.6%)	117 (0.8%)	-0.02	N/A	N/A	#VALUE!	3,478 (3.8%)	596 (3.3%)	0.03
Lab values- BUN (mg/dl) (within 6 months); n (%)	4,553 (20.1%)	704 (24.0%)	-0.09	559 (0.8%)	166 (1.1%)	-0.03	N/A	N/A	#VALUE!	5,112 (5.7%)	870 (4.9%)	0.04
Lab values- Creatinine (mg/dl) v2; n (%)	4,643 (20.5%)	718 (24.5%)	-0.10	577 (0.9%)	182 (1.2%)	-0.03	N/A	N/A	#VALUE!	5,220 (5.8%)	900 (5.0%)	0.04
Lab values- Creatinine (mg/dl) (within 3 months) v2;												
n (%)	3,146 (13.9%)	489 (16.7%)	-0.08	402 (0.6%)	125 (0.8%)	-0.02	N/A	N/A	#VALUE!	3,548 (3.9%)	614 (3.4%)	0.03
Lab values- Creatinine (mg/dl) (within 6 months) v2;												
n (%)	4,643 (20.5%)	718 (24.5%)	-0.10	577 (0.9%)	182 (1.2%)	-0.03	N/A	N/A	#VALUE!	5,220 (5.8%)	900 (5.0%)	0.04
Lab values- HDL level (mg/dl); n (%)	3,264 (14.4%)	532 (18.1%)	-0.10	539 (0.8%)	125 (0.8%)	0.00	N/A	N/A	#VALUE!	3,803 (4.2%)	657 (3.7%)	0.03
Lab values- HDL level (mg/dl) (within 3 months); n (%)	2,041 (9.0%)	340 (11.6%)	-0.09	367 (0.5%)	77 (0.5%)	0.00	N/A	N/A	#VALUE!	2,408 (2.7%)	417 (2.3%)	0.03
Lab values- HDL level (mg/dl) (within 6 months); n (%)	3,264 (14.4%)	532 (18.1%)	-0.10	539 (0.8%)	125 (0.8%)	0.00	N/A	N/A	#VALUE!	3,803 (4.2%)	657 (3.7%)	0.03
Lab values- LDL level (mg/dl) v2; n (%)	3,488 (15.4%)	561 (19.1%)	-0.10	689 (1.0%)	134 (0.9%)	0.01	N/A	N/A	#VALUE!	4,177 (4.6%)	695 (3.9%)	0.03
Lab values-LDL level (mg/dl) (within 3 months) v2; n												
(%)	2,174 (9.6%)	359 (12.2%)	-0.08	460 (0.7%)	83 (0.6%)	0.01	N/A	N/A	#VALUE!	2,634 (2.9%)	442 (2.5%)	0.02
Lab values-LDL level (mg/dl) (within 6 months) v2; n												
(%)	3,488 (15.4%)	561 (19.1%)	-0.10	689 (1.0%)	134 (0.9%)	0.01	N/A	N/A	#VALUE!	4,177 (4.6%)	695 (3.9%)	0.03
Lab values- NT-proBNP; n (%)	20 (0.1%)	2 (0.1%)	0.00	3 (0.0%)	0 (0.0%)	#DIV/0!	N/A	N/A	#VALUE!	23 (0.0%)	2 (0.0%)	#DIV/0!
Lab values- NT-proBNP (within 3 months); n (%)	16 (0.1%)	1 (0.0%)	0.04	2 (0.0%)	0 (0.0%)	#DIV/0!	N/A	N/A	#VALUE!	18 (0.0%)	1 (0.0%)	-
Lab values- NT-proBNP (within 6 months); n (%)	20 (0.1%)	2 (0.1%)	0.00	3 (0.0%)	0 (0.0%)	#DIV/0!	N/A	N/A	#VALUE!	23 (0.0%)	2 (0.0%)	-
Lab values-Total cholesterol (mg/dl) v2; n (%)	3,311 (14.6%)	542 (18.5%)	-0.11	560 (0.8%)	136 (0.9%)	-0.01	N/A	N/A	#VALUE!	3,871 (4.3%)	678 (3.8%)	0.03
Lab values-Total cholesterol (mg/dl) (within 3												
months) v2; n (%)	2,069 (9.1%)	346 (11.8%)	-0.09	377 (0.6%)	82 (0.5%)	0.01	N/A	N/A	#VALUE!	2,446 (2.7%)	428 (2.4%)	0.02
Lab values-Total cholesterol (mg/dl) (within 6											/	
months) v2; n (%)	3,311 (14.6%)	542 (18.5%)	-0.11	560 (0.8%)	136 (0.9%)	-0.01	N/A	N/A	#VALUE!	3,871 (4.3%)	678 (3.8%)	0.03
Lab values-Triglyceride level (mg/dl); n (%)	3,262 (14.4%)	537 (18.3%)	-0.11	535 (0.8%)	126 (0.8%)	0.00	N/A	N/A	#VALUE!	3,797 (4.2%)	663 (3.7%)	0.03
Lab values-Triglyceride level (mg/dl) (within 3	2,035 (9.0%)	343 (11.7%)	-0.09	358 (0.5%)	77 (0.5%)	0.00	N/A	N/A	#VALUE!	2,393 (2.6%)	420 (2.4%)	0.01
months); n (%)	2,035 (9.0%)	343 (11.7%)	-0.09	358 (0.5%)	77 (0.5%)	0.00	N/A	N/A	#VALUE!	2,393 (2.6%)	420 (2.4%)	0.01
Lab values-Triglyceride level (mg/dl) (within 6 months); n (%)	3,262 (14.4%)	537 (18.3%)	-0.11	535 (0.8%)	126 (0.8%)	0.00	N/A	N/A	#VALUE!	3,797 (4.2%)	663 (3.7%)	0.03
Lab result number- HbA1c (%) mean (only 2 to 20	3,202 (14.4%)	337 (18.3%)	-0.11	535 (0.8%)	120 (0.8%)	0.00	N/A	N/A	#VALUE!	3,/9/ (4.2%)	003 (3.7%)	0.03
included) v4	2,323	326		534	101		N/A	N/A		2,857	427	
mean (sd)	6.47 (1.11)	6.53 (1.34)	-0.05	6.97 (1.28)	6.79 (1.17)	0.15	N/A	N/A	#VALUE!	6.56 (1.14)	6.59 (1.30)	-0.02
	6.25 [5.80, 6.90]		-0.03			0.08		N/A	#VALUE!	6.32 (1.14)	6.35 (1.30)	-0.02
median [IQR]		6.30 [5.80, 6.91]		6.60 [6.15, 7.50]	6.50 [5.95, 7.35]		N/A	,		,		
Missing; n (%)	20,342 (89.8%)	2,610 (88.9%)	0.03	67,256 (99.2%)	14,828 (99.3%)	-0.01	N/A N/A	N/A N/A	#VALUE!	87,598 (96.8%) 272	17,438 (97.6%)	-0.05
Lab result number- BNP mean v2 mean (sd)	261.46 (277.83)	214.33 (164.51)	0.21	247.18 (218.19)	180.30 (209.53)	0.31	N/A N/A	N/A	#VALUE!	259.10 (269.51)	201.47 (184.72)	0.25
(,	198.60 [99.39, 339.40]	170.15 [69.72, 343.75]	0.21	174.00 [78.80, 330.50]	121.00 [59.00, 245.00]	0.31	N/A N/A	N/A N/A	#VALUE!	194.53 (269.51)	151.58 (184.72)	0.25
median [IQR]Missing: n (%)	22,438 (99.0%)	2,908 (99.0%)	0.12			0.25	N/A N/A	N/A N/A	#VALUE!	90,183 (99.7%)	17,820 (99.7%)	0.19
- 0, (,	22,438 (99.0%) 4,553	2,908 (99.0%) 704	0.00	67,745 (99.9%) 559	14,912 (99.9%) 166	0.00	N/A N/A	N/A N/A	#VALUE!		17,820 (99.7%)	0.00
Lab result number- BUN (mg/dl) mean v2 mean (sd)	4,553 18.85 (6.58)	17.70 (5.20)	0.19	19.96 (8.62)	18.29 (6.07)	0.22	N/A N/A	N/A N/A	#VALUE!	5,112 18.97 (6.83)	17.81 (5.38)	0.19
median [IQR]	18.00 [15.00, 22.00]	17.00 [14.00, 21.00]	0.17	18.50 [15.00, 23.00]	18.00 [14.88, 22.00]	0.22	N/A	N/A	#VALUE!	18.05 (6.83)	17.19 (5.38)	0.14
median [iQk] Missing; n (%)	18.00 [15.00, 22.00]	2,232 (76.0%)	0.17	18.50 [15.00, 23.00] 67,231 (99.2%)	14,763 (98.9%)	0.07	N/A N/A	N/A N/A	#VALUE!	85,343 (94.3%)	16,995 (95.1%)	-0.04
Lab result number- Creatinine (mg/dl) mean (only 0.1	10,112 (75.570)	2,232 (70.0%)	0.05	07,231 (33.270)	14,703 (30.3%)	0.03	N/A	N/A	#VALUE:	03,343 (34.370)	10,555 (55.1%)	-0.04
to 15 included) v3	4.611	714		571	178		N/A	N/A		5.182	892	
mean (sd)	1.01 (0.25)	0.98 (0.21)	0.13	1.05 (0.30)	0.98 (0.24)	0.26	N/A	N/A	#VALUE!	1.01 (0.26)	0.98 (0.22)	0.12
median [IQR]	0.98 [0.84, 1.14]	0.96 [0.83, 1.10]	0.09	1.00 [0.85, 1.18]	0.96 [0.80, 1.13]	0.15	N/A	N/A	#VALUE!	0.98 (0.26)	0.96 (0.22)	0.08
Missing; n (%)	18,054 (79.7%)	2,222 (75.7%)	0.10	67,219 (99.2%)	14,751 (98.8%)	0.04	N/A	N/A	#VALUE!	85,273 (94.3%)	16,973 (95.0%)	-0.03
Lab result number- HDL level (mg/dl) mean (only	20,034 (73.7%)	2,222 (13.1/0)	0.10	5,,215(55,270)	1-,/31 (30.070)	0.04	IV/A	13/5	ALUE:	05,275 (54.570)	10,075(00.000)	-0.03
=<5000 included) v2	3.264	532		539	125		N/A	N/A		3.803	657	
mean (sd)	51.06 (16.33)	52.25 (17.04)	-0.07	45.82 (14.49)	48.92 (17.38)	-0.19	N/A	N/A	#VALUE!	50.32 (16.08)	51.62 (17.12)	-0.08
median (IOR)	48.00 [40.00, 60.00]	49.00 [41.00, 61.00]	-0.06	44.00 [37.00, 53.00]	48.00 [36.75, 60.00]	-0.25	N/A	N/A	#VALUE!	47.43 (16.08)	48.81 (17.12)	-0.08
Missing; n (%)	19,401 (85.6%)	2,404 (81.9%)	0.10	67,251 (99.2%)	14,804 (99.2%)	0.00	N/A	N/A	#VALUE!	86,652 (95.8%)	17,208 (96.3%)	-0.03
Lab result number-LDL level (mg/dl) mean (only		_, 10 1 (01.570)	0.10	,-51 (55.270)	,554 (55.270)	0.00	, ^	,		,-52 (55.670)	,_00 (50.570)	0.03
=<5000 included) v2	3,405	545		552	128		N/A	N/A		3,957	673	
mean (sd)	86.00 (31.67)	87.70 (33.74)	-0.05	84.18 (33.47)	82.01 (35.36)	0.06	N/A	N/A	#VALUE!	85.75 (31.93)	86.62 (34.08)	-0.03
median [IQR]	82.00 [65.00, 104.00]	82.00 [66.00, 109.00]	0.00	81.00 [62.25, 101.00]	81.00 [59.00, 102.75]	0.00	N/A	N/A	#VALUE!	81.86 (31.93)	81.81 (34.08)	0.00
Missing; n (%)	19,260 (85.0%)	2,391 (81.4%)	0.10	67,238 (99.2%)	14,801 (99.1%)	0.01	N/A	N/A	#VALUE!	86,498 (95.6%)	17,192 (96.2%)	-0.03
			0.10	,(/0)	,501 (55.170)	0.01	.,,,	,		, .50 (55.070)	,(50.270)	0.03
	.,,											
Lab result number-Total cholesterol (mg/dl) mean (only =<5000 included) v2	3,310	542		560	136		N/A	N/A		3,870	678	
(only =<5000 included) v2mean (sd)		542 165.20 (40.26)	-0.05	560 157.07 (40.57)	136 160.25 (40.19)	-0.08	N/A N/A	N/A N/A	#VALUE!	3,870 162.25 (39.98)	678 164.21 (40.28)	-0.05

median (IOR)	159.00 [137.00. 186.00]	159.50 [138.00, 192.00]	-0.01	155.00 [132.00, 177.00]	160.50 [137.25, 183.38]	-0.14	N/A	N/A	#VALUE!	158.42 (39.98)	159.70 (40.28)	-0.03
Missing; n (%)	19,355 (85.4%)	2,394 (81.5%)	0.11	67,230 (99.2%)	14,793 (99.1%)	0.01	N/A	N/A	#VALUE!	86,585 (95.7%)	17,187 (96.2%)	-0.03
Lab result number-Triglyceride level (mg/dl) mean												
(only =<5000 included) v2	3,262	537		535	126		N/A	N/A		3,797	663	
mean (sd)	129.05 (78.48)	121.50 (66.86)	0.10	139.12 (74.65)	141.59 (94.40)	-0.03	N/A	N/A	#VALUE!	130.47 (77.96)	125.32 (72.93)	0.07
median [IQR] Missing; n (%)	111.00 [82.00, 156.00] 19,403 (85.6%)	107.00 [77.50, 145.00] 2,399 (81.7%)	0.05 0.11	122.00 [88.00, 175.00] 67,255 (99.2%)	125.50 [89.38, 157.38] 14.803 (99.2%)	-0.04 0.00	N/A N/A	N/A N/A	#VALUE! #VALUE!	112.55 (77.96) 86,658 (95.8%)	110.52 (72.93) 17,202 (96.3%)	0.03 -0.03
Lab result number- Hemoglobin mean (only >0	15,403 (63.0%)	2,333 (61.7%)	0.11	07,233 (55.270)	14,803 (55.2%)	0.00	N/A	N/A	#VALUE:	80,038 (33.8%)	17,202 (90.5%)	*0.03
included)	3,295	521		359	114		N/A	N/A		3,654	635	
mean (sd)	13.87 (1.59)	14.08 (1.40)	-0.14	13.42 (1.59)	13.63 (2.34)	-0.10	N/A	N/A	#VALUE!	13.83 (1.59)	14.00 (1.61)	-0.11
median [IQR]	13.90 [12.90, 14.90]	14.00 [13.20, 15.00]	-0.07	13.50 [12.40, 14.40]	13.95 [12.94, 15.00]	-0.22	N/A	N/A	#VALUE!	13.86 (1.59)	13.99 (1.61)	-0.08
Missing; n (%)	19,370 (85.5%)	2,415 (82.3%)	0.09	67,431 (99.5%)	14,815 (99.2%)	0.04	N/A	N/A	#VALUE!	86,801 (96.0%)	17,230 (96.4%)	-0.02
Lab result number- Serum sodium mean (only > 90 and < 190 included)	4,380	685		456	142		N/A	N/A		4,836	827	
mean (sd)	140.12 (2.88)	140.14 (3.00)	-0.01	139.70 (2.75)	139.32 (2.94)	0.13	N/A	N/A	#VALUE!	140.08 (2.87)	140.00 (2.99)	0.03
median [IQR]		140.00 [139.00, 142.00]	0.00	140.00 [138.00, 141.00]		0.24	N/A	N/A	#VALUE!	140.00 (2.87)	139.88 (2.99)	0.04
Missing; n (%)	18,285 (80.7%)	2,251 (76.7%)	0.10	67,334 (99.3%)	14,787 (99.0%)	0.03	N/A	N/A	#VALUE!	85,619 (94.7%)	17,038 (95.4%)	-0.03
Lab result number- Albumin mean (only >0 and <=10												
included)	3,911	632	0.45	366	120	0.00	N/A	N/A	#VALUE!	4,277	752	0.43
mean (sd)	4.14 (0.32)	4.19 (0.31)	-0.16	4.05 (0.49)	4.06 (0.47)	-0.02	N/A	N/A		4.13 (0.34)	4.17 (0.34)	-0.12
median [IQR] Missing; n (%)	4.15 [3.95, 4.35] 18,754 (82.7%)	4.20 [4.00, 4.40] 2,304 (78.5%)	-0.16 0.11	4.10 [3.85, 4.30] 67,424 (99.5%)	4.10 [3.90, 4.30] 14,809 (99.2%)	0.00 0.04	N/A N/A	N/A N/A	#VALUE! #VALUE!	4.15 (0.34) 86,178 (95.3%)	4.18 (0.34) 17,113 (95.8%)	-0.09 -0.02
Lab result number- Glucose (fasting or random) mean	10,754 (02.770)	2,304 (70.370)	0.11	07,424 (55.570)	14,005 (55.270)	0.04	11/1	14/0	#VALUE:	80,176 (55.576)	17,113 (33.070)	-0.02
(only 10-1000 included)	4,320	676		439	130		N/A	N/A		4,759	806	
mean (sd)	109.88 (33.22)	111.68 (39.94)	-0.05	130.34 (49.02)	127.55 (43.03)	0.06	N/A	N/A	#VALUE!	111.77 (34.98)	114.24 (40.48)	-0.07
median [IQR]	101.00 [91.00, 118.00]	100.17 [91.00, 116.88]	0.02	116.50 [98.00, 148.00]		0.04	N/A	N/A	#VALUE!	102.43 (34.98)	102.48 (40.48)	0.00
Missing; n (%)	18,345 (80.9%)	2,260 (77.0%)	0.10	67,351 (99.4%)	14,799 (99.1%)	0.03	N/A	N/A	#VALUE!	85,696 (94.7%)	17,059 (95.5%)	-0.04
Lab result number- Potassium mean (only 1-7	4.010			550	454		A-/-	A1/c		E 460	075	
included) mean (sd)	4,610 4.35 (0.44)	711 4.38 (0.44)	-0.07	552 4.33 (0.43)	164 4.37 (0.38)	-0.10	N/A N/A	N/A N/A	#VALUE!	5,162 4.35 (0.44)	875 4.38 (0.43)	-0.07
median [IQR]	4.30 [4.10, 4.60]	4.40 [4.10, 4.60]	-0.23	4.30 [4.10, 4.60]	4.40 [4.15, 4.60]	-0.10	N/A	N/A	#VALUE!	4.30 (0.44)	4.40 (0.43)	-0.23
Missing; n (%)	18,055 (79.7%)	2,225 (75.8%)	0.09	67,238 (99.2%)	14,765 (98.9%)	0.03	N/A	N/A	#VALUE!	85,293 (94.3%)	16,990 (95.1%)	-0.04
Comorbidity Scores	-,,	, ., ,		.,,.,	,,		•	•		, , ,	.,,	
CCI (180 days)-ICD9 and ICD10 v2												
mean (sd)	2.62 (1.44)	2.62 (1.34)	0.00	2.78 (1.68)	2.79 (1.56)	-0.01	1.42 (1.41)	1.32 (1.38)	0.07	1.95 (1.50)	1.92 (1.44)	0.02
median [IQR]	2.00 [2.00, 3.00]	2.00 [2.00, 3.00]	0.00	2.00 [2.00, 4.00]	2.00 [2.00, 4.00]	0.00	1.00 [0.00, 2.00]		0.00	1.40 (1.50)	1.41 (1.44)	-0.01
Non-Frailty; n (%)	12,577 (55.5%)	1,612 (54.9%)	0.01	33,237 (49.0%)	7,284 (48.8%)	0.00	3,400 (2.5%)	524 (2.1%)	0.03	49,214 (21.7%)	9,420 (21.9%)	0.00
Frailty Score (mean): Empirical Version 365 days, v2mean (sd)	0.17 (0.04)	0.17 (0.04)	0.00	0.18 (0.05)	0.17 (0.05)	0.20	12.15 (9.76)	10.54 (9.32)	0.17	7.37 (7.56)	6.24 (7.13)	0.15
median [IQR]	0.16 [0.14, 0.19]	0.16 [0.14, 0.19]	0.00	0.17 [0.15, 0.21]	0.17 (0.03)	0.20	10.13 [5.57, 16.45]		0.17	6.15 (7.56)	5.19 (7.13)	0.13
Healthcare Utilization	0.10 [0.14, 0.15]	0.10 [0.14, 0.15]	0.00	0.17 [0.13, 0.21]	0.10 [0.14, 0.15]	0.20	10.13 [5.57, 10.45]	0.75 [4.25, 14.71]	0.14	0.13 (7.30)	3.13 (7.13)	0.13
Any hospitalization; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	17,074 (25.2%)	4,804 (32.2%)	-0.16	19,589 (14.4%)	4,815 (19.1%)	-0.13	36,663 (16.2%)	9,619 (22.3%)	-0.16
Any hospitalization within prior 30 days; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	9,626 (14.2%)	3,296 (22.1%)	-0.21	11,829 (8.7%)	2,910 (11.5%)	-0.09	21455 (9.5%)	6206 (14.4%)	-0.15
Any hospitalization during prior 31-180 days; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	8,232 (12.1%)	1,717 (11.5%)	0.02	8,606 (6.3%)	2,082 (8.3%)	-0.08	16838 (7.4%)	3799 (8.8%)	-0.05
Endocrinologist Visit; n (%)	436 (1.9%)	84 (2.9%)	-0.07	1,932 (2.8%)	501 (3.4%)	-0.03	4,050 (3.0%)	874 (3.5%)	-0.03	6418 (2.8%)	1459 (3.4%)	-0.03
Endocrinologist Visit (30 days prior); n (%)	139 (0.6%)	21 (0.7%)	-0.01	633 (0.9%)	176 (1.2%)	-0.03	1,150 (0.8%)	276 (1.1%)	-0.03	1922 (0.8%)	473 (1.1%)	-0.03
Endocrinologist Visit (31 to 180 days prior); n (%)	381 (1.7%)	72 (2.5%)	-0.06	1,650 (2.4%)	413 (2.8%)	-0.03	3,536 (2.6%)	755 (3.0%)	-0.02	5567 (2.5%)	1240 (2.9%)	-0.02
Internal medicine/family medicine visits; n (%) Internal medicine/family medicine visits (30 days	19,784 (87.3%)	2,435 (82.9%)	0.12	52,971 (78.1%)	11,827 (79.2%)	-0.03	108,913 (80.0%)	20,381 (80.8%)	-0.02	181668 (80.2%)	34643 (80.4%)	-0.01
prior) v2; n (%)	13,564 (59.8%)	1,529 (52.1%)	0.16	33,572 (49.5%)	7,777 (52.1%)	-0.05	68,566 (50.4%)	12,510 (49.6%)	0.02	115702 (51.1%)	21816 (50.6%)	0.01
Internal medicine/family medicine visits (31 to 180	,,	_,=== (==:=:-,		,(,	.,(=====,		,(,,	,,				
days prior) v2; n (%)	17,797 (78.5%)	2,119 (72.2%)	0.15	48,286 (71.2%)	10,294 (69.0%)	0.05	95,817 (70.4%)	17,389 (68.9%)	0.03	161900 (71.5%)	29802 (69.2%)	0.05
Cardiologist visit; n (%)	11,235 (49.6%)	1,976 (67.3%)	-0.37	35,004 (51.6%)	9,003 (60.3%)	-0.18	85,057 (62.5%)	19,330 (76.6%)	-0.31	131296 (58.0%)	30309 (70.3%)	-0.26
Number of Cardiologist visits (30 days prior); n (%)	6,801 (30.0%)	1,379 (47.0%)	-0.35	20,128 (29.7%)	6,908 (46.3%)	-0.35	53,448 (39.3%)	14,249 (56.5%)	-0.35	80377 (35.5%)	22536 (52.3%)	-0.34
Number of Cardiologist visits (31 to 180 days prior); n (%)	8.195 (36.2%)	1,255 (42.7%)	-0.13	27,617 (40.7%)	5,842 (39.1%)	0.03	61,773 (45.4%)	12.141 (48.1%)	-0.05	97585 (43.1%)	19238 (44.6%)	-0.03
Electrocardiogram v2; n (%)	11,225 (49.5%)	2,064 (70.3%)	-0.13	39,015 (57.6%)	11,173 (74.8%)	-0.37	77,673 (57.1%)	12,141 (48.1%)	-0.05	127913 (56.5%)	32671 (75.8%)	-0.42
Use of glucose test strips; n (%)	176 (0.8%)	33 (1.1%)	-0.43	475 (0.7%)	11,173 (74.8%)	-0.01	1,262 (0.9%)	261 (1.0%)	-0.43	1913 (0.8%)	407 (0.9%)	-0.01
Dialysis; n (%)	4 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	4 (0.0%)	0 (0.0%)	#DIV/0!	8 (0.0%)	0 (0.0%)	#DIV/0!
number of different/distinct medication												
prescriptions												
mean (sd)	7.72 (3.82)	8.13 (4.07)	-0.10	9.26 (4.52)	9.27 (4.58)	0.00	8.30 (3.85)	8.59 (4.06)	-0.07	8.53 (4.06)	8.79 (4.25)	0.00
median [IQR] Number of Hospitalizations	7.00 [5.00, 10.00]	8.00 [5.00, 10.00]	-0.25	9.00 [6.00, 12.00]	9.00 [6.00, 12.00]	0.00	8.00 [6.00, 10.00]	8.00 [6.00, 11.00]	0.00	5.79 (4.76)	6.43 (4.80)	0.00
mean (sd)	0.00 (0.00)	0.00 (0.00)	#DIV/0!	0.28 (0.51)	0.35 (0.55)	-0.13	0.16 (0.43)	0.21 (0.47)	-0.11	0.18 (0.43)	0.24 (0.48)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	#DIV/0!	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 0.00]		0.00	0.00 (0.52)	0.00 (0.55)	0.00
Number of hospital days	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]		0.00 (0.00, 1.00)	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.52)	0.00 (0.55)	0.00
mean (sd)	0.00 (0.11)	0.00 (0.00)	0.00	1.61 (4.76)	1.50 (3.28)	0.03	0.80 (2.85)	0.85 (2.46)	-0.02	0.96 (3.41)	1.02 (2.70)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 2.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (4.30)	0.00 (3.14)	0.00
Number of Emergency Department (ED) visits v3												
mean (sd)	0.33 (0.88)	0.42 (1.03)	-0.09	0.38 (1.65)	0.45 (1.73)	-0.04	0.57 (1.27)	0.63 (1.27)	-0.05	0.49 (1.36)	0.55 (1.43)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	U.00 [0.00, 1.00]	0.00	0.00 (1.64)	0.00 (1.66)	0.00
Number of Office visits mean (sd)	5.17 (4.16)	5.24 (3.67)	-0.02	6.39 (5.10)	5.79 (4.33)	0.13	11.99 (11.24)	11.79 (10.20)	0.02	9.63 (9.24)	9.27 (8.27)	0.00
median [IQR]	4.00 [2.00, 7.00]	4.00 [3.00, 7.00]	0.02	5.00 [3.00, 9.00]	5.00 [3.00, 8.00]	0.13	9.00 [4.00, 16.00]	,	0.02	4.59 (9.66)	5.12 (8.53)	0.00
Number of Endocrinologist visits			3.30	2.23 [3.00, 3.00]	2.22 [5.00, 6.00]	0.00	2.22 [00, 20.00]	[, 10.00]	0.00	(5.00)	3.12 (0.33)	0.00
mean (sd)	0.07 (0.76)	0.11 (1.08)	-0.04	0.11 (0.99)	0.11 (0.87)	0.00	0.13 (1.28)	0.17 (1.51)	-0.03	0.12 (1.16)	0.15 (1.29)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]		0.00	0.00 (1.28)	0.00 (1.36)	0.00

Number of internal medicine/family medicine visits												
mean (sd)	10.57 (13.09)	8.08 (12.69)	0.19	7.44 (10.97)	6.42 (9.19)	0.10	7.40 (9.26)	6.44 (7.85)	0.11	7.73 (10.23)	6.54 (8.74)	0.00
median [IQR]	6.00 [2.00, 15.00]	4.00 [1.00, 10.00]	0.16	4.00 [1.00, 10.00]	4.00 [1.00, 8.00]	0.00	4.00 [1.00, 10.00]	4.00 [1.00, 9.00]	0.00	2.99 (11.87)	3.04 (9.82)	0.00
Number of Cardiologist visits												
mean (sd)	2.53 (4.49)	3.44 (4.50)	-0.20	3.04 (5.45)	3.42 (5.10)	-0.07	3.93 (6.21)	4.80 (5.92)	-0.14	3.52 (5.84)	4.23 (5.56)	0.00
median [IQR]	0.00 [0.00, 3.00]	2.00 [0.00, 5.00]	-0.44	1.00 [0.00, 4.00]	2.00 [0.00, 5.00]	-0.19	2.00 [0.00, 5.00]	3.00 [1.00, 7.00]	-0.16	0.90 (6.56)	1.87 (6.09)	0.00
Number electrocardiograms received v2	0.05 (4.50)	4 54 (4 07)	0.20	4.25 (4.02)	4 70 (4 00)	0.20	4 24 (4 50)	4 00 (4 05)	0.25	4 22 (4 24)	4.04 (4.05)	0.00
mean (sd) median (IQR)	0.96 (1.50) 0.00 (0.00, 1.00)	1.61 (1.87) 1.00 [0.00, 2.00]	-0.38 -0.59	1.26 (1.82) 1.00 [0.00, 2.00]	1.79 (1.99) 1.00 [0.00, 2.00]	-0.28 0.00	1.24 (1.68) 1.00 [0.00, 2.00]	1.89 (1.96)	-0.36 0.00	1.22 (1.71) 0.60 (1.98)	1.84 (1.96) 0.76 (2.19)	0.00
median [iQK] Number of HbA1c tests ordered	0.00 [0.00, 1.00]	1.00 [0.00, 2.00]	-0.59	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0.00	1.00 [0.00, 2.00]	1.00 [1.00, 3.00]	0.00	0.60 (1.98)	0.76 (2.19)	0.00
mean (sd)	0.36 (0.67)	0.39 (0.70)	-0.04	0.14 (0.45)	0.16 (0.48)	-0.04	0.37 (0.69)	0.41 (0.72)	-0.06	0.30 (0.63)	0.32 (0.65)	0.00
median (IOR)	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]		0.00	0.00 (0.67)	0.00 (0.69)	0.00
Number of glucose tests ordered	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (0.07)	0.00 (0.03)	0.00
mean (sd)	0.11 (0.90)	0.16 (0.94)	-0.05	0.10 (0.54)	0.11 (0.58)	-0.02	0.11 (0.52)	0.13 (0.49)	-0.04	0.11 (0.58)	0.13 (0.56)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]		0.00	0.00 (0.65)	0.00 (0.63)	0.00
Number of lipid tests ordered												
mean (sd)	0.59 (0.80)	0.69 (0.85)	-0.12	0.22 (0.62)	0.26 (0.68)	-0.06	0.59 (0.71)	0.70 (0.75)	-0.15	0.48 (0.69)	0.55 (0.73)	0.00
median [IQR]	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-1.21	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-1.37	0.00 (0.77)	0.41 (0.81)	-0.01
Number of creatinine tests ordered												
mean (sd)	0.06 (0.32)	0.07 (0.32)	-0.03	0.07 (0.41)	0.05 (0.27)	0.06	0.09 (0.38)	0.09 (0.37)	0.00	0.08 (0.38)	0.07 (0.34)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.44)	0.00 (0.36)	0.00
Number of BUN tests ordered												
mean (sd)	0.03 (0.24)	0.05 (0.25)	-0.08	0.04 (0.31)	0.03 (0.23)	0.04	0.05 (0.29)	0.06 (0.28)	-0.04	0.05 (0.29)	0.05 (0.26)	0.00
median [IQR] Number of tests for microalbuminuria	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.34)	0.00 (0.28)	0.00
mean (sd)	0.18 (0.61)	0.19 (0.64)	-0.02	0.06 (0.36)	0.08 (0.39)	-0.05	0.10 (0.37)	0.12 (0.39)	-0.05	0.10 (0.40)	0.11 (0.41)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.02	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	,	0.00 [0.00, 0.00]	0.00	0.00 (0.44)	0.00 (0.41)	0.00
Total N distinct ICD9/ICD10 diagnoses at the 3rd	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.44)	0.00 (0.43)	0.00
digit level Copy												
mean (sd)	3.20 (4.99)	3.00 (5.09)	0.04	2.23 (5.06)	2.21 (4.86)	0.00	3.88 (6.40)	3.93 (6.39)	-0.01	3.32 (5.90)	3.27 (5.82)	0.00
median [IQR]	0.00 [0.00, 5.00]	0.00 [0.00, 5.00]	0.00	0.00 [0.00, 2.00]	0.00 [0.00, 2.00]	0.00	0.00 [0.00, 6.00]	0.00 [0.00, 6.00]	0.00	0.00 (6.52)	0.00 (6.28)	0.00
For PS												
Hemorrhagic stroke+Other cerebrovascular												
disease+Cerebrovascular procedure (for PS); n (%)	392 (1.7%)	56 (1.9%)	-0.02	1,508 (2.2%)	344 (2.3%)	-0.01	2,242 (1.6%)	461 (1.8%)	-0.02	4142 (1.8%)	861 (2.0%)	-0.01
Occurrence of creatinine tests ordered (for PS): n (%)	1.003 (4.4%)	167 (5.7%)	-0.06	3.079 (4.5%)	535 (3.6%)	0.05	9.217 (6.8%)	1.813 (7.2%)	-0.02	13299 (5.9%)	2515 (5.8%)	0.00
Occurrence of BUN tests ordered (for PS); n (%)	611 (2.7%)	112 (3.8%)	-0.06	1,812 (2.7%)	365 (2.4%)	0.03	5,615 (4.1%)	1,169 (4.6%)	-0.02	8038 (3.5%)	1646 (3.8%)	-0.02
Occurrence of chronic renal insufficiency w/o CKD	011 (2.7%)	112 (3.0%)	-0.00	1,012 (2.770)	303 (2.4%)	0.02	3,013 (4.1%)	1,109 (4.0%)	-0.02	8038 (3.3%)	1040 (3.8%)	*0.02
(for PS) v2: n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Chronic kidney disease Stage 1-2 (for PS); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0	0	#VALUE!	#VALUE!	#VALUE!	#VALUE!
			•									
Chronic kidney disease Stage 3-6 (for PS); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%)	0 (0.0%) 187 (0.8%)	0 (0.0%) 36 (1.2%)	#DIV/0! -0.04	0 (0.0%) 861 (1.3%)	0 (0.0%) 245 (1.6%)	#DIV/0! -0.03	0 (0.0%) 1,494 (1.1%)	0 (0.0%) 311 (1.2%)	#DIV/0! -0.01	0 (0.0%) 2542 (1.1%)	0 (0.0%) 592 (1.4%)	#DIV/0! -0.03
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory												
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with	187 (0.8%)	36 (1.2%)	-0.04	861 (1.3%)	245 (1.6%)	-0.03	1,494 (1.1%)	311 (1.2%)	-0.01	2542 (1.1%)	592 (1.4%)	-0.03
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%)												
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or	187 (0.8%) 601 (2.7%)	36 (1.2%) 51 (1.7%)	0.07	861 (1.3%) 1,554 (2.3%)	245 (1.6%) 285 (1.9%)	-0.03	1,494 (1.1%) 3,124 (2.3%)	311 (1.2%) 485 (1.9%)	-0.01	2542 (1.1%) 5279 (2.3%)	592 (1.4%) 821 (1.9%)	-0.03
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene+Ostenowylitis(for PS) v3 with ICDIO Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%)	187 (0.8%)	36 (1.2%)	-0.04	861 (1.3%)	245 (1.6%)	-0.03	1,494 (1.1%)	311 (1.2%)	-0.01	2542 (1.1%)	592 (1.4%)	-0.03
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Kangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic	187 (0.8%) 601 (2.7%)	36 (1.2%) 51 (1.7%)	0.07	861 (1.3%) 1,554 (2.3%)	245 (1.6%) 285 (1.9%)	-0.03	1,494 (1.1%) 3,124 (2.3%)	311 (1.2%) 485 (1.9%)	-0.01	2542 (1.1%) 5279 (2.3%)	592 (1.4%) 821 (1.9%)	-0.03
Bladder stones-Kitidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous	187 (0.8%) 601 (2.7%)	36 (1.2%) 51 (1.7%)	0.07	861 (1.3%) 1,554 (2.3%)	245 (1.6%) 285 (1.9%)	-0.03	1,494 (1.1%) 3,124 (2.3%)	311 (1.2%) 485 (1.9%)	-0.01	2542 (1.1%) 5279 (2.3%)	592 (1.4%) 821 (1.9%)	-0.03
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene-Ostemyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation	187 (0.8%) 601 (2.7%)	36 (1.2%) 51 (1.7%)	0.07	861 (1.3%) 1,554 (2.3%)	245 (1.6%) 285 (1.9%)	-0.03	1,494 (1.1%) 3,124 (2.3%)	311 (1.2%) 485 (1.9%)	-0.01	2542 (1.1%) 5279 (2.3%)	592 (1.4%) 821 (1.9%)	-0.03
Bladder stones-Kitidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous	187 (0.8%) 601 (2.7%) 0 (0.0%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%)	-0.04 0.07 #DIV/0! 0.00	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%)	245 (1.6%) 285 (1.9%) 0 (0.0%)	-0.03 0.03 #DIV/0!	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%)	311 (1.2%) 485 (1.9%) 0 (0.0%)	-0.01 0.03 #DIV/0!	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%)	-0.03 0.03 #DIV/0!
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations*-Retinal detachment, vitreous hemorrhage, vitrectomy*-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders*-Other CVD (for PS) v2 Copy; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%)	36 (1.2%) 51 (1.7%) 0 (0.0%)	-0.04 0.07 #DIV/0!	861 (1.3%) 1,554 (2.3%) 0 (0.0%)	245 (1.6%) 285 (1.9%) 0 (0.0%)	-0.03 0.03 #DIV/0!	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%)	311 (1.2%) 485 (1.9%) 0 (0.0%)	-0.01 0.03 #DIV/0!	2542 (1.1%) 5279 (2.3%) 0 (0.0%)	592 (1.4%) 821 (1.9%) 0 (0.0%)	-0.03 0.03 #DIV/0!
Bladder stones-Kildney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitre-tomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-other CVU (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) +	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%)	-0.04 0.07 #DIV/0! 0.00 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%)	-0.03 0.03 #DIV/0! 0.02 -0.03	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%)	-0.01 0.03 #DIV/0! 0.00 -0.02	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%)	-0.03 0.03 #DIV/0! 0.00 -0.05
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%)	-0.04 0.07 #DIV/0! 0.00	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%)	245 (1.6%) 285 (1.9%) 0 (0.0%)	-0.03 0.03 #DIV/0!	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%)	311 (1.2%) 485 (1.9%) 0 (0.0%)	-0.01 0.03 #DIV/0!	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%)	-0.03 0.03 #DIV/0!
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations*Retinal detachment, vitreous hemorrhage, vitrectomy*Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders*Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%)	-0.04 0.07 #DIV/0! 0.00 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%)	-0.03 0.03 #DIV/0! 0.02 -0.03 -0.03	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%)	-0.03 0.03 #DIV/0! 0.00 -0.05 -0.06
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene+Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atheroscierosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%)	0.04 0.07 #DIV/0! 0.00 -0.03 -0.02	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%)	-0.03 0.03 #DIV/0! 0.02 -0.03 -0.03	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%)	-0.03 0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene+Ostemyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA for Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%)	-0.04 0.07 #DIV/0! 0.00 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%)	-0.03 0.03 #DIV/0! 0.02 -0.03 -0.03	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%)	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 0.02	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%)	-0.03 0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.03
Bladder stones-Kildney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 0.02 -0.01 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%)	-0.03 0.03 #DIV/01 0.02 -0.03 -0.03 0.00 0.07 0.00	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (33.7%) 551 (1.3%) 151 (0.4%)	-0.03 0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene+Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS)v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of AGIs (for PS); n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%) 17 (0.1%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 0.02 -0.01 0.03 0.00	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%)	-0.03 0.03 #DIV/0! 0.02 -0.03 -0.03 0.00 0.07	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 151 (0.4%) 62 (0.1%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.03 -0.02 0.00
Bladder stones-Kildney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 0.02 -0.01 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%)	-0.03 #DIV/0! 0.02 -0.03 -0.03 0.00 0.07 0.00 -0.03	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%)	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (33.7%) 551 (1.3%) 151 (0.4%)	-0.03 0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.03 -0.02
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders*Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA for Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitnides (for PS); n (%) Any use of Meglitnides (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 -0.01 0.03 0.00 #DIV/01	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (1.0%) 44,683 (65.9%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 0 (0.0%) 1,623 (10.9%) 10,110 (67.7%)	-0.03 #DIV/01 0.02 -0.03 -0.03 -0.00 0.07 0.00 -0.03 #DIV/01	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 0 (0.0%) 3,212 (12.7%) 16,625 (56.9%)	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 0.02 0.00 #DIV/01 -0.01 -0.03	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 145908 (64.4%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 558 (13.7%) 551 (1.3%) 151 (0.4%) 62 (0.1%) 0 (0.0%) 5177 (12.0%) 28555 (66.3%)	-0.03 #DIV/01 0.00 -0.05 -0.06 -0.01 0.03 -0.02 0.00 #DIV/01 0.00 -0.04
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelits(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitre-tomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of AGIs (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of thiazide- United; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,075 (36.6%)	-0.04 0.07 #DIV/0! 0.00 -0.03 -0.02 -0.01 -0.03 -0.00 #DIV/0! 0.02 -0.01 -0.03 -0.00 -0.00	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (55.9%) 24,743 (36.5%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 1,623 (10.9%) 1,0110 (67.7%) 5,699 (8.2%)	-0.03 #DIV/0! 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0!	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 48,655 (35.8%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0(0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/0! -0.01 -0.03	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.1%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 145908 (64.4%) 81135 (35.8%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 151 (0.4%) 62 (0.1%) 0 (0.0%) 5177 (12.0%) 28555 (66.3%) 16552 (38.6%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.03 #DIV/0! #DIV/0! -0.00 -0.04 -0.04
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Koangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of AGIs (for PS); n (%) Any use of AGIs (for PS); n (%) Use of thiadied- United; n (%) Use of thaidade- United; n (%) Use of calcium channel blockers; n (%) All antidiabetic medications except insulin; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,075 (36.6%) 615 (20.9%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 0.02 -0.01 0.03 -0.00 #DIV/01 -0.03 -0.05 -0.07	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 0 (0.0%) 1,623 (0.9%) 10,110 (67.7%) 5,699 (38.2%) 2,931 (19.6%)	-0.03 #DIV/0! 0.02 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0!	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 87,512 (64.3%) 48,655 (35.8%) 25,209 (18.5%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/0! -0.01 -0.03 -0.07 -0.04	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 3591 (1.6%) 8 (0.0%) 2710 (12.0%) 145908 (64.4%) 81135 (35.8%) 41628 (18.4%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 62 (0.1%) 0 (0.0%) 5177 (12.0%) 28555 (66.3%) 1652 (38.6%) 8628 (20.0%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.03 +0.02 0.00 #DIV/0! 0.00 -0.04 -0.04 -0.04
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Kangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Eardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Mcglitrinides (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3 6 + dialysis (for PS); n (%) Use of the blockers; n (%) Use of beta blockers; n (%) Use of beta blockers; n (%) All antidiabetic medications except Insulin; n (%) DM Medications - Insulin (Copy; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 -0.01 0.03 0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 0 (0.0%) 1,623 (10.9%) 10,110 (67.7%) 5,699 (38.2%) 2,931 (19.6%) 795 (5.3%)	-0.03 #DIV/01 0.02 -0.03 -0.03 -0.00 -0.07 -0.00 -0.03 #DIV/01 -0.00 -0.04 -0.04 -0.04 -0.04	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 4 (0.0%) 16,971 (12.5%) 47,512 (64.3%) 48,655 (35.8%) 25,209 (18.5%) 5,129 (3.8%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%)	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 0.02 0.00 #DIV/01 -0.01 -0.03 -0.07 -0.04 0.01	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 145908 (6.4%) 81135 (35.8%) 41628 (18.4%) 9881 (4.4%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 151 (0.4%) 0 (0.0%) 5177 (12.0%) 28555 (66.3%) 16652 (38.6%) 8628 (20.0%) 1849 (4.3%)	-0.03 #DIV/01 0.00 -0.05 -0.06 -0.01 0.03 -0.02 0.00 #DIV/01 0.00 -0.04 -0.06 -0.04 -0.06
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteromyleitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of thiazide- United; n (%) Use of beta blockers; n (%) All antidiabetic medications except Insulin; n (%) DM Medications - Insulin Copy; n (%) Use of Low Intensity Statins; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 18 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 8,138 (35.9%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%) 964 (22.8%)	-0.04 0.07 #DIV/0I 0.00 -0.03 -0.02 0.02 -0.01 0.03 0.00 #DIV/0I 0.02 -0.03 -0.05 -0.07	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 28 (0.2%) 0 (0.0%) 1,623 (10.9%) 10,110 (67.7%) 2,931 (19.6%) 795 (5.3%) 4,901 (22.8%)	-0.03 #DIV/0! 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0! 0.00 -0.04 -0.04 0.02 0.05	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 25,209 (18.5%) 5,129 (3.8%) 48,9521 (35.9%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/0! -0.01 -0.03 -0.07 -0.04 0.01 0.02	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3551 (1.6%) 3591 (0.1%) 8 (0.0%) 27210 (12.0%) 145908 (64.4%) 81135 (35.8%) 41628 (18.4%) 9881 (4.4%) 9881 (4.4%) 9881 (4.4%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (33.7%) 551 (1.3%) 551 (1.3%) 62 (0.1%) 0 (0.0%) 5177 (12.0%) 28555 (66.3%) 16502 (38.6%) 8628 (20.0%) 1849 (4.3%) 14719 (34.2%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 -0.02 0.00 #DIV/0! -0.06 -0.04 -0.06 -0.04 -0.06 -0.04 -0.00 0.03
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Koangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitimides (for PS); n (%) Any use of Meglitimides (for PS); n (%) Use of thaide-United; n (%) Use of thaide-United; n (%) Use of beta blockers; n (%) All antidiabetic medications except insulin; n (%) DM Medications - insulin Copy; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 8,138 (35.9%) 4,085 (18.0%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,075 (86.6%) 615 (20.9%) 128 (4.4%) 964 (32.8%) 619 (21.1%)	-0.04 0.07 #DIV/0! 0.00 -0.03 -0.02 0.02 -0.01 0.03 -0.00 #DIV/0! 0.02 -0.03 -0.05 -0.07 -0.03 0.07 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 0 (0.0%) 1,623 (10.9%) 10,110 (67.7%) 5,699 (38.2%) 795 (5.3%) 4,901 (32.8%) 3,233 (21.7%)	-0.03 #DIV/0! 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0! 0.00 -0.04 -0.04 0.02 0.05 -0.04	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 48,655 (35.8%) 52,209 (18.5%) 5,129 (3.8%) 48,921 (35.9%) 26,098 (19.2%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/0! -0.01 -0.03 -0.07 -0.04 -0.01 -0.02 -0.06	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 2710 (12.0%) 145908 (64.4%) 81135 (35.8%) 9881 (4.4%) 9881 (4.4%) 80879 (35.7%) 43735 (19.3%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 62 (0.1%) 0 (0.0%) 5177 (2.0%) 28555 (66.3%) 16552 (38.6%) 16552 (38.6%) 1849 (4.3%) 9311 (21.6%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 -0.02 0.00 #DIV/0! 0.00 -0.04 -0.04 -0.06 -0.04 -0.06 -0.07 -0.06
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Koangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Eardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of AGIs (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of theat blockers; n (%) Use of theat blockers; n (%) Use of theat blockers; n (%) All antidiabetic medications except insulin; n (%) DM Medications - Insulin Copy; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 8,138 (35.9%) 4,085 (18.0%) 693 (3.1%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%) 964 (32.8%) 619 (21.1%) 107 (3.6%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 -0.01 0.03 -0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.03 -0.07 -0.08 -0.08	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 0 (0.0%) 1,623 (10.9%) 2,931 (19.6%) 2,931 (19.6%) 3,931 (23.8%) 4,901 (82.8%) 3,233 (21.7%) 6,491 (43.5%)	-0.03 #DIV/01 0.02 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/01 0.00 -0.04 -0.04 -0.04 -0.05 -0.04 -0.04 -0.07	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 4 (0.0%) 16,971 (12.5%) 47,512 (64.3%) 48,655 (35.8%) 25,209 (18.5%) 5,129 (3.8%) 48,921 (35.9%) 26,098 (19.2%) 16,757 (12.3%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%)	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 -0.02 -0.00 #DIV/01 -0.01 -0.03 -0.07 -0.04 -0.01 -0.02 -0.06 -0.12	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 415908 (64.4%) 81135 (35.8%) 41628 (18.4%) 9881 (4.4%) 80879 (35.7%) 43735 (19.3%) 44503 (19.6%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 151 (0.4%) 62 (0.1%) 62 (0.1%) 62 (0.1%) 8628 (20.0%) 8628 (20.0%) 1849 (4.3%) 14719 (34.2%) 9311 (21.6%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 #DIV/0! 0.00 #DIV/0! 0.00 -0.04 -0.04 0.00 0.03 -0.04 -0.04 -0.06 -0.13
Bladder stones-Kildney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitre-tomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglithindes (for PS); n (%) Any use of Meglithindes (for PS); n (%) Use of thiazide-United; n (%) Use of beta blockers; n (%) Use of teluicum channel blockers; n (%) All antidiabetic medications except Insulin; n (%) DM Medications - Insulin Copy; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Malignant hypertension; n (%) Cardiovascular strest test; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 3 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 864 (3.8%) 8,138 (35.9%) 4,095 (18.0%) 693 (3.1%) 58 (0.3%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%) 964 (21.8%) 619 (21.1%) 107 (3.6%) 13 (0.4%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 -0.01 0.03 0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.08 -0.08 -0.08 -0.08	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,828 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%) 449 (0.7%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 0 (0.0%) 1,623 (0.2%) 0 (1.10 (67.7%) 5,699 (83.2%) 2,931 (19.6%) 795 (5.3%) 4,901 (22.8%) 3,233 (21.7%) 6,91 (43.5%) 69 (0.5%)	-0.03 #DIV/01 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/01 0.00 -0.04 -0.04 -0.02 0.05 -0.04 -0.07 -0.07 -0.07 -0.09	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 48,655 (35.8%) 5,129 (3.8%) 5,129 (3.8%) 48,921 (35.9%) 26,098 (19.2%) 16,757 (12.3%) 579 (0.4%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%) 107 (0.4%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 9.00 #DIV/0! -0.01 -0.03 -0.07 -0.04 0.01 0.02 -0.06 -0.12 0.00	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 8 (0.0%) 27710 (12.0%) 145908 (64.4%) 98114 (3.5.8%) 41628 (18.4%) 9881 (4.4%) 9881 (4.4%) 9881 (9.3%) 43735 (19.3%) 43735 (19.3%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 62 (0.1%) 151 (0.4%) 62 (0.1%) 1652 (28.6%) 8628 (20.0%) 1849 (4.3%) 14719 (34.2%) 9311 (21.6%) 1731 (24.9%) 189 (0.4%)	-0.03 #DIV/01 0.00 -0.05 -0.06 -0.01 0.00 -0.02 0.00 #DIV/01 0.00 -0.04 -0.06 -0.04 0.00 0.03 -0.04 0.00 0.00 0.00 0.00 0.01
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-fangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-fother CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid [gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thaide-United; n (%) Use of thaide-United; n (%) Use of beta blockers; n (%) Use of Low intensity Statins; n (%) DM Medications-insulin Copy; n (%) Use of Low intensity Statins; n (%) Malignant hypertension; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 8,138 (35.9%) 4,085 (18.0%) 693 (3.1%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%) 964 (32.8%) 619 (21.1%) 107 (3.6%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 -0.01 0.03 -0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.03 -0.07 -0.08 -0.08	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 0 (0.0%) 1,623 (10.9%) 2,931 (19.6%) 2,931 (19.6%) 3,931 (23.8%) 4,901 (82.8%) 3,233 (21.7%) 6,491 (43.5%)	-0.03 #DIV/01 0.02 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/01 0.00 -0.04 -0.04 -0.04 -0.05 -0.04 -0.04 -0.07	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 4 (0.0%) 16,971 (12.5%) 47,512 (64.3%) 48,655 (35.8%) 25,209 (18.5%) 5,129 (3.8%) 48,921 (35.9%) 26,098 (19.2%) 16,757 (12.3%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%)	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 -0.02 -0.00 #DIV/01 -0.01 -0.03 -0.07 -0.04 -0.01 -0.02 -0.06 -0.12	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 415908 (64.4%) 81135 (35.8%) 41628 (18.4%) 9881 (4.4%) 80879 (35.7%) 43735 (19.3%) 44503 (19.6%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 151 (0.4%) 62 (0.1%) 62 (0.1%) 62 (0.1%) 8628 (20.0%) 8628 (20.0%) 1849 (4.3%) 14719 (34.2%) 9311 (21.6%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 #DIV/0! 0.00 #DIV/0! 0.00 -0.04 -0.04 0.00 0.03 -0.04 -0.04 -0.06 -0.13
Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thiazide-United; n (%) Use of beta blockers; n (%) Use of beta blockers; n (%) Use of tolium channel blockers; n (%) All antidiabetic medications except Insulin; n (%) DM Medications - Insulin Copy; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Malignant hypertension; n (%)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 4,185 (18.0%) 693 (3.1%) 58 (0.3%) 3,464 (15.3%)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,975 (36.6%) 615 (20.9%) 128 (4.4%) 964 (22.8%) 619 (21.1%) 107 (3.6%) 13 (0.4%) 835 (28.4%)	-0.04 0.07 #DIV/0! 0.00 -0.03 -0.02 -0.01 0.03 0.00 #DIV/0! 0.02 -0.03 -0.05 -0.07 -0.08 -0.03 -0.07 -0.08 -0.03 -0.02 -0.32	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%) 449 (0.7%) 23,390 (34.5%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 1,00 (0.0%) 1,623 (10.9%) 1,0110 (67.7%) 2,931 (19.6%) 795 (5.3%) 4,901 (32.8%) 3,233 (21.7%) 6,991 (43.5%) 6,991 (43.5%) 6,9(0.5%) 7,438 (49.8%)	-0.03 #DIV/0! 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0! 0.00 -0.04 -0.04 -0.04 -0.05 -0.04 -0.07 0.00 -0.03 -0.03 -0.03	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 26,098 (19.2%) 5,797 (12.3%) 5,79 (0.4%) 29,798 (21.9%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 31 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,554 (21.6%) 4,133 (16.4%) 107 (0.4%) 9,331 (37.0%)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/0! -0.01 -0.04 0.01 0.02 -0.06 -0.12 0.00 -0.34	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 145908 (64.4%) 98114 (35.8%) 41628 (18.4%) 9881 (4.4%) 43735 (19.3%) 44753 (19.3%) 1086 (0.5%) 56652 (25.0%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 151 (0.4%) 62 (0.1%) 0 (0.0%) 5177 (12.0%) 8658 (20.0%) 1849 (4.3%) 1471 (34.2%) 9311 (21.6%) 193 (1.4.9%) 189 (0.4%) 17604 (40.8%)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 -0.02 0.00 #DIV/0! -0.06 -0.04 0.00 -0.04 0.00 -0.04 0.00 -0.04 0.00 -0.04 0.00 -0.04 0.00 -0.04 0.00 -0.04 0.00 -0.04 0.00 -0.03 -0.06 -0.13
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) CKD stage 3 - 4 ialysis (for PS); n (%) Use of thiazide- United; n (%) Use of beta blockers; n (%) Use of thiazide- United; n (%) Use of High Intensity Statins; n (%) Use of High Intensity Statins; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BMP tests	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 8,138 (35.9%) 4,085 (18.0%) 693 (3.1%) 58 (0.3%) 3,464 (15.3%) 0.08 (0.35)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%) 964 (21.8%) 619 (21.1%) 107 (3.6%) 13 (0.4%)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 -0.01 0.03 0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.08 -0.08 -0.08 -0.08	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,828 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%) 449 (0.7%)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 0 (0.0%) 1,623 (0.2%) 0 (1.10 (67.7%) 5,699 (83.2%) 2,931 (19.6%) 795 (5.3%) 4,901 (22.8%) 3,233 (21.7%) 6,91 (43.5%) 69 (0.5%)	-0.03 #DIV/01 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/01 0.00 -0.04 -0.04 -0.02 0.05 -0.04 -0.07 -0.07 -0.07 -0.09	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 48,655 (35.8%) 5,129 (3.8%) 5,129 (3.8%) 48,921 (35.9%) 26,098 (19.2%) 16,757 (12.3%) 579 (0.4%)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%) 107 (0.4%) 9,331 (37.0%) 0.13 (0.42)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 9.00 #DIV/0! -0.01 -0.03 -0.07 -0.04 0.01 0.02 -0.06 -0.12 0.00	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 8 (0.0%) 27710 (12.0%) 145908 (64.4%) 98114 (3.5.8%) 41628 (18.4%) 9881 (4.4%) 9881 (4.4%) 9881 (9.3%) 43735 (19.3%) 43735 (19.3%)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 62 (0.1%) 151 (0.4%) 62 (0.1%) 1652 (28.6%) 8628 (20.0%) 1849 (4.3%) 14719 (34.2%) 9311 (21.6%) 1731 (24.9%) 189 (0.4%)	-0.03 #DIV/01 0.00 -0.05 -0.06 -0.01 0.00 -0.02 0.00 #DIV/01 0.00 -0.04 -0.06 -0.04 0.00 0.03 -0.04 0.00 0.00 0.00 0.00 0.01
Bladder stones-Kildney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Ostemyelits(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglithindes (for PS); n (%) Any use of Meglithindes (for PS); n (%) Use of thiazide-United; n (%) Use of beta blockers; n (%) Use of teluic mchannel blockers; n (%) Use of teluic mchannel blockers; n (%) Use of thiazide-United; n (%) Use of the intensity Statins; n (%) Use of High Intensity Statins; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BNP testsmean (sd)median [UR]	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 3 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 4,138 (35.9%) 4,085 (18.0%) 693 (3.1%) 58 (0.3%) 3,464 (15.3%) 0.08 (0.35) 0.00 (0.00, 0.00]	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,075 (36.6%) 128 (4.4%) 964 (22.8%) 619 (21.1%) 107 (3.6%) 13 (0.4%) 835 (28.4%) 0.09 (0.36)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 -0.01 0.03 0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.08 -0.03 -0.02 -0.03 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%) 449 (0.7%) 23,390 (34.5%) 0.07 (0.40)	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 0 (0.0%) 1,623 (10.9%) 1,010 (67.7%) 5,699 (38.2%) 2,931 (19.6%) 795 (5.3%) 4,901 (22.8%) 3,233 (21.7%) 6,491 (43.5%) 6,90 (55%) 7,438 (49.8%) 0.08 (0.35)	-0.03 #DIV/0! 0.02 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0! 0.00 -0.04 -0.04 -0.04 -0.05 -0.04 -0.07 0.03 -0.31	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 87,512 (64.3%) 48,655 (35.8%) 52,09 (18.5%) 5,129 (3.8%) 48,921 (35.9%) 48,921 (35.9%) 579 (0.4%) 29,798 (21.9%) 0.11 (0.41)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%) 107 (0.4%) 9,331 (37.0%) 0.13 (0.42)	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 4DIV/0! -0.01 -0.03 -0.07 -0.04 0.01 0.02 -0.06 -0.12 0.00 -0.34 -0.05	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 8 (0.0%) 145908 (64.4%) 81135 (35.8%) 41628 (18.4%) 9881 (4.4%) 9881 (4.4%) 43735 (19.3%) 44503 (19.6%) 1086 (0.5%) 56652 (25.0%) 0.10 (0.40)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 0 (0.0%) 151 (0.4%) 62 (0.1%) 0 (0.0%) 28555 (66.3%) 16652 (38.6%) 8628 (20.0%) 1849 (4.3%) 14719 (34.2%) 9311 (21.6%) 10731 (24.9%) 17604 (40.8%) 0.11 (0.39)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 -0.02 0.00 -0.04 -0.04 -0.06 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05 -0.04 -0.05
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Koangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS); n (%) Any use of Meglitimides (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitimides (for PS); n (%) Any use of Meglitimides (for PS); n (%) Use of thaidade-United; n (%) Use of thaidade-United; n (%) Use of beta blockers; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%) Use of High Intensity Statins; n (%) Walignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BNP testsmean (sQ)median [IQR] Number of Cardiac biomarkers tests (tropnin, CK-MBs, M)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 8,138 (35.9%) 4,085 (18.0%) 693 (3.1%) 58 (0.3%) 3,464 (15.3%) 0.08 (0.35) 0.00 (0.00, 0.00)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%) 964 (32.8%) 619 (21.1%) 107 (3.6%) 13 (0.4%) 835 (28.4%) 0.09 (0.36) 0.00 (0.00, 0.00)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 0.02 -0.01 0.03 -0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.03 -0.05 -0.07 -0.08 -0.03 -0.02 -0.03 -0.03 -0.03 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%) 44,07%) 23,390 (34.5%) 0.07 (0.40) 0.00 [0.00,0.00]	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 0 (0.0%) 1,623 (10.9%) 10,110 (67.7%) 5,699 (38.2%) 7,931 (19.6%) 7,955 (3.3%) 4,901 (32.8%) 3,233 (21.7%) 6,491 (43.5%) 6,9 (0.5%) 7,438 (49.8%) 0.08 (0.35) 0.00 (0.00,0.00)	-0.03 #DIV/0! 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0! 0.04 -0.04 -0.04 -0.05 -0.04 -0.07 0.03 -0.03 -0.03 -0.01 -0.03 -0.03 -0.04	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 48,655 (35.8%) 52,209 (18.5%) 5,129 (3.8%) 48,921 (35.9%) 26,098 (19.2%) 16,757 (12.3%) 29,798 (21.9%) 0.11 (0.41) 0.00 (0.00, 0.00)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 311 (1.2%) 74 (0.3%) 30 (0.1%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%) 107 (0.4%) 9,331 (37.0%) 0.13 (0.42) 0.00 [0.00, 0.00]	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/01 -0.01 -0.03 -0.07 -0.04 0.01 0.02 -0.06 -0.12 0.00 -0.34 -0.05 0.00	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 145908 (64.4%) 81135 (35.8%) 9881 (4.4%) 80879 (35.7%) 43735 (19.3%) 1086 (0.5%) 56652 (25.0%) 0.10 (0.40) 0.00 (0.46)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 62 (0.1%) 0 (0.0%) 5177 (2.0%) 28555 (66.3%) 1652 (38.6%) 1652 (38.6%) 1849 (4.3%) 1911 (21.6%) 1931 (21.6%) 1931 (21.6%) 1939 (0.4%) 17604 (40.8%) 0.11 (0.39) 0.00 (0.43)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 -0.04 -0.04 -0.06 -0.01 -0.03 -0.02 -0.03 -0.03 -0.03 -0.04 -0.04 -0.05
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osterowyleitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) CXD stage 3-6 + dialysis (for PS); n (%) Use of thiazide-United; n (%) Use of beta blockers; n (%) Use of thiazide-United; n (%) Use of thiazide-United; n (%) Use of thiazidisms - Insulin Copy; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BNP testsmean (sd)median [IOR] Number of Cardiac biomarkers tests (tropnin, CK-MBs, M)mean (sd)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 4,138 (35.9%) 4,085 (18.0%) 693 (3.1%) 58 (0.3%) 3,464 (15.3%) 0.00 (0.00, 0.00) yoglobin, CPK)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,820 (62.0%) 1,820 (62.0%) 1,975 (86.6%) 615 (20.9%) 128 (4.4%) 964 (32.8%) 619 (21.1%) 107 (3.6%) 13 (0.4%) 835 (28.4%) 0.09 (0.36) 0.00 [0.00, 0.00]	-0.04 0.07 #DIV/0! 0.00 -0.03 -0.02 -0.01 -0.03 -0.00 #DIV/0! 0.02 -0.03 -0.05 -0.07 -0.08 -0.03 -0.00 -0.03 -0.00 -0.03 -0.00 -0.03 -0.05 -0.07 -0.08 -0.03 -0.07 -0.08 -0.03 -0.00 -0.03 -0.02 -0.32 -0.03 -0.00	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%) 49 (0.7%) 23,390 (34.5%) 0.07 (0.40) 0.00 [0.00, 0.00]	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 1,0110 (67.7%) 5,699 (8.2%) 2,931 (19.6%) 79 (5.3%) 4,901 (32.8%) 3,233 (21.7%) 6,90 (4.5%) 6,91 (4.5%) 6,92 (4.5%) 7,438 (49.8%) 0.08 (0.35) 0.00 (0.00,0.00)	-0.03 #DIV/0! 0.02 -0.03 -0.03 -0.03 -0.00 -0.07 -0.00 -0.04 -0.04 -0.04 -0.04 -0.04 -0.04 -0.03 -0.03 -0.03 -0.03 -0.03 -0.05 -0.04 -0.04 -0.04 -0.04 -0.04 -0.04 -0.04 -0.05 -0.04 -0.04 -0.05 -0.04 -0.04 -0.05 -0.05 -0.04 -0.07 -0.03 -0.31	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 109 (0.1%) 377 (0.3%) 109 (0.1%) 40,055 (35.8%) 5,129 (38.5%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 5,129 (3.8%) 6,098 (19.2%) 5,129 (3.8%) 5,129 (3.8%) 6,098 (19.2%) 11 (0.41) 0.00 (0.00,0.00)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%) 107 (0.4%) 9,331 (37.0%) 0.13 (0.42) 0.00 [0.00,00]	-0.01 0.03 #DIV/0! 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/0! -0.01 -0.02 -0.04 0.01 0.02 -0.06 -0.12 0.00 -0.34 -0.05 0.00	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 1359 (0.1%) 185 (0.1%) 185 (0.1%) 185 (0.1%) 18103 (3.5.8%) 41628 (18.4%) 98814 (4.4%) 80879 (35.7%) 43735 (19.3%) 1086 (0.5%) 56652 (25.0%) 0.10 (0.40) 0.00 (0.46)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 511 (0.4%) 62 (0.1%) 0 (0.0%) 5177 (12.0%) 8628 (20.0%) 1849 (4.3%) 14719 (34.2%) 9311 (21.6%) 1931 (24.9%) 193 (0.4%) 17604 (40.8%) 0.11 (0.39) 0.00 (0.43) 0.28 (0.93)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 -0.02 0.00 #DIV/0! -0.06 -0.01 -0.03 -0.04 -0.06 -0.04 -0.05 -0.04 -0.06 -0.04 -0.00 -0.03 -0.06 -0.04 -0.00 -0.03 -0.00 -0.00 -0.03 -0.00
Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Koangrene-Ostemyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS); n (%) Any use of Meglitimides (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitimides (for PS); n (%) Any use of Meglitimides (for PS); n (%) Use of thaidade-United; n (%) Use of thaidade-United; n (%) Use of beta blockers; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%) Use of High Intensity Statins; n (%) Walignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BNP testsmean (sQ)median [IQR] Number of Cardiac biomarkers tests (tropnin, CK-MBs, M)	187 (0.8%) 601 (2.7%) 0 (0.0%) 86 (0.4%) 3,880 (17.1%) 1,033 (4.6%) 3,831 (16.9%) 198 (0.9%) 38 (0.2%) 17 (0.1%) 4 (0.0%) 2,786 (12.3%) 13,713 (60.5%) 7,737 (34.1%) 4,109 (18.1%) 864 (3.8%) 8,138 (35.9%) 4,085 (18.0%) 693 (3.1%) 58 (0.3%) 3,464 (15.3%) 0.08 (0.35) 0.00 (0.00, 0.00)	36 (1.2%) 51 (1.7%) 0 (0.0%) 11 (0.4%) 540 (18.4%) 148 (5.0%) 479 (16.3%) 29 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 342 (11.6%) 1,075 (36.6%) 615 (20.9%) 128 (4.4%) 964 (32.8%) 619 (21.1%) 107 (3.6%) 13 (0.4%) 835 (28.4%) 0.09 (0.36) 0.00 (0.00, 0.00)	-0.04 0.07 #DIV/01 0.00 -0.03 -0.02 0.02 -0.01 0.03 -0.00 #DIV/01 0.02 -0.03 -0.05 -0.07 -0.03 -0.05 -0.07 -0.08 -0.03 -0.02 -0.03 -0.03 -0.03 -0.03	861 (1.3%) 1,554 (2.3%) 0 (0.0%) 937 (1.4%) 21,635 (31.9%) 3,026 (4.5%) 8,436 (12.4%) 1,554 (2.3%) 324 (0.5%) 69 (0.1%) 0 (0.0%) 7,453 (11.0%) 44,683 (65.9%) 24,743 (36.5%) 12,310 (18.2%) 3,888 (5.7%) 23,820 (35.1%) 13,552 (20.0%) 27,053 (39.9%) 44,07%) 23,390 (34.5%) 0.07 (0.40) 0.00 [0.00,0.00]	245 (1.6%) 285 (1.9%) 0 (0.0%) 183 (1.2%) 4,994 (33.5%) 771 (5.2%) 1,861 (12.5%) 211 (1.4%) 74 (0.5%) 28 (0.2%) 0 (0.0%) 1,623 (10.9%) 10,110 (67.7%) 5,699 (38.2%) 7,931 (19.6%) 7,955 (3.3%) 4,901 (32.8%) 3,233 (21.7%) 6,491 (43.5%) 6,9 (0.5%) 7,438 (49.8%) 0.08 (0.35) 0.00 (0.00,0.00)	-0.03 #DIV/0! 0.02 -0.03 -0.03 -0.03 0.00 0.07 0.00 -0.03 #DIV/0! 0.04 -0.04 -0.04 -0.05 -0.04 -0.07 0.03 -0.03 -0.03 -0.01 -0.03 -0.03 -0.04	1,494 (1.1%) 3,124 (2.3%) 0 (0.0%) 1,247 (0.9%) 20,779 (15.3%) 8,489 (6.2%) 17,662 (13.0%) 1,839 (1.4%) 377 (0.3%) 109 (0.1%) 4 (0.0%) 16,971 (12.5%) 87,512 (64.3%) 48,655 (35.8%) 52,209 (18.5%) 5,129 (3.8%) 48,921 (35.9%) 26,098 (19.2%) 16,757 (12.3%) 29,798 (21.9%) 0.11 (0.41) 0.00 (0.00, 0.00)	311 (1.2%) 485 (1.9%) 0 (0.0%) 226 (0.9%) 4,065 (16.1%) 2,092 (8.3%) 3,549 (14.1%) 311 (1.2%) 74 (0.3%) 0 (0.0%) 3,212 (12.7%) 16,625 (65.9%) 9,878 (39.2%) 5,082 (20.1%) 926 (3.7%) 8,854 (35.1%) 5,459 (21.6%) 4,133 (16.4%) 107 (0.4%) 9,331 (37.0%) 0.13 (0.42) 0.00 [0.00,00]	-0.01 0.03 #DIV/01 0.00 -0.02 -0.08 -0.03 0.02 0.00 0.00 #DIV/01 -0.01 -0.03 -0.07 -0.04 0.01 0.02 -0.06 -0.12 0.00 -0.34 -0.05 0.00	2542 (1.1%) 5279 (2.3%) 0 (0.0%) 2270 (1.0%) 46294 (20.4%) 12548 (5.5%) 29929 (13.2%) 3591 (1.6%) 739 (0.3%) 195 (0.1%) 8 (0.0%) 27210 (12.0%) 145908 (64.4%) 81135 (35.8%) 9881 (4.4%) 80879 (35.7%) 43735 (19.3%) 1086 (0.5%) 56652 (25.0%) 0.10 (0.40) 0.00 (0.46)	592 (1.4%) 821 (1.9%) 0 (0.0%) 420 (1.0%) 9599 (22.3%) 3011 (7.0%) 5889 (13.7%) 551 (1.3%) 62 (0.1%) 0 (0.0%) 5177 (2.0%) 28555 (66.3%) 1652 (38.6%) 1652 (38.6%) 1849 (4.3%) 1911 (21.6%) 1931 (21.6%) 1931 (21.6%) 1939 (0.4%) 17604 (40.8%) 0.11 (0.39) 0.00 (0.43)	-0.03 #DIV/0! 0.00 -0.05 -0.06 -0.01 0.00 -0.04 -0.04 -0.06 -0.01 -0.03 -0.02 -0.03 -0.03 -0.03 -0.04 -0.04 -0.05

Company Comp	Number of Ambulatory Blood pressure monitoring tests												
Control Cont		0.00 (0.03)	0.00 (0.03)	0.00	0.00 (0.04)	0.00 (0.04)	0.00	0.00 (0.02)	0.00 (0.04)	0.00	0.00 (0.03)	0.00 (0.04)	0.00
Part		0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]		0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00			
Part													
Part		120 02 (50 05)	120.05 (55.04)	0.00	125 76 (65 70)	121.05 (57.52)	0.00	-	-	0.03	126 67 (65 12)	124 02 (CE EC)	0.00
Part													
Part		1.00 [05.00, 101.00]	100.00 [51.00, 101.00]	0.04	174.00 [110.00, 101.00]	171.00 [54.00, 101.00]	0.04	0	0	0.02	121.24 (74.47)	130.01 (73.42)	0.00
Procession of control contro		1,750.74 (1,238.00)	1,753.82 (1,191.57)	0.00	2,172.37 (1,246.30)	2,083.21 (1,203.95)	0.07	833.53 (537.51)	873.46 (457.48)	-0.08	1325.93 (889.77)	1352.52 (849.34)	0.00
Part													
Common C	median [IQR]	2,568.00]	2,511.00]	-0.05 2	2.00 [1,052.00, 3,178.25] (94.00 [997.50, 3,086.00]	0.1058	38.00 [448.00, 1,064.00] [530.00, 1,095.00]	-0.25	1024.96 (1122.48)	1116.67 (1033.38)	0.00
Common C	Mean Consy for per prescription cost (charges in LLS \$\/186	1-1 day prior)						0	0				
March Marc			31.24 (39.86)	-0.03	20.81 (20.98)	22.85 (23.53)	-0.09	•		0.05	81.24 (90.18)	76.83 (91.42)	0.00
Part		18.00 [8.44, 36.45]		-0.07		17.50 [8.75, 30.19]	-0.07	,	,	0.04		38.66 (92.15)	0.00
Material Processing March	Missing; n (%)	897 (4.0%)		0.11	1,967 (2.9%)	447 (3.0%)	-0.01	3,658 (2.7%)	516 (2.0%)	0.05	6522 (2.9%)	1025 (2.4%)	0.03
Procession Pro													
Personant Pers													
Power Professional Profession					-,,				-, (,			,	
Pose content (Proposed Conte		, ,							, ,				
Part						,		, . , . ,					
Description Property Proper													
Designation 19				-0.03									
March Configuration March Continue		45 (0.2%)	11 (0.4%)	-0.04	231 (0.3%)		-0.04	267 (0.2%)	61 (0.2%)	0.00	543 (0.2%)	163 (0.4%)	-0.04
March Marc	Use of CNS stimulants; n (%)	24 (0.1%)	3 (0.1%)	0.00	250 (0.4%)	84 (0.6%)	-0.03	183 (0.1%)	33 (0.1%)	0.00	457 (0.2%)	120 (0.3%)	-0.02
Control Cont	Use of estrogens, progestins, androgens; n (%)	465 (2.1%)	88 (3.0%)			696 (4.7%)			880 (3.5%)				
Control periode minimitation of periode minimitation		. (,-)						(,					
Secretary of Process													
Control Cont		3 (0.0%)	1 (0.0%)	#DIV/0!	61 (0.1%)	11 (0.1%)	0.00	61 (0.0%)	2 (0.0%)	#DIV/0!	125 (0.1%)	14 (0.0%)	0.04
Description (CDC (CD, ng) CDC (C		0 (0 0%)	0 (0 0%)	#DIV/01	0 (0 0%)	0 (0 0%)	#DIV/01	0 (0 0%)	0 (0 0%)	#DIV/OI	0 (0 0%)	0 (0 0%)	#DIV/01
				,			,						
		= (=.=,-)			()			(,	- ()				
March Color March Color March Color March Marc	Number of D-dimer tests	,	,			,		,					
Numer of CFF Neghenstrivity CFF Neghenstrivit	mean (sd)	0.01 (0.12)	0.02 (0.15)	-0.07	0.01 (0.12)	0.02 (0.16)	-0.07	0.02 (0.16)	0.03 (0.18)	-0.06	0.02 (0.15)	0.03 (0.17)	0.00
	median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.16)	0.00 (0.19)	0.00
Common profit													
Number of Fire of PiT Least Number of Fire of Fi													
		0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.34)	0.00 (0.33)	0.00
March Marc		2 26 (4 06)	0.45 (1.50)	0.05	1 07 /2 42)	0.29 (1.42)	0.61	2 72 (4 21)	0.40 (1.20)	1.05	2 17 (4 04)	0.40/1.26\	0.01
Numerical Policy Numerical P													
		2.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.03	0.00 [0.00, 5.00]	0.00 [0.00, 0.00]	0.00	2.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.03	0.00 (4.40)	0.00 (1.52)	0.00
Horizont Circle Plant (Circle Plant (Circl		0.00 (0.01)	0.00 (0.00)	0.00	0.00 (0.01)	0.00 (0.01)	0.00	0.00 (0.02)	0.00 (0.02)	0.00	0.00 (0.02)	0.00 (0.02)	0.00
	median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.02)	0.00 (0.02)	0.00
No fement membrugs													
menian (ol) 15.76 (13.47)		3.00 [3.00, 3.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	2.10 (0.75)	2.28 (0.77)	0.00
median 10R 12.00 70.00 10.00 6.00, 10.00 10.00 6.00, 10.00 10.00 6.00, 16.00 0.21 13.00 80.01, 19.00 12.00 70.01, 19.00 0.90 8.68 12.21 8.37 11.93 0.00 1		45.75(40.47)	44 42 (42 55)	0.40	42.57 (0.50)	42.24 (0.54)	0.45	45 47 (44 22)	4450(4457)	2.25	44.70 (44.02)	42.74 (40.00)	0.00
No first and namedrugs													
mes (ad)		12.00 [7.00, 20.00]	11.00 [0.00, 15.00]	0.08	12.00 [7.00, 18.00]	10.00 [0.00, 10.00]	0.21	13.00 [8.00, 13.00] [2.00 [7.00, 15.00]	0.09	0.00 (12.21)	0.37 (11.53)	0.00
median (IQR) 1.00 (1.00, 0.01) 3.00 (1.00, 6.00) 0.41 3.00 (1.00, 6.00) 4.00 (2.00, 8.00) 0.20 2.00 (10.00, 5.00) 3.00 (1.00, 7.00) 0.21 1.60 (5.13) 2.63 (5.92) 0.00 Use of (opidage'; n/K) 1.10 (6.5%) 1.10		2.94 (4.50)	4.77 (5.14)	-0.38	4.27 (4.65)	5.81 (5.28)	-0.31	3.12 (4.33)	5.05 (5.37)	-0.40	3.45 (4.45)	5.29 (5.32)	0.00
Systemic embolism; n (%) 117 (0.5%) 12 (0.4%) 0.01 5.88 (0.9%) 5.8 (0.4%) 0.06 713 (0.5%) 87 (0.3%) 0.03 1418 (0.5%) 157 (0.4%) 0.03	median [IQR]						-0.20		3.00 [1.00, 7.00]				
DVT; n(%) 887 (3.9%) 33 (1.1%) 0.18 3,510 (5.2%) 214 (1.4%) 0.21 6,63 (5.0%) 280 (1.1%) 0.23 11160 (4.9%) 527 (1.2%) 0.12 Diabetes: inpatient or 2 outpatient claims within 183 days; n (%) 5,727 (5.3%) 79 (26.9%) -0.04 16,089 (23.7%) 3,565 (23.9%) 0.00 33,792 (24.8%) 6,369 (25.2%) -0.01 55608 (24.5%) 10725 (24.9%) -0.01 Intracranial or retroperitoneal hemorrhage: 1 inpatient or 2 outpatient claims within 183 days; n (%) 27 (0.1%) 1 (0.0%) 0.04 89 (0.1%) 8 (0.1%) 0.00 90 (0.1%) 18 (0.1%) 0.00 206 (0.1%) 27 (0.1%) 27 (0.1%) 0.00 Peptic Ulcer Disease; n (%) 1,599 (7.1%) 222 (7.6%) -0.02 3,997 (5.9%) 908 (6.1%) -0.01 8,879 (6.5%) 15557 (7.4%) -0.04 14475 (6.4%) 2985 (6.9%) -0.02 Upper Gi bleed; n (%) 12 (0.0%) 21 (0.0%) 17 (0.0%) 17 (0.0%) 40 (0.0%) 18 (0.0%) 1	Use of clopidogrel ; n (%)	1,016 (4.5%)	190 (6.5%)	-0.09	5,477 (8.1%)	1,823 (12.2%)	-0.14	8,774 (6.4%)	2,571 (10.2%)	-0.14	15267 (6.7%)	4584 (10.6%)	-0.14
PER (%)													
Diabetes: Impatient or 2 outpatient claims within 183 days; n (%) 5,727 (25.3%) 791 (26.9%) -0.04 16,089 (23.7%) 3,565 (23.9%) 0.00 33,792 (24.8%) 6,369 (25.2%) -0.01 55608 (24.5%) 10725 (24.9%) -0.01 10725 (24.9%) -0.01 10725 (24.9%) -0.01 10725 (24.9%) -0.01 -		,				, ,							
183 days; n (%)	,	406 (1.8%)	4 (0.1%)	0.18	2,009 (3.0%)	91 (0.6%)	0.18	3,175 (2.3%)	74 (0.3%)	0.18	5590 (2.5%)	169 (0.4%)	0.18
Intracranial or retroperitoneal hemorrhage: 1 inpatient of 2 outpatient claims within 183 days; n (%)		E 727 /2E 20/\	701 /26 09/\	0.04	16 090 (22 79/)	2 565 (22 00/)	0.00	22 702 /24 99/\	6 260 (25 29/)	0.01	EE 600 (24 EW)	10775 /24 09/\	0.01
inpatient or 2 outpatient claims within 183 days; n (%) 27 (0.1%) 1 (0.0%) 0.04 89 (0.1%) 8 (0.1%) 0.00 90 (0.1%) 18 (0.1%) 0.00 26 (0.1%) 27 (0.1%) 0.00 Peptic Ulcer Disease; n (%) 1,599 (7.1%) 22 (7.6%) 0.02 3,997 (5.9%) 908 (6.1%) 0.01 8,879 (6.5%) 1,855 (7.4%) 0.04 1447 (6.4%) 2985 (6.9%) 0.02 Upper Gi bleed; n (%) 2 (0.0%) 2 (0.0%) 0 (0.0%) #DIV/0! 17 (0.0%) 4 (0.0%) #DIV/0! 18 (0.0%) 154 (0.6%) 40.0% #DIV/0! 37 (0.0%) 5 (0.0%) 0 (0.0%) 491 (0.7%) 0.00 Urogenital bleed; n (%) 25 (0.9%) 29 (1.3%) 0.03 491 (0.7%) 0.00 705 (0.5%) 154 (0.6%) 0.01 1323 (0.6%) 0.21 (0.7%) 0.00 Urogenital bleed; n (%) 29 (1.3%) 29 (1.3%) 0.03 1,189 (1.3%) 0.03 1,189 (1.3%) 0.02 4,121 (3.0%) 72 (2.9%) 0.01 7096 (3.1%) 1269 (2.9%) 0.01 Urogenital bleed; n (%) 29 (1.3%) 30 (1.0.%) 0.03 1,189 (1.8%) 163 (1.1%) 0.06 1,191 (1.4%) 259 (1.0%) 0.04 3405 (1.5%) 450 (1.0%) 0.05 Prior cancer; n (%) 2,605 (1.1%) 30 (7.0.%) 0.03 6,555 (9.7%) 136 (9.1%) 0.06 1,399 (1.3%) 2,591 (0.3%) 0.04 3405 (1.5%) 450 (1.0%) 0.05 Aspirin; n (%) 58 (0.3%) 13 (0.4%) 0.02 593 (0.9%) 180 (1.2%) 0.03 348 (0.3%) 118 (0.5%) 0.03 999 (0.4%) 311 (0.7%) 0.04 Aspirin/dipyridamole; n (%) 36 (0.2%) 11 (0.4%) 0.04 243 (0.4%) 83 (0.5%) 0.03 348 (0.3%) 118 (0.5%) 0.03 1119 (0.5%) 0.04 Aspirin/dipyridamole; n (%) 1.08 (0.0%) 1.08 (0.		3,727 (23.3%)	751 (20.5%)	-0.04	10,005 (23.7%)	3,303 (23.5%)	0.00	33,732 (24.6%)	0,303 (23.2%)	-0.01	33008 (24.3%)	10723 (24.5%)	-0.01
(%) 27 (0.1%) 1 (0.0%) 0.04 89 (0.1%) 8 (0.1%) 0.00 99 (0.1%) 18 (0.1%) 0.00 206 (0.1%) 27 (0.1%) 2.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0													
Upger Gibleed; n (%) $2(0.0\%)$ $0(0.0\%)$ 0		27 (0.1%)	1 (0.0%)	0.04	89 (0.1%)	8 (0.1%)	0.00	90 (0.1%)	18 (0.1%)	0.00	206 (0.1%)	27 (0.1%)	0.00
Lower/unspecified Gl bleed; n (%) 127 (0.6%) 25 (0.9%) -0.03 491 (0.7%) 102 (0.7%) 0.00 705 (0.5%) 154 (0.6%) -0.01 1323 (0.6%) 281 (0.7%) -0.01 Urogenital bleed; n (%) 686 (0.0%) 91 (3.1%) -0.01 2,289 (3.4%) 451 (3.0%) 0.02 4,121 (3.0%) 727 (2.9%) 0.01 7096 (3.1%) 1269 (2.9%) 0.01 Urogenital bleed; n (%) 297 (1.3%) 281 (0.0%) 0.03 1,189 (1.8%) 163 (1.1%) 0.06 1,191 (1.4%) 259 (1.0%) 0.04 4305 (1.5%) 450 (1.0%) 0.05 Prior cancer; n (%) 2,605 (11.5%) 307 (10.5%) 0.03 6,550 (9.7%) 1,366 (9.1%) 0.02 13,998 (10.3%) 2,691 (10.7%) 0.01 23153 (10.2%) 4364 (10.1%) 0.00 Aspirin; n (%) 58 (0.3%) 13 (0.4%) 0.02 593 (0.9%) 180 (1.2%) 0.03 348 (0.3%) 118 (0.5%) 0.03 999 (0.4%) 311 (0.7%) 0.04 Aspirin; n (%) 36 (0.2%) 110 (3.4%) 0.01 407 (0.6%) 83 (0.6%) 0.03 295 (0.2%) 103 (0.4%) 0.04 574 (0.3%) 179 (0.5%) 0.03 Urber antiplatelet agents; n (%) 108 (0.5%) 13 (0.4%) 0.01 407 (0.6%) 83 (0.6%) 0.00 604 (0.4%) 148 (0.6%) 0.03 1119 (0.5%) 244 (0.6%) 0.01 PGP inhibitors; n (%) 8, 231 (36.3%) 1,160 (39.5%) 0.03 30,813 (45.5%) 7,267 (48.7%) 0.06 54,573 (40.1%) 11,181 (44.3%) 0.09 93617 (41.3%) 19608 (45.5%) 0.08 Urber antiplated expents; n (%) 0.05 (1.5%) 0.03 (1.5%) 0.03 (1.5%) 0.03 (1.5%) 0.05 (Peptic Ulcer Disease; n (%)	1,599 (7.1%)	222 (7.6%)	-0.02	3,997 (5.9%)	908 (6.1%)	-0.01	8,879 (6.5%)	1,855 (7.4%)	-0.04	14475 (6.4%)	2985 (6.9%)	-0.02
Urogenital bleed; n (%) $686 (3.0\%)$ $91 (3.1\%)$ 0.01 $2,289 (3.4\%)$ $451 (3.0\%)$ 0.02 $4,121 (3.0\%)$ $727 (2.9\%)$ 0.01 $7096 (3.1\%)$ $1269 (2.9\%)$ 0.01 Other bleeds; n (%) $297 (1.3\%)$ $28 (1.0\%)$ 0.03 $1,189 (1.5\%)$ $163 (1.1\%)$ 0.06 $1,191 (1.4\%)$ $259 (1.0\%)$ 0.04 $3405 (1.5\%)$ $450 (1.0\%)$ 0.05 $4364 (10.1\%)$ 0.05													
Other bleeds; $n(\%)$ 29 (1.3%) 28 (1.0%) 0.03 1,189 (1.8%) 163 (1.1%) 0.06 1,919 (1.4%) 2.59 (1.0%) 0.04 3405 (1.5%) 450 (1.0%) 0.05 Prior cancer; $n(\%)$ 2,605 (11.5%) 307 (10.5%) 0.03 6,550 (9.7%) 1,366 (9.1%) 0.02 13,998 (10.3%) 2,691 (10.7%) 0.01 23153 (10.2%) 436 (10.1%) 0.00 Aspirin; $n(\%)$ 58 (0.3%) 13 (0.4%) 0.02 593 (0.9%) 180 (1.2%) 0.03 348 (0.3%) 118 (0.5%) 0.03 999 (0.4%) 311 (0.4%) 0.04 Aspirin/dipyridamole; $n(\%)$ 36 (0.2%) 11 (0.4%) 0.04 243 (0.4%) 83 (0.6%) 0.03 255 (0.2%) 103 (0.4%) 0.04 574 (0.3%) 197 (0.5%) 0.03 Other antiplatel agents; $n(\%)$ 108 (0.5%) 13 (0.4%) 0.01 407 (0.6%) 83 (0.6%) 0.00 604 (0.4%) 148 (0.5%) 0.03 1119 (0.5%) 244 (0.5%) 0.01 PG inhibitors; $n(\%)$ 8,231 (36.3%) 1,160 (39.5%) 0.03 30,813 (45.5%) 7,267 (48.7%) 0.05 54,573 (40.1%) 11,181 (44.3%) 0.09 93617 (41.3%) 19608 (45.5%) 0.08 Other eastroprotective agents; $n(\%)$ 89 (0.4%) 17 (0.5%) 0.03 525 (0.8%) 142 (1.0%) 0.02 866 (0.5%) 178 (0.7%) 0.01 1480 (0.7%) 337 (0.8%) 0.01 Number of lipid tests ordered													
Prior cancer; $n(\%)$ 2,605 (11.5%) 307 (10.5%) 0.03 6,550 (9.7%) 1,366 (9.1%) 0.02 13,998 (10.3%) 2,691 (10.7%) 0.01 23153 (10.2%) 4364 (10.1%) 0.00 Aspirin; $n(\%)$ 58 (0.3%) 13 (0.4%) 0.02 593 (0.9%) 180 (1.2%) 0.03 348 (0.3%) 118 (0.5%) 0.03 999 (0.4%) 311 (0.7%) 0.04 Aspirin; $n(\%)$ 36 (0.2%) 11 (0.4%) 0.04 243 (0.4%) 83 (0.6%) 0.03 295 (0.2%) 103 (0.4%) 0.04 574 (0.3%) 197 (0.5%) 0.03 Other antiplatelet agents; $n(\%)$ 108 (0.5%) 13 (0.4%) 0.01 407 (0.6%) 83 (0.6%) 0.00 604 (0.4%) 148 (0.6%) 0.03 1119 (0.5%) 244 (0.6%) 0.01 PGP inhibitors; $n(\%)$ 8, 231 (36.3%) 1,160 (39.5%) 0.07 30,813 (45.5%) 7,267 (48.7%) 0.06 54,573 (40.1%) 11,181 (44.3%) 0.09 93617 (41.3%) 19608 (45.5%) 0.08 CHIP registroprotective agents; $n(\%)$ 89 (0.4%) 17 (0.6%) 0.03 525 (0.8%) 142 (1.0%) 0.02 866 (0.6%) 178 (0.7%) 0.01 1480 (0.7%) 337 (0.8%) 0.05 CHIP registroprotective agents; $n(\%)$ 0.05 CHIP registroprotective agents; $n(\%)$ 0.07 CHIP registroprotective agents; $n(\%)$ 0.08 CHIP registroprotective agents; $n(\%)$ 0.09 PGP registroprotective agents; $n(\%)$ 0.09													
Aspirin; n (%) 58 (0.3%) 13 (0.4%) -0.02 593 (0.9%) 180 (1.2%) -0.03 348 (0.3%) 118 (0.5%) -0.03 999 (0.4%) 311 (0.7%) -0.04 Aspirin, n (%) 36 (0.2%) 11 (0.4%) -0.04 243 (0.4%) 83 (0.5%) -0.03 255 (0.2%) 103 (0.4%) -0.04 574 (0.3%) 197 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03 119 (0.5%) -0.03								, , . ,	(,			,	
Aspirin/dipyridamole; n (%) 36 (0.2%) 11 (0.4%) -0.04 243 (0.4%) 83 (0.6%) -0.03 295 (0.2%) 103 (0.4%) -0.04 574 (0.3%) 197 (0.5%) -0.03 CM (0.4%) -0.04 574 (0.3%) 197 (0.5%) -0.05 CM (0.4%) -0.04 574 (0.3%) 197 (0.5%) -0.05 CM (0.4%)													
Other antiplatelet agents; n (%) 108 (0.5%) 13 (0.4%) 0.01 407 (0.6%) 83 (0.6%) 0.00 604 (0.4%) 148 (0.6%) 0.03 1119 (0.5%) 244 (0.6%) 0.01 PCP inhibitors; n (%) $8,231$ (36.3%) $1,160$ (39.5%) 0.07 $30,813$ (45.5%) $7,267$ (48.7%) 0.06 $54,573$ (40.1%) $11,181$ (44.3%) 0.09 93617 (41.3%) 19608 (45.5%) 0.08 17 (0.6%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17 (0.8%) 0.08 17													
PGP inhibitors; n (%) 8,231 (36.3%) 1,160 (39.5%) -0.07 30,813 (45.5%) 7,267 (48.7%) -0.06 54,573 (40.1%) 11,181 (44.3%) -0.09 93617 (41.3%) 19608 (45.5%) -0.08 Other gastroprotective agents; n (%) 89 (0.4%) 17 (0.6%) -0.03 525 (0.8%) 142 (1.0%) -0.02 866 (0.6%) 178 (0.7%) -0.01 1480 (0.7%) 337 (0.8%) -0.01 Number of light dests ordered									,				
Other gastroprotective agents; n (%) 89 (0.4%) 17 (0.6%) -0.03 525 (0.8%) 142 (1.0%) -0.02 866 (0.6%) 178 (0.7%) -0.01 1480 (0.7%) 337 (0.8%) -0.01 Number of lipid tests ordered													
Number of lipid tests ordered													
	mean (sd)	0.59 (0.80)	0.69 (0.85)	-0.12	0.22 (0.62)	0.26 (0.68)	-0.06	0.62 (0.78)	0.74 (0.83)	-0.15	0.50 (0.74)	0.57 (0.78)	0.00

median [IQR]	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-1.21	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-1.24	0.00 (0.81)	0.41 (0.85)	0.00
Proton pump inhibitor; n (%)	3,648 (16.1%)	468 (15.9%)	0.01	13,322 (19.7%)	2,930 (19.6%)	0.00	25,610 (18.8%)	4,816 (19.1%)	-0.01	42580 (18.8%)	8214 (19.1%)	-0.01
H2 receptor antagonist; n (%)	704 (3.1%)	99 (3.4%)	-0.02	2,254 (3.3%)	422 (2.8%)	0.03	5,175 (3.8%)	1,006 (4.0%)	-0.01	8133 (3.6%)	1527 (3.5%)	0.01
Vitamin K therapy; n (%)	18 (0.1%)	0 (0.0%)	0.04	180 (0.3%)	8 (0.1%)	0.04	101 (0.1%)	4 (0.0%)	0.04	299 (0.1%)	12 (0.0%)	0.04
Number of neurologist visits	- (/				- (/						, , , ,	
mean (sd)	0.15 (0.97)	0.17 (1.00)	-0.02	0.18 (1.18)	0.21 (1.01)	-0.03	0.20 (1.29)	0.24 (1.22)	-0.03	0.19 (1.23)	0.22 (1.14)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.39)	0.00 (1.24)	0.00
Number of INR (prothrombin) tests ordered												
mean (sd)	3.26 (3.99)	0.35 (1.30)	0.98	1.88 (3.34)	0.29 (1.24)	0.63	3.71 (4.27)	0.37 (1.27)	1.06	3.12 (3.99)	0.34 (1.26)	0.01
median [IQR]	1.00 [0.00, 6.00]	0.00 [0.00, 0.00]	0.34	0.00 [0.00, 2.00]	0.00 [0.00, 0.00]	0.00	2.00 [0.00, 6.00]	0.00 [0.00, 0.00]	0.63	0.70 (4.39)	0.00 (1.40)	0.00
Treating prescriber - Cardiologist; n (%)	6,838 (30.2%)	1,387 (47.2%)	-0.35	23,716 (35.0%)	8,267 (55.4%)	-0.42	53,448 (39.3%)	14,249 (56.5%)	-0.35	84002 (37.1%)	23903 (55.5%)	-0.38
Treating prescriber - Primary Care Physician; n (%)	14,075 (62.1%)	1,646 (56.1%)	0.12	18,447 (27.2%)	4,421 (29.6%)	-0.05	32,984 (24.2%)	5,914 (23.4%)	0.02	65506 (28.9%)	11981 (27.8%)	0.02
Treating prescriber - Other; n (%)	16,132 (71.2%)	2,151 (73.3%)	-0.05	50,911 (75.1%)	11,444 (76.7%)	-0.04	103,947 (76.4%)	19,204 (76.1%)	0.01	170990 (75.5%)	32799 (76.1%)	-0.01
Alpha blockers; n (%)	3,017 (13.3%)	415 (14.1%)	-0.02	9,114 (13.4%)	1,933 (12.9%)	0.01	18,132 (13.3%)	3,523 (14.0%)	-0.02	30263 (13.4%)	5871 (13.6%)	-0.01
CHADS2 score, 180 days, V	.,. , ,	,		-, , , ,	,,		.,	.,,		,	,	
mean (sd)	1.86 (1.00)	1.87 (1.01)	-0.01	1.97 (1.09)	1.90 (1.08)	0.06	3.02 (1.28)	2.92 (1.27)	0.08	2.59 (1.20)	2.50 (1.19)	0.00
median [IQR]	2.00 [1.00, 2.00]	2.00 [1.00, 2.00]	0.00	2.00 [1.00, 3.00]	2.00 [1.00, 2.50]	0.00	3.00 [2.00, 4.00]	3.00 [2.00, 4.00]	0.00	1.70 (1.34)	1.87 (1.30)	0.00
Use of Prasugrel; n (%)	14 (0.1%)	7 (0.2%)	-0.03	138 (0.2%)	72 (0.5%)	-0.05	11 (0.0%)	2 (0.0%)	#DIV/0!	163 (0.1%)	81 (0.2%)	-0.03
Use of Loop Diuretics+other diuretics+other	,	,		,	(,						. (,	
hypertension drugs; n (%)	6,341 (28.0%)	695 (23.7%)	0.10	25,337 (37.4%)	4,384 (29.4%)	0.17	43.001 (31.6%)	6,494 (25.7%)	0.13	74679 (33.0%)	11573 (26.9%)	0.13
Commercial vs Medicare Advantage- Business Type	.,. , ,	,		.,	, ,		.,,	., ,		,		
Code - CORRECT ONE - OPTUM												
Commercial; n (%)	2,194 (9.7%)	653 (22.2%)	-0.35	61,780 (91.1%)	12,464 (83.5%)	0.23		-	#VALUE!	63,974 (70.7%)	13,117 (73.4%)	-0.06
Medicare Advantage; n (%)	20,471 (90.3%)	2283 (77.8%)	0.35	6,010 (8.9%)	2,465 (16.5%)	-0.23		-	#VALUE!	26,481 (29.3%)	4,748 (26.6%)	0.06
Commercial vs Medicare Advantage- Business Type												
Code												
COM = COMMERCIAL; n (%)	2,194 (9.7%)	653 (22.2%)	-0.35				-	-	#VALUE!	2,194 (9.7%)	653 (22.2%)	-0.35
MCR = MEDICARE; n (%)	20,471 (90.3%)	2,283 (77.8%)	0.35				-	-	#VALUE!	20,471 (90.3%)	2,283 (77.8%)	0.35
MCD = MEDICAID; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!						#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
NONE = NO BUSINESS LINE CODE (added in 2015); n												
(%)	0 (0.0%)	0 (0.0%)	#DIV/0!						#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
UNK = UNKNOWN (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!						#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
Commercial vs Medicare Advantage- Data Type												
1 - Fee For Service; n (%)				5,285 (7.8%)	2,211 (14.8%)	-0.22				5,285 (7.8%)	2,211 (14.8%)	-0.22
2 - Encounter; n (%)				725 (1.1%)	254 (1.7%)	-0.05				725 (1.1%)	254 (1.7%)	-0.05
3 - Medicare; n (%)				54,723 (80.7%)	11,573 (77.5%)	0.08	-	-		54,723 (80.7%)	11,573 (77.5%)	0.08
4 - Medicare Encounter; n (%)				7,057 (10.4%)	891 (6.0%)	0.16	-	-		7,057 (10.4%)	891 (6.0%)	0.16
Metropolitan Statistical Area - Urban (any MSA) vs												
Rural (non-MSA)										0	0	0.00
Urban; n (%)	-			53,890 (79.5%)	11,905 (79.7%)	0.00	-			53,890 (79.5%)	11,905 (79.7%)	0.00
Rural; n (%)				649 (1.0%)	117 (0.8%)	0.02		-		649 (1.0%)	117 (0.8%)	0.02
Unknown/Missing; n (%)	-			13,251 (19.5%)	2,907 (19.5%)	0.00	-			13,251 (19.5%)	2,907 (19.5%)	0.00

Table 1: Dabigatran vs Warfarin

					PS-matched							
	Optur	n	I	MarketS	ican		Medica	are			POOLED	
Variable	WARFARIN	Dabigatran 150mg	St. Diff.	Reference - warfarin po	sure - Dabigatran 150mg	St. Diff.	Reference - warfarin po	sure - Dabigatran 150mg	St. Diff.	Reference - warfarin	Exposure - Dabigatran 150mg	St. Diff.
Number of patients	2,790	2,790		13,960	13,960		22,320	22,320		39,070	39,070	
Age												
mean (sd)	75.41 (7.35)	75.41 (7.13)	0.00	74.41 (10.11)	74.76 (9.22)	-0.04	77.04 (7.31)	77.18 (6.88)	-0.02	75.98 (8.42)	76.19 (7.81)	-0.03
median [IQR]	77.00 [71.00, 81.00]	77.00 [71.00, 81.00]	0.00	76.00 [69.00, 81.00]	76.00 [69.00, 81.00]	0.00	77.00 [73.00, 82.00]	77.00 [73.00, 82.00]	0.00	76.64 (8.42)	76.64 (7.81)	0.00
Age categories without zero category	50 (4.00()	22 (4.40)	0.05	520 (4.50)	420 (2.40()	0.07	200 (0.00()	02 (0.40/)	0.05	007 (2.20()	553 (4.40()	0.07
18 - 54; n (%) 55 - 64; n (%)	50 (1.8%) 145 (5.2%)	32 (1.1%) 153 (5.5%)	0.06 -0.01	628 (4.5%) 1,527 (10.9%)	428 (3.1%) 1,634 (11.7%)	0.07 -0.03	209 (0.9%) 414 (1.9%)	92 (0.4%) 310 (1.4%)	0.06 0.04	887 (2.3%) 2,086 (5.3%)	552 (1.4%) 2,097 (5.4%)	0.07 0.00
65 - 74; n (%)	661 (23.7%)	665 (23.8%)	0.00	3,394 (24.3%)	3,359 (24.1%)	0.00	6,138 (27.5%)	6,223 (27.9%)	-0.01	10,193 (26.1%)	10,247 (26.2%)	0.00
>=75; n (%)	1,934 (69.3%)	1,940 (69.5%)	0.00	8,411 (60.3%)	8,539 (61.2%)	-0.02	15,559 (69.7%)	15,695 (70.3%)	-0.01	25,904 (66.3%)	26,174 (67.0%)	-0.01
Gender without zero category- United	1,554 (65.570)	1,540 (65.570)	0.00	0,411 (00.5%)	0,555 (01.270)	0.02	13,333 (03.770)	13,033 (70.370)	0.01	25,504 (00.5%)	20,274 (07.070)	0.01
Males; n (%)	1,675 (60.0%)	1,675 (60.0%)	0.00	8,106 (58.1%)	8,134 (58.3%)	0.00	12,689 (56.9%)	12,580 (56.4%)	0.01	22,470 (57.5%)	22,389 (57.3%)	0.00
Females; n (%)	1,115 (40.0%)	1,115 (40.0%)	0.00	5,854 (41.9%)	5,826 (41.7%)	0.00	9,631 (43.1%)	9,740 (43.6%)	-0.01	16,600 (42.5%)	16,681 (42.7%)	0.00
Race												
White; n (%)							20,699 (92.7%)	20,744 (92.9%)		20,699 (92.7%)	20,744 (92.9%)	0.00
Black; n (%)							663 (3.0%)	656 (2.9%)		663 (3.0%)	656 (2.9%)	0.00
Asian; n (%)							289 (1.3%)	290 (1.3%)		289 (1.3%)	290 (1.3%)	0.00
Hispanic; n (%)							242 (1.1%)	219 (1.0%)		242 (1.1%)	219 (1.0%)	0.00
North American Native; n (%)							73 (0.3%)	67 (0.3%)		73 (0.3%)	67 (0.3%)	0.00
Other/Unknown; n (%) Region without zero category- United v3 (lumping							354 (1.6%)	344 (1.5%)		354 (1.6%)	344 (1.5%)	0.00
missing&other category with West)												
Northeast; n (%)	407 (14.6%)	401 (14.4%)	0.01	3,208 (23.0%)	3,249 (23.3%)	-0.01	4,283 (19.2%)	4,272 (19.1%)	0.00	7,898 (20.2%)	7,922 (20.3%)	0.00
South; n (%)	945 (33.9%)	945 (33.9%)	0.00	3,797 (27.2%)	3,765 (27.0%)	0.00	8,706 (39.0%)	8,595 (38.5%)	0.01	13,448 (34.4%)	13,305 (34.1%)	0.01
Midwest; n (%)	453 (16.2%)	456 (16.3%)	0.00	4,767 (34.1%)	4,766 (34.1%)	0.00	5,278 (23.6%)	5,344 (23.9%)	-0.01	10,498 (26.9%)	10,566 (27.0%)	0.00
West; n (%)	985 (35.3%)	988 (35.4%)	0.00	2,126 (15.2%)	2,119 (15.2%)	0.00	4,053 (18.2%)	4,109 (18.4%)	-0.01	7,164 (18.3%)	7,216 (18.5%)	-0.01
Unknown+missing; n (%)	N/A	N/A	#VALUE!	62 (0.4%)	61 (0.4%)	0.00	N/A	N/A	#VALUE!	62 (0.4%)	61 (0.4%)	0.00
CV Covariates												
Ischemic heart disease; n (%)	815 (29.2%)	800 (28.7%)	0.01	4,873 (34.9%)	4,841 (34.7%)	0.00	7,025 (31.5%)	6,988 (31.3%)	0.00	12,713 (32.5%)	12,629 (32.3%)	0.00
Acute MI; n (%)	18 (0.6%)	19 (0.7%)	-0.01	394 (2.8%)	378 (2.7%)	0.01	320 (1.4%)	337 (1.5%)	-0.01	732 (1.9%)	734 (1.9%)	0.00
ACS/unstable angina; n (%)	28 (1.0%)	28 (1.0%)	0.00	386 (2.8%)	384 (2.8%)	0.00	405 (1.8%)	400 (1.8%)	0.00	819 (2.1%)	812 (2.1%)	0.00
Old MI; n (%)	76 (2.7%)	69 (2.5%)	0.01	486 (3.5%)	464 (3.3%)	0.01	992 (4.4%)	952 (4.3%)	0.00	1554 (4.0%)	1485 (3.8%)	0.01
Stable angina; n (%)	100 (3.6%)	94 (3.4%)	0.01	556 (4.0%)	549 (3.9%)	0.01	864 (3.9%)	822 (3.7%)	0.01	1,520 (3.9%)	1,465 (3.7%)	0.01
Coronary atherosclerosis and other forms of chronic ischemic heart disease; n (%)	759 (27.2%)	754 (27.0%)	0.00	4.442 (31.8%)	4.376 (31.3%)	0.01	6.399 (28.7%)	6.373 (28.6%)	0.00	11.600 (29.7%)	11.503 (29.4%)	0.01
Other atherosclerosis with ICD10 v2 Copy: n (%)	759 (27.2%) 49 (1.8%)	754 (27.0%) 44 (1.6%)	0.00	4,442 (51.8%)	223 (1.6%)	0.01	296 (1.3%)	296 (1.3%)	0.00	586 (1.5%)	563 (1.4%)	0.01
Previous cardiac procedure (CABG or PTCA or Stent)	45 (1.0%)	44 (1.0%)	0.02	241 (1.770)	223 (1.0%)	0.01	250 (1.3%)	250 (1.3%)	0.00	360 (1.3%)	303 (1.4%)	0.01
v4; n (%)	3 (0.1%)	7 (0.3%)	-0.04	221 (1.6%)	142 (1.0%)	0.05	222 (1.0%)	125 (0.6%)	0.04	446 (1.1%)	274 (0.7%)	0.04
History of CABG or PTCA; n (%)	152 (5.4%)	139 (5.0%)	0.02	585 (4.2%)	611 (4.4%)	-0.01	1,677 (7.5%)	1,720 (7.7%)	-0.01	2,414 (6.2%)	2,470 (6.3%)	0.00
Any stroke; n (%)	244 (8.7%)	243 (8.7%)	0.00	1,310 (9.4%)	1,263 (9.0%)	0.01	1,529 (6.9%)	1,560 (7.0%)	0.00	3,083 (7.9%)	3,066 (7.8%)	0.00
Ischemic stroke (w and w/o mention of cerebral												
infarction); n (%)	243 (8.7%)	243 (8.7%)	0.00	1,307 (9.4%)	1,258 (9.0%)	0.01	1,521 (6.8%)	1,552 (7.0%)	-0.01	3,071 (7.9%)	3,053 (7.8%)	0.00
Hemorrhagic stroke; n (%)	3 (0.1%)	2 (0.1%)	0.00	6 (0.0%)	8 (0.1%)	-0.04	8 (0.0%)	9 (0.0%)	#DIV/0!	017 (0.0%)	19 (0.0%)	#DIV/0!
TIA; n (%)	132 (4.7%)	137 (4.9%)	-0.01	655 (4.7%)	636 (4.6%)	0.00	690 (3.1%)	663 (3.0%)	0.01	1477 (3.8%)	1436 (3.7%)	0.01
Other cerebrovascular disease; n (%)	43 (1.5%)	51 (1.8%)	-0.02	274 (2.0%)	290 (2.1%)	-0.01	390 (1.7%)	375 (1.7%)	0.00	707 (1.8%)	716 (1.8%)	0.00
Late effects of cerebrovascular disease; n (%)	11 (0.4%)	9 (0.3%)	0.02	17 (0.1%)	19 (0.1%)	0.00	66 (0.3%)	68 (0.3%)	0.00	94 (0.2%)	96 (0.2%)	0.00
Cerebrovascular procedure; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	21 (0.2%)	21 (0.2%)	0.00	19 (0.1%)	16 (0.1%)	0.00	040 (0.1%)	37 (0.1%)	0.00
Heart failure (CHF); n (%) Peripheral Vascular Disease (PVD) or PVD Surgery v2;	325 (11.6%)	326 (11.7%)	0.00	3,066 (22.0%)	3,013 (21.6%)	0.01	2,500 (11.2%)	2,580 (11.6%)	-0.01	5,891 (15.1%)	5,919 (15.1%)	0.00
n (%)	209 (7.5%)	203 (7.3%)	0.01	898 (6.4%)	922 (6.6%)	-0.01	1.212 (5.4%)	1.199 (5.4%)	0.00	2.319 (5.9%)	2.324 (5.9%)	0.00
Atrial fibrillation; n (%)	2,634 (94.4%)	2,641 (94.7%)	-0.01	13,289 (95.2%)	13,224 (94.7%)	0.02	19,244 (86.2%)	19,278 (86.4%)	-0.01	35,167 (90.0%)	35,143 (89.9%)	0.00
Other cardiac dysrhythmia; n (%)	1,200 (43.0%)	1.187 (42.5%)	0.01	4.384 (31.4%)	4.311 (30.9%)	0.01	8,194 (36.7%)	8,120 (36.4%)	0.01	13.778 (35.3%)	13.618 (34.9%)	0.00
Cardiac conduction disorders; n (%)	145 (5.2%)	174 (6.2%)	-0.04	894 (6.4%)	888 (6.4%)	0.00	1,301 (5.8%)	1,265 (5.7%)	0.00	2340 (6.0%)	2327 (6.0%)	0.00
Other CVD; n (%)	363 (13.0%)	333 (11.9%)	0.03	4,082 (29.2%)	4,009 (28.7%)	0.01	2,342 (10.5%)	2,297 (10.3%)	0.01	6,787 (17.4%)	6,639 (17.0%)	0.01
Diabetes-related complications												
Diabetic retinopathy; n (%)	38 (1.4%)	40 (1.4%)	0.00	187 (1.3%)	176 (1.3%)	0.00	222 (1.0%)	201 (0.9%)	0.01	#VALUE!	417 (1.1%)	#VALUE!
Diabetes with other ophthalmic manifestations; n		•										
(%)	1 (0.0%)	2 (0.1%)	-0.04	154 (1.1%)	121 (0.9%)	0.02	154 (0.7%)	137 (0.6%)	0.01	309 (0.8%)	260 (0.7%)	0.01
Retinal detachment, vitreous hemorrhage,												
vitrectomy; n (%)	9 (0.3%)	7 (0.3%)	0.00	36 (0.3%)	31 (0.2%)	0.02	31 (0.1%)	33 (0.1%)	0.00	076 (0.2%)	71 (0.2%)	0.00
Retinal laser coagulation therapy; n (%)	1 (0.0%)	2 (0.1%)	-0.04	26 (0.2%)	31 (0.2%)	0.00	43 (0.2%)	31 (0.1%)	0.03	70 (0.2%)	64 (0.2%)	0.00
Occurrence of Diabetic Neuropathy v2 Copy; n (%)	103 (3.7%)	110 (3.9%)	-0.01	436 (3.1%)	455 (3.3%)	-0.01	570 (2.6%)	569 (2.5%)	0.01	1109 (2.8%)	1134 (2.9%)	-0.01
Occurrence of diabetic nephropathy V3 with ICD10	0 (0.0%)	0 (0.0%)	#DIV/0!	0.00.000	0 (0 00/)	#DIV/0!	0.00.000	0 (0.0%)	#DIV/0!	0./0.00/1	0.00.000	#DIV/0!
Copy; n (%) Hypoglycemia v2; n (%)	0 (0.0%) 15 (0.5%)	0 (0.0%) 18 (0.6%)	#DIV/0! -0.01	0 (0.0%) 151 (1.1%)	0 (0.0%) 128 (0.9%)	#DIV/0! 0.02	0 (0.0%) 244 (1.1%)	0 (0.0%) 190 (0.9%)	#DIV/0! 0.02	0 (0.0%) 410 (1.0%)	0 (0.0%) 336 (0.9%)	#DIV/0! 0.01
Hyperglycemia; n (%)	15 (0.5%)	18 (0.6%)	0.01	255 (1.8%)	128 (0.9%) 282 (2.0%)	-0.01	1,028 (4.6%)	1,049 (4.7%)	0.02	410 (1.0%) 1400 (3.6%)	1436 (3.7%)	-0.01
Disorders of fluid electrolyte and acid-base balance; n	11/(4.270)	103 (3.0%)	0.02	233 (1.0/6)	202 (2.070)	-0.01	1,020 (4.0%)	1,047 (4.7/0)	0.00	1400 (3.0%)	1430 (3.7%)	-0.01
(%)	105 (3.8%)	107 (3.8%)	0.00	872 (6.2%)	880 (6.3%)	0.00	1,011 (4.5%)	1,061 (4.8%)	-0.01	1988 (5.1%)	2048 (5.2%)	0.00
Diabetic ketoacidosis; n (%)	2 (0.1%)	2 (0.1%)	0.00	19 (0.1%)	8 (0.1%)	0.00	24 (0.1%)	16 (0.1%)	0.00	45 (0.1%)	26 (0.1%)	0.00
Hyperosmolar hyperglycemic nonketotic syndrome	- (/9)	= (=:=:=/		-= (=:=:=)	= (=:=:=/		(/9)	== \=:=:=/		.= (=.=/0)	(/9)	2.50
(HONK); n (%)	2 (0.1%)	1 (0.0%)	0.04	12 (0.1%)	5 (0.0%)	0.04	17 (0.1%)	21 (0.1%)	0.00	31 (0.1%)	27 (0.1%)	0.00
Diabetes with peripheral circulatory disorders with												
ICD-10 v2 Copy; n (%)	68 (2.4%)	46 (1.6%)	0.06	242 (1.7%)	225 (1.6%)	0.01	361 (1.6%)	384 (1.7%)	-0.01	671 (1.7%)	655 (1.7%)	0.00
Diabetic Foot; n (%)	46 (1.6%)	38 (1.4%)	0.02	243 (1.7%)	261 (1.9%)	-0.02	358 (1.6%)	423 (1.9%)	-0.02	647 (1.7%)	722 (1.8%)	-0.01
Gangrene v2; n (%)	3 (0.1%)	1 (0.0%)	0.04	13 (0.1%)	15 (0.1%)	0.00	14 (0.1%)	11 (0.0%)	0.04	030 (0.1%)	27 (0.1%)	0.00

Lower extremity amputation; n (%)	2 (0.1%)	8 (0.3%)	-0.04	15 (0.1%)	27 (0.2%)	-0.03	33 (0.1%)	38 (0.2%)	-0.03	050 (0.1%)	073 (0.2%)	-0.03
Osteomyelitis: n (%)	5 (0.2%)	4 (0.1%)	0.03	40 (0.3%)	48 (0.3%)	0.00	43 (0.2%)	47 (0.2%)	0.00	88 (0.2%)	99 (0.3%)	-0.02
Skin infections v2; n (%)	119 (4.3%)	131 (4.7%)	-0.02	711 (5.1%)	748 (5.4%)	-0.01	967 (4.3%)	1,042 (4.7%)	-0.02	1797 (4.6%)	1921 (4.9%)	-0.01
Erectile dysfunction; n (%)	58 (2.1%)	63 (2.3%)	-0.01	215 (1.5%)	215 (1.5%)	0.00	223 (1.0%)	192 (0.9%)	0.01	496 (1.3%)	470 (1.2%)	0.01
Diabetes with unspecified complication; n (%)	19 (0.7%)	19 (0.7%)	0.00	115 (0.8%)	92 (0.7%)	0.01	150 (0.7%)	125 (0.6%)	0.01	284 (0.7%)	236 (0.6%)	0.01
Diabetes mellitus without mention of complications;												
n (%)	803 (28.8%)	788 (28.2%)	0.01	3,509 (25.1%)	3,454 (24.7%)	0.01	6,004 (26.9%)	5,993 (26.9%)	0.00	10,316 (26.4%)	10,235 (26.2%)	0.00
Hypertension: 1 inpatient or 2 outpatient claims												
within 365 days; n (%)	2,143 (76.8%)	2,129 (76.3%)	0.01	9,249 (66.3%)	9,189 (65.8%)	0.01	18,608 (83.4%)	18,599 (83.3%)	0.00	30,000 (76.8%)	29,917 (76.6%)	0.00
Hyperlipidemia v2; n (%) Edema: n (%)	1,705 (61.1%) 233 (8.4%)	1,697 (60.8%) 230 (8.2%)	0.01 0.01	5,935 (42.5%) 1,038 (7.4%)	5,767 (41.3%) 981 (7.0%)	0.02 0.02	11,060 (49.6%) 1.262 (5.7%)	10,934 (49.0%) 1.296 (5.8%)	0.01	18,700 (47.9%) 2533 (6.5%)	18,398 (47.1%) 2507 (6.4%)	0.02 0.00
	/	1 (0.0%)	#DIV/0!	1,038 (7.4%)		#DIV/0!	1,262 (5.7%)	, ,	#DIV/0!	2533 (6.5%)		#DIV/0!
Renal Dysfunction (non-diabetic) v2; n (%) Occurrence of acute renal disease v2: n (%)	1 (0.0%) 0 (0.0%)	1 (0.0%)	#DIV/0!	6 (0.0%)	6 (0.0%) 6 (0.0%)	#DIV/0!	3 (0.0%)	3 (0.0%) 3 (0.0%)	#DIV/0!	9 (0.0%)	10 (0.0%) 10 (0.0%)	#DIV/0!
Occurrence of chronic renal insufficiency; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Chronic kidney disease v2: n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
CKD Stage 3-4; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Occurrence of hypertensive nephropathy; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Occurrence of miscellaneous renal insufficiency v2; n	,	,		,	,		,			,	,	
(%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Glaucoma or cataracts v2; n (%)	605 (21.7%)	645 (23.1%)	-0.03	3,101 (22.2%)	3,062 (21.9%)	0.01	4,898 (21.9%)	5,044 (22.6%)	-0.02	8,604 (22.0%)	8,751 (22.4%)	-0.01
Cellulitis or abscess of toe; n (%)	15 (0.5%)	16 (0.6%)	-0.01	68 (0.5%)	89 (0.6%)	-0.01	143 (0.6%)	150 (0.7%)	-0.01	226 (0.6%)	255 (0.7%)	-0.01
Foot ulcer; n (%)	48 (1.7%)	39 (1.4%)	0.02	248 (1.8%)	264 (1.9%)	-0.01	310 (1.4%)	369 (1.7%)	-0.02	606 (1.6%)	672 (1.7%)	-0.01
Bladder stones; n (%)	8 (0.3%)	5 (0.2%)	0.02	15 (0.1%)	26 (0.2%)	-0.03	28 (0.1%)	23 (0.1%)	0.00	51 (0.1%)	54 (0.1%)	0.00
Kidney stones; n (%)	29 (1.0%)	32 (1.1%)	-0.01	181 (1.3%)	213 (1.5%)	-0.02	270 (1.2%)	257 (1.2%)	0.00	480 (1.2%)	502 (1.3%)	-0.01
Urinary tract infections (UTIs); n (%)	194 (7.0%)	181 (6.5%)	0.02	860 (6.2%)	893 (6.4%)	-0.01	1,803 (8.1%)	1,851 (8.3%)	-0.01	2,857 (7.3%)	2,925 (7.5%)	-0.01
Dipstick urinalysis; n (%)	817 (29.3%)	853 (30.6%)	-0.03	2,796 (20.0%)	2,903 (20.8%)	-0.02	7,125 (31.9%)	7,263 (32.5%)	-0.01	10,738 (27.5%)	11,019 (28.2%)	-0.02
Non-dipstick urinalysis; n (%)	355 (12.7%)	332 (11.9%)	0.02	689 (4.9%)	710 (5.1%)	-0.01	2,558 (11.5%)	2,600 (11.6%)	0.00	3,602 (9.2%)	3,642 (9.3%)	0.00
Urine function test; n (%)	106 (3.8%) 40 (1.4%)	93 (3.3%) 37 (1.3%)	0.03 0.01	623 (4.5%) 357 (2.6%)	599 (4.3%) 338 (2.4%)	0.01 0.01	888 (4.0%) 365 (1.6%)	889 (4.0%) 391 (1.8%)	0.00 -0.02	1617 (4.1%) 762 (2.0%)	1581 (4.0%) 766 (2.0%)	0.01 0.00
Cytology; n (%) Cystoscopy; n (%)	40 (1.4%) 50 (1.8%)	37 (1.3%) 45 (1.6%)	0.01	357 (2.6%) 342 (2.4%)	338 (2.4%) 361 (2.6%)	-0.01	493 (2.2%)	456 (2.0%)	0.02	762 (2.0%) 885 (2.3%)	862 (2.2%)	0.00
Other Covariates	30 (1.6%)	43 (1.0%)	0.02	342 (2.470)	301 (2.0%)	-0.01	455 (2.270)	430 (2.0%)	0.01	003 (2.3%)	802 (2.270)	0.01
Liver disease: n (%)	12 (0.4%)	13 (0.5%)	-0.01	85 (0.6%)	84 (0.6%)	0.00	93 (0.4%)	90 (0.4%)	0.00	190 (0.5%)	187 (0.5%)	0.00
Osteoarthritis: n (%)	488 (17.5%)	471 (16.9%)	0.02	2,145 (15.4%)	2,035 (14.6%)	0.02	3,559 (15.9%)	3,519 (15.8%)	0.00	6192 (15.8%)	6025 (15.4%)	0.01
Other arthritis, arthropathies and musculoskeletal	400 (17.5%)	471 (10.5%)	0.02	2,245 (25.476)	2,033 (24.070)	0.02	3,333 (13.370)	3,313 (13.0%)	0.00	0132 (13.0%)	0023 (23.476)	0.01
pain; n (%)	865 (31.0%)	849 (30.4%)	0.01	4,550 (32.6%)	4,451 (31.9%)	0.01	6,586 (29.5%)	6,545 (29.3%)	0.00	12001 (30.7%)	11845 (30.3%)	0.01
Dorsopathies; n (%)	503 (18.0%)	500 (17.9%)	0.00	2,553 (18.3%)	2,541 (18.2%)	0.00	3,859 (17.3%)	3,772 (16.9%)	0.01	6915 (17.7%)	6813 (17.4%)	0.01
Fractures; n (%)	56 (2.0%)	62 (2.2%)	-0.01	474 (3.4%)	477 (3.4%)	0.00	701 (3.1%)	699 (3.1%)	0.00	1231 (3.2%)	1238 (3.2%)	0.00
Falls v2; n (%)	74 (2.7%)	67 (2.4%)	0.02	124 (0.9%)	135 (1.0%)	-0.01	260 (1.2%)	252 (1.1%)	0.01	458 (1.2%)	454 (1.2%)	0.00
Osteoporosis; n (%)	159 (5.7%)	177 (6.3%)	-0.03	973 (7.0%)	963 (6.9%)	0.00	1,668 (7.5%)	1,687 (7.6%)	0.00	2800 (7.2%)	2827 (7.2%)	0.00
Hyperthyroidism; n (%)	23 (0.8%)	23 (0.8%)	0.00	122 (0.9%)	92 (0.7%)	0.02	187 (0.8%)	207 (0.9%)	-0.01	332 (0.8%)	322 (0.8%)	0.00
Hypothyroidism v2; n (%)	381 (13.7%)	405 (14.5%)	-0.02	1,399 (10.0%)	1,455 (10.4%)	-0.01	2,639 (11.8%)	2,604 (11.7%)	0.00	4419 (11.3%)	4464 (11.4%)	0.00
Other disorders of thyroid gland V2; n (%)	56 (2.0%)	68 (2.4%)	-0.03	344 (2.5%)	361 (2.6%)	-0.01	593 (2.7%)	567 (2.5%)	0.01	993 (2.5%)	996 (2.5%)	0.00
Depression; n (%)	132 (4.7%)	135 (4.8%)	0.00	675 (4.8%)	663 (4.7%)	0.00	1,132 (5.1%)	1,065 (4.8%)	0.01	1939 (5.0%)	1863 (4.8%)	0.01
Anxiety; n (%)	144 (5.2%)	141 (5.1%)	0.00	545 (3.9%)	540 (3.9%)	0.00	1,013 (4.5%)	973 (4.4%)	0.00	1702 (4.4%)	1654 (4.2%)	0.01
Sleep_Disorder; n (%)	267 (9.6%)	255 (9.1%)	0.02	1,617 (11.6%)	1,579 (11.3%)	0.01 -0.01	1,438 (6.4%)	1,405 (6.3%)	0.00	3322 (8.5%)	3239 (8.3%)	0.01
Dementia; n (%) Delirium; n (%)	117 (4.2%) 21 (0.8%)	106 (3.8%) 15 (0.5%)	0.02	466 (3.3%) 110 (0.8%)	469 (3.4%) 121 (0.9%)	-0.01 -0.01	822 (3.7%) 135 (0.6%)	843 (3.8%) 133 (0.6%)	-0.01 0.00	1405 (3.6%) 266 (0.7%)	1418 (3.6%) 269 (0.7%)	0.00
Psychosis; n (%)	9 (0.3%)	12 (0.4%)	-0.02	100 (0.8%)	102 (0.7%)	0.00	168 (0.8%)	150 (0.0%)	0.00	277 (0.7%)	264 (0.7%)	0.00
Obesity; n (%)	273 (9.8%)	266 (9.5%)	0.02	1.009 (7.2%)	980 (7.0%)	0.01	2.080 (9.3%)	2.050 (9.2%)	0.00	3362 (8.6%)	3296 (8.4%)	0.00
Overweight: n (%)	79 (2.8%)	79 (2.8%)	0.00	102 (0.7%)	92 (0.7%)	0.00	424 (1.9%)	405 (1.8%)	0.01	605 (1.5%)	576 (1.5%)	0.00
Smoking; n (%)	230 (8.2%)	213 (7.6%)	0.02	743 (5.3%)	741 (5.3%)	0.00	3,157 (14.1%)	3.046 (13.6%)	0.01	4130 (10.6%)	4000 (10.2%)	0.01
Alcohol abuse or dependence; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Drug abuse or dependence; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
COPD; n (%)	295 (10.6%)	294 (10.5%)	0.00	1,844 (13.2%)	1,797 (12.9%)	0.01	2,146 (9.6%)	2,079 (9.3%)	0.01	4285 (11.0%)	4170 (10.7%)	0.01
Asthma; n (%)	127 (4.6%)	130 (4.7%)	0.00	754 (5.4%)	749 (5.4%)	0.00	917 (4.1%)	881 (3.9%)	0.01	1798 (4.6%)	1760 (4.5%)	0.00
Obstructive sleep apnea; n (%)	270 (9.7%)	242 (8.7%)	0.03	1,345 (9.6%)	1,319 (9.4%)	0.01	1,262 (5.7%)	1,225 (5.5%)	0.01	2877 (7.4%)	2786 (7.1%)	0.01
Pneumonia; n (%)	33 (1.2%)	45 (1.6%)	-0.03	833 (6.0%)	848 (6.1%)	0.00	772 (3.5%)	783 (3.5%)	0.00	1638 (4.2%)	1676 (4.3%)	0.00
Imaging; n (%)	0 (0.0%)	1 (0.0%)	#DIV/0!	25 (0.2%)	17 (0.1%)	0.03	26 (0.1%)	30 (0.1%)	0.00	51 (0.1%)	48 (0.1%)	0.00
Other Medications	961 (34.4%)	951 (34.1%)	0.01	4.040 (25.40()	4.936 (35.4%)	0.00	7.744 (34.7%)	7.830 (35.1%)	-0.01	13645 (34.9%)	13717 (35.1%)	0.00
Use of ACE inhibitors; n (%)	961 (34.4%) 543 (19.5%)	951 (34.1%) 542 (19.4%)	0.01	4,940 (35.4%) 3.304 (23.7%)	4,936 (35.4%)	0.00	7,744 (34.7%) 4.971 (22.3%)	7,830 (35.1%) 4.922 (22.1%)	-0.01	13645 (34.9%) 8818 (22.6%)	13/1/ (35.1%) 8749 (22.4%)	0.00
Use of ARBs; n (%) Use of Loop Diuretics - United; n (%)	467 (16.7%)	542 (19.4%) 464 (16.6%)	0.00	3,441 (24.6%)	3,285 (23.5%)	0.00	4,971 (22.3%) 4,396 (19.7%)	4,922 (22.1%) 4,390 (19.7%)	0.00	8818 (22.6%) 8304 (21.3%)	8749 (22.4%) 8134 (20.8%)	0.00
Use of other diuretics - United; n (%)	80 (2.9%)	84 (3.0%)	-0.01	716 (5.1%)	693 (5.0%)	0.00	727 (3.3%)	4,390 (19.7%) 771 (3.5%)	-0.01	1523 (3.9%)	1548 (4.0%)	-0.01
Use of nitrates-United; n (%)	170 (6.1%)	137 (4.9%)	0.05	1,278 (9.2%)	1,156 (8.3%)	0.03	1,979 (8.9%)	1,698 (7.6%)	0.05	3427 (8.8%)	2991 (7.7%)	0.04
Use of other hypertension drugs; n (%)	225 (8.1%)	220 (7.9%)	0.01	904 (6.5%)	997 (7.1%)	-0.02	1,616 (7.2%)	1,612 (7.2%)	0.00	2745 (7.0%)	2829 (7.2%)	-0.01
Use of digoxin- United; n (%)	319 (11.4%)	302 (10.8%)	0.02	2.692 (19.3%)	2.018 (14.5%)	0.13	2.933 (13.1%)	2,579 (11.6%)	0.05	5944 (15.2%)	4899 (12.5%)	0.08
Use of Anti-arrhythmics; n (%)	395 (14.2%)	406 (14.6%)	-0.01	2,766 (19.8%)	2,652 (19.0%)	0.02	3,619 (16.2%)	3,526 (15.8%)	0.01	6780 (17.4%)	6584 (16.9%)	0.01
Use of COPD/asthma meds- United; n (%)	436 (15.6%)	410 (14.7%)	0.03	2,621 (18.8%)	2,717 (19.5%)	-0.02	3,827 (17.1%)	3,626 (16.2%)	0.02	6884 (17.6%)	6753 (17.3%)	0.01
Use of statins; n (%)	1,516 (54.3%)	1,505 (53.9%)	0.01	7,744 (55.5%)	7,735 (55.4%)	0.00	12,406 (55.6%)	12,391 (55.5%)	0.00	21666 (55.5%)	21631 (55.4%)	0.00
Use of other lipid-lowering drugs; n (%)	228 (8.2%)	203 (7.3%)	0.03	1,425 (10.2%)	1,428 (10.2%)	0.00	1,695 (7.6%)	1,671 (7.5%)	0.00	3348 (8.6%)	3302 (8.5%)	0.00
Use of antiplatelet agents; n (%)	261 (9.4%)	258 (9.2%)	0.01	2,273 (16.3%)	2,255 (16.2%)	0.00	2,842 (12.7%)	2,828 (12.7%)	0.00	5376 (13.8%)	5341 (13.7%)	0.00
Use of heparin and other low-molecular weight												
heparins; n (%)	10 (0.4%)	11 (0.4%)	0.00	1 (0.0%)	2 (0.0%)	#DIV/0!	113 (0.5%)	125 (0.6%)	-0.01	124 (0.3%)	138 (0.4%)	-0.02
Use of NSAIDs; n (%)	284 (10.2%)	269 (9.6%)	0.02	1,482 (10.6%)	1,438 (10.3%)	0.01	2,600 (11.6%)	2,593 (11.6%)	0.00	4366 (11.2%)	4300 (11.0%)	0.01
Use of oral corticosteroids; n (%)	443 (15.9%)	443 (15.9%)	0.00	2,669 (19.1%)	2,624 (18.8%)	0.01	4,130 (18.5%)	4,126 (18.5%)	0.00	7242 (18.5%)	7193 (18.4%)	0.00
Use of bisphosphonate (United); n (%)	85 (3.0%)	102 (3.7%)	-0.04	671 (4.8%)	644 (4.6%)	0.01	894 (4.0%)	892 (4.0%)	0.00	1650 (4.2%)	1638 (4.2%)	0.00
Use of opioids- United; n (%)	534 (19.1%)	536 (19.2%)	0.00	3,392 (24.3%)	3,321 (23.8%)	0.01	5,044 (22.6%)	4,995 (22.4%)	0.00	8970 (23.0%)	8852 (22.7%) 6787 (17.4%)	0.01
Use of antidepressants; n (%)	452 (16.2%)	448 (16.1%)	0.00	2,414 (17.3%)	2,392 (17.1%)	0.01	4,003 (17.9%)	3,947 (17.7%)	0.01	6869 (17.6%)	0/8/(1/.4%)	0.01

Use of antipsychotics; n (%)	23 (0.8%)	23 (0.8%)	0.00	158 (1.1%)	158 (1.1%)	0.00	337 (1.5%)	349 (1.6%)	-0.01	518 (1.3%)	530 (1.4%)	-0.01
Use of anticonvulsants; n (%)	262 (9.4%)	232 (8.3%)	0.00	1,177 (8.4%)	1,202 (8.6%)	-0.01	2,161 (9.7%)	2,125 (9.5%)	0.01	3600 (9.2%)	3559 (9.1%)	0.00
Use of lithium- United; n (%)	3 (0.1%)	3 (0.1%)	0.00	12 (0.1%)	13 (0.1%)	0.00	11 (0.0%)	19 (0.1%)	-0.04	26 (0.1%)	35 (0.1%)	0.00
Use of Benzos- United; n (%)	177 (6.3%)	186 (6.7%)	-0.02	1,811 (13.0%)	1,800 (12.9%)	0.00	1,595 (7.1%)	1,599 (7.2%)	0.00	3583 (9.2%)	3585 (9.2%)	0.00
Use of anxiolytics/hypnotics- United; n (%)	167 (6.0%)	165 (5.9%)	0.00	1,000 (7.2%)	984 (7.0%)	0.01	1,478 (6.6%)	1,447 (6.5%)	0.00	2645 (6.8%)	2596 (6.6%)	0.01
Use of dementia meds- United; n (%)	103 (3.7%)	94 (3.4%)	0.02	447 (3.2%)	458 (3.3%)	-0.01	856 (3.8%)	821 (3.7%)	0.01	1406 (3.6%)	1373 (3.5%)	0.01
Use of antiparkinsonian meds- United; n (%)	41 (1.5%)	42 (1.5%)	0.00	345 (2.5%)	349 (2.5%)	0.00	623 (2.8%)	604 (2.7%)	0.01	1009 (2.6%)	995 (2.5%)	0.01
Any use of pramlintide; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	3 (0.0%)	7 (0.1%)	-0.04	3 (0.0%)	1 (0.0%)	#DIV/0!	6 (0.0%)	8 (0.0%)	#DIV/0!
Any use of 1st generation sulfonylureas; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	6 (0.0%)	5 (0.0%)	#DIV/0!	3 (0.0%)	4 (0.0%)	#DIV/0!	9 (0.0%)	9 (0.0%)	0.00
Entresto (sacubitril/valsartan); n (%) Labs	6 (0.2%)	3 (0.1%)	0.03	7 (0.1%)	1 (0.0%)	0.04	4 (0.0%)	7 (0.0%)	#DIV/0!	17 (0.0%) 16,750	11 (0.0%) 16,750	0.00
Lab values- HbA1c (%) v3; n (%)	319 (11.4%)	309 (11.1%)	0.01	113 (0.8%)	94 (0.7%)	0.01	N/A	N/A	#VALUE!	432 (2.6%)	403 (2.4%)	0.01
Lab values- HbA1c (%) (within 3 months) v3; n (%)	205 (7.3%)	202 (7.2%)	0.00	87 (0.6%)	61 (0.4%)	0.03	N/A	N/A	#VALUE!	292 (1.7%)	263 (1.6%)	0.01
Lab values- HbA1c (%) (within 6 months) v3; n (%)	319 (11.4%)	309 (11.1%)	0.01	113 (0.8%)	94 (0.7%)	0.01	N/A	N/A	#VALUE!	432 (2.6%)	403 (2.4%)	0.01
Lab values- BNP; n (%)	27 (1.0%)	28 (1.0%)	0.00	10 (0.1%)	17 (0.1%)	0.00	N/A	N/A	#VALUE!	37 (0.2%)	45 (0.3%)	-0.02
Lab values- BNP (within 3 months); n (%)	23 (0.8%)	24 (0.9%)	-0.01	8 (0.1%)	14 (0.1%)	0.00	N/A	N/A	#VALUE!	31 (0.2%)	38 (0.2%)	0.00
Lab values- BNP (within 6 months); n (%)	27 (1.0%)	28 (1.0%)	0.00	10 (0.1%)	17 (0.1%)	0.00	N/A	N/A	#VALUE!	37 (0.2%)	45 (0.3%)	-0.02
Lab values- BUN (mg/dl); n (%)	604 (21.6%)	673 (24.1%)	-0.06	111 (0.8%)	144 (1.0%)	-0.02	N/A	N/A	#VALUE!	715 (4.3%)	817 (4.9%)	-0.03
Lab values- BUN (mg/dl) (within 3 months); n (%)	421 (15.1%)	456 (16.3%)	-0.03	83 (0.6%)	105 (0.8%)	-0.02	N/A	N/A	#VALUE!	504 (3.0%)	561 (3.3%)	-0.02
Lab values- BUN (mg/dl) (within 6 months); n (%) Lab values- Creatinine (mg/dl) v2; n (%)	604 (21.6%) 614 (22.0%)	673 (24.1%) 686 (24.6%)	-0.06 -0.06	111 (0.8%) 111 (0.8%)	144 (1.0%) 159 (1.1%)	-0.02 -0.03	N/A N/A	N/A N/A	#VALUE! #VALUE!	715 (4.3%) 725 (4.3%)	817 (4.9%) 845 (5.0%)	-0.03 -0.03
Lab values- Creatinine (mg/dl) (within 3 months) v2;	014 (22.0%)	080 (24.0%)	-0.00	111 (0.6%)	135 (1.1%)	-0.03	N/A	IV/A	#VALUE:	723 (4.3%)	843 (3.0%)	-0.03
n (%)	427 (15.3%)	465 (16.7%)	-0.04	82 (0.6%)	112 (0.8%)	-0.02	N/A	N/A	#VALUE!	509 (3.0%)	577 (3.4%)	-0.02
Lab values- Creatinine (mg/dl) (within 6 months) v2;												
n (%)	614 (22.0%)	686 (24.6%)	-0.06	111 (0.8%)	159 (1.1%)	-0.03	N/A	N/A	#VALUE!	725 (4.3%)	845 (5.0%)	-0.03
Lab values- HDL level (mg/dl); n (%)	464 (16.6%)	500 (17.9%)	-0.03	94 (0.7%)	106 (0.8%)	-0.01	N/A	N/A	#VALUE!	558 (3.3%)	606 (3.6%)	-0.02
	291 (10.4%)	320 (11.5%)	-0.04	70 (0.5%)	68 (0.5%)	0.00	N/A	N/A	#VALUE!	361 (2.2%)	388 (2.3%)	-0.01
Lab values- HDL level (mg/dl) (within 3 months); n (%)	291 (10.4%)	320 (11.5%)	-0.04	70 (0.5%)	08 (0.5%)	0.00	N/A	N/A	#VALUE!	301 (2.2%)	388 (2.3%)	-0.01
Lab values- HDL level (mg/dl) (within 6 months); n (%)	464 (16.6%)	500 (17.9%)	-0.03	94 (0.7%)	106 (0.8%)	-0.01	N/A	N/A	#VALUE!	558 (3.3%)	606 (3.6%)	-0.02
Lab values-LDL level (mg/dl) v2; n (%)	487 (17.5%)	527 (18.9%)	-0.04	117 (0.8%)	115 (0.8%)	0.00	N/A	N/A	#VALUE!	604 (3.6%)	642 (3.8%)	-0.01
Lab values- LDL level (mg/dl) (within 3 months) v2; n												
(%)	305 (10.9%)	338 (12.1%)	-0.04	88 (0.6%)	74 (0.5%)	0.01	N/A	N/A	#VALUE!	393 (2.3%)	412 (2.5%)	-0.01
Lab values- LDL level (mg/dl) (within 6 months) v2; n	487 (17.5%)	527 (18.9%)	-0.04	117 (0.8%)	115 (0.8%)	0.00	N/A	N/A	#VALUE!	604 (3.6%)	642 (3.8%)	-0.01
(%) Lab values- NT-proBNP; n (%)	487 (17.5%) 4 (0.1%)	1 (0.0%)	0.04	0 (0.0%)	0 (0.0%)	#DIV/0!	N/A N/A	N/A	#VALUE!	04 (0.0%)	1 (0.0%)	#DIV/0!
Lab values- NT-proBNP (within 3 months): n (%)	3 (0.1%)	0 (0.0%)	0.04	0 (0.0%)	0 (0.0%)	#DIV/0!	N/A	N/A	#VALUE!	03 (0.0%)	0 (0.0%)	#DIV/O:
Lab values- NT-proBNP (within 6 months): n (%)	4 (0.1%)	1 (0.0%)	0.04	0 (0.0%)	0 (0.0%)	#DIV/0!	N/A	N/A	#VALUE!	04 (0.0%)	1 (0.0%)	-
Lab values-Total cholesterol (mg/dl) v2; n (%)	467 (16.7%)	508 (18.2%)	-0.04	95 (0.7%)	117 (0.8%)	-0.01	N/A	N/A	#VALUE!	562 (3.4%)	625 (3.7%)	-0.02
Lab values- Total cholesterol (mg/dl) (within 3												
months) v2; n (%)	294 (10.5%)	325 (11.6%)	-0.04	70 (0.5%)	73 (0.5%)	0.00	N/A	N/A	#VALUE!	364 (2.2%)	398 (2.4%)	-0.01
Lab values-Total cholesterol (mg/dl) (within 6 months) v2; n (%)	467 (16.7%)	508 (18.2%)	-0.04	95 (0.7%)	117 (0.8%)	-0.01	N/A	N/A	#VALUE!	562 (3.4%)	625 (3.7%)	-0.02
Lab values-Triglyceride level (mg/dl); n (%)	464 (16.6%)	508 (18.2%)	-0.04	94 (0.7%)	107 (0.8%)	-0.01	N/A N/A	N/A N/A	#VALUE!	558 (3.3%)	610 (3.6%)	-0.02
Lab values-Triglyceride level (mg/dl) (within 3	404 (10.0%)	303 (18.0%)	-0.04	54 (0.7%)	107 (0.8%)	-0.01	N/A	N/A	#VALUE:	330 (3.370)	010 (3.0%)	-0.02
months); n (%)	291 (10.4%)	322 (11.5%)	-0.04	71 (0.5%)	68 (0.5%)	0.00	N/A	N/A	#VALUE!	362 (2.2%)	390 (2.3%)	-0.01
Lab values-Triglyceride level (mg/dl) (within 6												
months); n (%)	464 (16.6%)	503 (18.0%)	-0.04	94 (0.7%)	107 (0.8%)	-0.01	N/A	N/A	#VALUE!	558 (3.3%)	610 (3.6%)	-0.02
Lab result number-HbA1c (%) mean (only 2 to 20	315	307		100	87		N/A	N/A		415	394	
included) v4 mean (sd)	6.57 (1.13)	6.54 (1.37)	0.02	7.01 (1.41)	6.75 (1.08)	0.21	N/A N/A	N/A N/A	#VALUE!	6.68 (1.20)	6.59 (1.31)	0.07
median [IQR]	6.20 [5.80, 7.00]	6.30 [5.80, 7.00]	-0.08	6.60 [6.10, 7.77]	6.50 [6.00, 7.25]	0.21	N/A	N/A	#VALUE!	6.30 (1.20)	6.34 (1.31)	-0.03
Missing; n (%)	2,475 (88.7%)	2,483 (89.0%)	-0.01	13,860 (99.3%)	13,873 (99.4%)	-0.01	N/A	N/A	#VALUE!	16,335 (97.5%)	16,356 (97.6%)	-0.01
Lab result number- BNP mean v2	27	28		10	17		N/A	N/A		37	45	
mean (sd)	358.65 (541.48)	214.33 (164.51)	0.36	217.51 (147.78)	180.30 (209.53)	0.21	N/A	N/A	#VALUE!	320.50 (479.58)	201.47 (184.72)	0.33
median [IQR]	216.30 [103.00, 361.00]	170.15 [69.72, 343.75]	0.12	233.50 [71.50, 328.00]	121.00 [59.00, 245.00]	0.62	N/A	N/A	#VALUE!	220.95 (479.58)	151.58 (184.72)	0.19
Missing; n (%)	2,763 (99.0%)	2,762 (99.0%)	0.00	13,950 (99.9%)	13,943 (99.9%)	0.00	N/A	N/A	#VALUE!	16,713 (99.8%)	16,705 (99.7%)	0.02
Lab result number- BUN (mg/dl) mean v2	604 17.89 (5.80)	673	0.03	111	144	-0.14	N/A N/A	N/A N/A	#VALUE!	715	817 17.87 (5.34)	0.00
mean (sd) median [IQR]	17.89 (5.80)	17.74 (5.21) 17.00 [14.00, 21.00]	0.03	17.65 (5.69) 17.00 [14.00, 21.00]	18.46 (5.89) 18.00 [15.00, 22.00]	-0.14 -0.17	N/A N/A	N/A N/A	#VALUE!	17.85 (5.79) 17.42 (5.79)	17.18 (5.34)	0.00
Missing; n (%)	2,186 (78.4%)	2,117 (75.9%)	0.06	13,849 (99.2%)	13,816 (99.0%)	0.02	N/A	N/A	#VALUE!	16,035 (95.7%)	15,933 (95.1%)	0.04
Lab result number- Creatinine (mg/dl) mean (only 0.1	2,200 (70.470)	2,227 (75.570)	0.00	13,043 (33.270)	15,010 (55.0%)	0.02	1971	.,,,	www.coc.	10,033 (33.770)	13,555 (55.170)	0.03
to 15 included) v3	607	682		110	157		N/A	N/A		717	839	
mean (sd)	0.98 (0.25)	0.98 (0.21)	0.00	0.98 (0.22)	0.98 (0.24)	0.00	N/A	N/A	#VALUE!	0.98 (0.25)	0.98 (0.22)	0.00
median [IQR]	0.95 [0.82, 1.10]	0.96 [0.83, 1.10]	-0.04	0.96 [0.81, 1.10]	0.94 [0.80, 1.10]	0.09	N/A	N/A	#VALUE!	0.95 (0.25)	0.96 (0.22)	-0.04
Missing; n (%)	2,183 (78.2%)	2,108 (75.6%)	0.06	13,850 (99.2%)	13,803 (98.9%)	0.03	N/A	N/A	#VALUE!	16,033 (95.7%)	15,911 (95.0%)	0.03
Lab result number- HDL level (mg/dl) mean (only =<5000 included) v2	464	500		94	106		N/A	N/A		558	606	
mean (sd)	51.27 (15.97)	52.85 (17.18)	-0.10	45.87 (15.62)	48.01 (17.14)	-0.13	N/A N/A	N/A N/A	#VALUE!	50.36 (15.93)	52.00 (17.19)	-0.10
median [IQR]	48.25 [40.00, 60.00]	50.00 [41.00, 62.00]	-0.11	45.50 [34.00, 54.12]	47.50 [35.75, 59.25]	-0.12	N/A	N/A	#VALUE!	47.79 (15.93)	49.56 (17.19)	-0.11
Missing; n (%)	2,326 (83.4%)	2,290 (82.1%)	0.03	13,866 (99.3%)	13,854 (99.2%)	0.01	N/A	N/A	#VALUE!	16,192 (96.7%)	16,144 (96.4%)	0.02
Lab result number- LDL level (mg/dl) mean (only												
=<5000 included) v2	472	512		95	110		N/A	N/A		567	622	
mean (sd)	89.15 (32.99)	87.59 (33.46)	0.05	82.89 (29.91)	79.99 (36.33)	0.09	N/A	N/A	#VALUE!	88.10 (32.53)	86.25 (34.01)	0.06
median [IQR]	84.83 [68.50, 108.00]	82.00 [66.00, 109.00]	0.09	80.00 [64.50, 101.00]	79.25 [57.38, 101.25]	0.02	N/A	N/A	#VALUE!	84.02 (32.53)	81.51 (34.01)	0.08
Missing; n (%) Lab result number-Total cholesterol (mg/dl) mean	2,318 (83.1%)	2,278 (81.6%)	0.04	13,865 (99.3%)	13,850 (99.2%)	0.01	N/A	N/A	#VALUE!	16,183 (96.6%)	16,128 (96.3%)	0.02
(only =<5000 included) v2	467	508		95	117		N/A	N/A		562	625	
mean (sd)	166.51 (40.78)	165.12 (40.18)	0.03	154.47 (33.16)	157.68 (41.05)	-0.09	N/A	N/A	#VALUE!	164.47 (39.64)	163.73 (40.38)	0.02
					,					. ,		

median [IQR] Missing; n (%)	2,323 (83.3%)	159.00 [138.00, 192.00] 2,282 (81.8%)	0.07	154.00 [132.50, 175.00] 13,865 (99.3%)	13,843 (99.2%)	-0.13 0.01	N/A N/A	N/A N/A	#VALUE! #VALUE!	160.65 (39.64) 16,188 (96.6%)	159.00 (40.38) 16,125 (96.3%)	0.04 0.02
virssing; n (%) Lab result number-Triglyceride level (mg/dl) mean	2,323 (83.3%)	2,282 (81.8%)	0.04	13,803 (99.3%)	13,843 (99.2%)	0.01	N/A	N/A	#VALUE!	10,188 (90.0%)	10,125 (90.3%)	0.02
(only =<5000 included) v2	464	503		94	107		N/A	N/A		558	610	
mean (sd)	129.01 (76.77)	119.47 (64.42)	0.13	130.38 (67.84)	144.37 (97.89)	-0.17	N/A	N/A	#VALUE!	129.24 (75.42)	123.84 (71.45)	0.07
median [IQR]	112.00 [81.00, 151.38]	105.00 [77.00, 144.00]	0.10	114.50 [81.38, 175.00]	126.00 [91.00, 155.00]	-0.14	N/A	N/A	#VALUE!	112.42 (75.42)	108.68 (71.45)	0.05
Missing; n (%)	2,326 (83.4%)	2,287 (82.0%)	0.04	13,866 (99.3%)	13,853 (99.2%)	0.01	N/A	N/A	#VALUE!	16,192 (96.7%)	16,140 (96.4%)	0.03
Lab result number- Hemoglobin mean (only >0	2,320 (03.470)	2,207 (02.070)	0.04	13,000 (33.370)	15,055 (55.270)	0.01	.,,,,	,	WW.LOL.	10,132 (30.770)	10,140 (50.470)	0.02
included)	447	494		69	99		N/A	N/A		516	593	
mean (sd)	13.95 (1.46)	14.06 (1.41)	-0.08	13.65 (1.51)	13.64 (2.06)	0.01	N/A	N/A	#VALUE!	13.91 (1.47)	13.99 (1.54)	-0.05
median [IQR]	14.00 [13.00, 14.90]	14.00 [13.10, 15.00]	0.00	13.88 [12.70, 14.65]	13.80 [12.90, 14.80]	0.04	N/A	N/A	#VALUE!	13.98 (1.47)	13.97 (1.54)	0.01
Missing; n (%)	2,343 (84.0%)	2,296 (82.3%)	0.05	13,891 (99.5%)	13,861 (99.3%)	0.03	N/A	N/A	#VALUE!	16,234 (96.9%)	16,157 (96.5%)	0.02
Lab result number- Serum sodium mean (only > 90	. , ,									. , .		
and < 190 included)	579	654		92	122		N/A	N/A		671	776	
mean (sd)	140.03 (2.74)	140.11 (3.01)	-0.03	139.22 (2.71)	139.28 (2.99)	-0.02	N/A	N/A	#VALUE!	139.92 (2.74)	139.98 (3.01)	-0.02
median [IQR]	140.00 [138.50, 142.00]	140.00 [139.00, 142.00]	0.00	139.80 [138.00, 141.00]	139.83 [137.50, 141.00]	-0.01	N/A	N/A	#VALUE!	139.97 (2.74)	139.97 (3.01)	0.00
Missing; n (%)	2,211 (79.2%)	2,136 (76.6%)	0.06	13,868 (99.3%)	13,838 (99.1%)	0.02	N/A	N/A	#VALUE!	16,079 (96.0%)	15,974 (95.4%)	0.03
Lab result number- Albumin mean (only >0 and <=10												
included)	530	601		72	102		N/A	N/A		602	703	
mean (sd)	4.17 (0.31)	4.19 (0.31)	-0.06	4.10 (0.58)	4.03 (0.49)	0.13	N/A	N/A	#VALUE!	4.16 (0.35)	4.17 (0.34)	-0.03
median [IQR]	4.20 [4.00, 4.40]	4.20 [4.00, 4.40]	0.00	4.20 [3.90, 4.40]	4.10 [3.89, 4.30]	0.19	N/A	N/A	#VALUE!	4.20 (0.35)	4.19 (0.34)	0.03
Missing; n (%)	2,260 (81.0%)	2,189 (78.5%)	0.06	13,888 (99.5%)	13,858 (99.3%)	0.03	N/A	N/A	#VALUE!	16,148 (96.4%)	16,047 (95.8%)	0.03
Lab result number- Glucose (fasting or random) mean												
(only 10-1000 included)	576	645		91	111		N/A	N/A		667	756	
mean (sd)	110.45 (33.39)	111.79 (39.37)	-0.04	139.94 (58.19)	128.83 (44.07)	0.22	N/A	N/A	#VALUE!	114.47 (37.74)	114.29 (40.12)	0.00
median [IQR]	101.00 [91.00, 118.88]	100.50 [91.00, 117.00]	0.01		117.00 [102.00, 140.00]	0.10	N/A	N/A	#VALUE!	103.87 (37.74)	102.92 (40.12)	0.02
Missing; n (%)	2,214 (79.4%)	2,145 (76.9%)	0.06	13,869 (99.3%)	13,849 (99.2%)	0.01	N/A	N/A	#VALUE!	16,083 (96.0%)	15,994 (95.5%)	0.02
Lab result number- Potassium mean (only 1-7 included)	603	679		108	143		N/A	N/A		711	822	
	4.35 (0.43)	4.38 (0.44)	-0.07	4.35 (0.37)	4.34 (0.38)	0.03			#VALUE!	4.35 (0.42)		-0.05
mean (sd) median (IOR)	4.30 [4.10, 4.60]	4.40 [4.10, 4.65]	-0.07	4.30 (4.10, 4.60)	4.36 [4.10, 4.60]	-0.16	N/A N/A	N/A N/A	#VALUE!	4.35 (0.42)	4.37 (0.43) 4.39 (0.43)	-0.05
Missing; n (%)	2,187 (78.4%)	2,111 (75.7%)	0.06	13,852 (99.2%)	13,817 (99.0%)	0.02	N/A	N/A	#VALUE!	16,039 (95.8%)	15,928 (95.1%)	0.03
Comorbidity Scores	2,107 (70.470)	2,111 (/3.//0)	0.00	13,032 (33.270)	13,017 (33.0%)	0.02	N/A	IN/A	#VALUE:	10,039 (53.670)	13,520 (53.1%)	0.03
CCI (180 days)-ICD9 and ICD10 v2												
mean (sd)	2.63 (1.40)	2.62 (1.35)	0.01	2.81 (1.57)	2.78 (1.56)	0.02	1.33 (1.37)	1.33 (1.39)	0.00	1.95 (1.45)	1.94 (1.45)	0.01
median [IQR]	2.00 [2.00, 3.00]	2.00 [2.00, 3.00]	0.00	2.00 [2.00, 4.00]	2.00 [2.00, 4.00]	0.00	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0.00	1.43 (1.45)	1.43 (1.45)	0.00
Non-Frailty; n (%)	1,525 (54.7%)	1,532 (54.9%)	0.00	6,845 (49.0%)	6,801 (48.7%)	0.01	669 (3.0%)	465 (2.1%)	0.06	9,039 (23.1%)	8,798 (22.5%)	0.01
Frailty Score (mean): Empirical Version 365 days, v2	-/ (/-/	_, ()		2,010 (101011)	-,(,		()	(=.=)		0,000 (20.2)	-, (,	
mean (sd)	0.17 (0.04)	0.17 (0.04)	0.00	0.17 (0.05)	0.17 (0.05)	0.00	10.70 (9.15)	10.66 (9.45)	0.00	6.19 (6.92)	6.16 (7.14)	0.00
median [IQR]	0.16 [0.14, 0.19]	0.16 [0.14, 0.19]	0.00	0.17 [0.14, 0.20]	0.17 [0.14, 0.20]	0.00	8.94 [4.50, 14.92]	8.82 [4.32, 14.85]	0.01	5.18 (6.92)	5.11 (7.14)	0.01
Healthcare Utilization					,					(/	. ,	
Any hospitalization; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	4,495 (32.2%)	4,381 (31.4%)	0.02	4,193 (18.8%)	4,147 (18.6%)	0.01	8,688 (22.2%)	8,528 (21.8%)	0.01
Any hospitalization within prior 30 days; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	3,098 (22.2%)	2,998 (21.5%)	0.02	2,640 (11.8%)	2,607 (11.7%)	0.00	5738 (14.7%)	5605 (14.3%)	0.01
Any hospitalization during prior 31-180 days; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	1,606 (11.5%)	1,567 (11.2%)	0.01	1,741 (7.8%)	1,691 (7.6%)	0.01	3347 (8.6%)	3258 (8.3%)	0.01
Endocrinologist Visit; n (%)	67 (2.4%)	77 (2.8%)	-0.03	474 (3.4%)	451 (3.2%)	0.01	783 (3.5%)	731 (3.3%)	0.01	1324 (3.4%)	1259 (3.2%)	0.01
Endocrinologist Visit (30 days prior); n (%)	24 (0.9%)	19 (0.7%)	0.02	165 (1.2%)	156 (1.1%)	0.01	233 (1.0%)	222 (1.0%)	0.00	422 (1.1%)	397 (1.0%)	0.01
Endocrinologist Visit (31 to 180 days prior); n (%)	56 (2.0%)	66 (2.4%)	-0.03	395 (2.8%)	374 (2.7%)	0.01	669 (3.0%)	636 (2.8%)	0.01	1120 (2.9%)	1076 (2.8%)	0.01
Internal medicine/family medicine visits; n (%)	2,317 (83.0%)	2,336 (83.7%)	-0.02	11,221 (80.4%)	11,040 (79.1%)	0.03	17,647 (79.1%)	17,982 (80.6%)	-0.04	31185 (79.8%)	31358 (80.3%)	-0.01
Internal medicine/family medicine visits (30 days												
prior) v2; n (%)	1,469 (52.7%)	1,468 (52.6%)	0.00	7,381 (52.9%)	7,282 (52.2%)	0.01	11,348 (50.8%)	11,109 (49.8%)	0.02	20198 (51.7%)	19859 (50.8%)	0.02
Internal medicine/family medicine visits (31 to 180												
days prior) v2; n (%)	2,048 (73.4%)	2,033 (72.9%)	0.01	9,897 (70.9%)	9,621 (68.9%)	0.04	14,888 (66.7%)	15,277 (68.4%)	-0.04	26833 (68.7%)	26931 (68.9%)	0.00
Cardiologist visit; n (%)	1,715 (61.5%)	1,844 (66.1%)	-0.10	8,643 (61.9%)	8,241 (59.0%)	0.06	15,939 (71.4%)	16,749 (75.0%)	-0.08	26297 (67.3%)	26834 (68.7%)	-0.03
Number of Cardiologist visits (30 days prior); n (%)	1,278 (45.8%)	1,272 (45.6%)	0.00	6,331 (45.4%)	6,217 (44.5%)	0.02	12,337 (55.3%)	12,208 (54.7%)	0.01	19946 (51.1%)	19697 (50.4%)	0.01
Number of Cardiologist visits (31 to 180 days prior);	1.089 (39.0%)	1 170 (41 00)	-0.06	5.859 (42.0%)	E 254 /20 40/\	0.07	9.733 (43.6%)	10.383 (46.5%)	-0.06	16681 (42.7%)	16907 (43.3%)	-0.01
n (%) Electrocardiogram v2; n (%)	1,089 (39.0%)	1,170 (41.9%) 1.931 (69.2%)	-0.06 -0.03	5,859 (42.0%) 9.862 (70.6%)	5,354 (38.4%) 10.320 (73.9%)	-0.07	9,733 (43.6%)	10,383 (46.5%) 16,887 (75.7%)	-0.06 -0.03	16681 (42.7%) 28403 (72.7%)	16907 (43.3%) 29138 (74.6%)	-0.01 -0.04
Use of glucose test strips; n (%)	26 (0.9%)	30 (1.1%)	-0.03	9,862 (70.6%)	10,320 (73.9%)	0.00	241 (1.1%)	229 (1.0%)	0.01	364 (0.9%)	360 (0.9%)	0.04
Dialysis; n (%)	1 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	1 (0.0%)	0 (0.0%)	#DIV/0!
number of different/distinct medication	1 (0.0%)	0 (0.0%)	#514/0:	0 (0.0%)	0 (0.0%)	#514/0:	0 (0.070)	0 (0.0%)	#514/0:	1 (0.070)	0 (0.070)	#514/0:
prescriptions												
mean (sd)	8.18 (4.00)	8.05 (4.00)	0.03	9.29 (4.50)	9.24 (4.56)	0.01	8.57 (3.98)	8.52 (4.04)	0.01	8.80 (4.17)	8.74 (4.23)	0.01
median (IOR)	8.00 [5.00, 10.00]	7.00 [5.00, 10.00]	0.25	9.00 [6.00, 12.00]	9.00 [6.00, 12.00]	0.00	8.00 [6.00, 11.00]	8.00 [6.00, 11.00]	0.00	6.65 (4.66)	6.57 (4.73)	0.02
Number of Hospitalizations										,		
mean (sd)	0.00 (0.00)	0.00 (0.00)	#DIV/0!	0.35 (0.55)	0.34 (0.54)	0.02	0.21 (0.47)	0.21 (0.46)	0.00	0.25 (0.48)	0.24 (0.47)	0.02
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	#DIV/0!	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.55)	0.00 (0.54)	0.00
Number of hospital days								• •			. ,	
mean (sd)	0.00 (0.00)	0.00 (0.00)	#DIV/0!	1.59 (3.38)	1.50 (3.34)	0.03	0.88 (2.32)	0.85 (2.52)	0.01	1.07 (2.68)	1.02 (2.76)	0.02
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	#DIV/0!	0.00 [0.00, 3.00]	0.00 [0.00, 2.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (3.10)	0.00 (3.16)	0.00
Number of Emergency Department (ED) visits v3												
mean (sd)	0.40 (0.94)	0.40 (0.99)	0.00	0.44 (1.54)	0.44 (1.72)	0.00	0.64 (1.46)	0.63 (1.26)	0.01	0.55 (1.46)	0.55 (1.43)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (1.62)	0.00 (1.63)	0.00
Number of Office visits												
mean (sd)	5.25 (3.98)	5.16 (3.64)	0.02	5.89 (4.47)	5.77 (4.32)	0.03	11.61 (10.64)	11.48 (9.99)	0.01	9.11 (8.54)	8.99 (8.04)	0.01
median [IQR]	4.00 [3.00, 7.00]	4.00 [3.00, 7.00]	0.00	5.00 [3.00, 8.00]	5.00 [3.00, 8.00]	0.00	9.00 [5.00, 15.00]	9.00 [5.00, 15.00]	0.00	5.29 (8.79)	5.29 (8.28)	0.00
Number of Endocrinologist visits												
mean (sd)	0.09 (0.81)	0.09 (0.86)	0.00	0.13 (1.13)	0.11 (0.87)	0.02	0.17 (1.45)	0.15 (1.39)	0.01	0.15 (1.31)	0.13 (1.19)	0.02
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.41)	0.00 (1.26)	0.00

Number of internal medicine/family medicine visits												
mean (sd)	8.11 (10.84)	8.19 (12.81)	-0.01	6.56 (9.62)	6.46 (9.25)	0.01	6.41 (8.10)	6.38 (7.75)	0.00	6.58 (8.88)	6.54 (8.75)	0.00
median [IQR]	5.00 [2.00, 10.00]	5.00 [1.00, 10.00]	0.00	4.00 [1.00, 8.00]	4.00 [1.00, 8.00]	0.00	4.00 [1.00, 9.00]	4.00 [1.00, 9.00]	0.00	3.22 (9.94)	3.22 (9.74)	0.00
Number of Cardiologist visits											,	
mean (sd)	3.29 (4.91)	3.30 (4.42)	0.00	3.35 (4.99)	3.29 (5.01)	0.01	4.52 (6.31)	4.46 (5.54)	0.01	4.01 (5.78)	3.96 (5.28)	0.01
median [IQR]	2.00 [0.00, 5.00]	2.00 [0.00, 5.00]	0.00	2.00 [0.00, 5.00]	1.50 [0.00, 5.00]	0.10	2.00 [0.00, 6.00]	3.00 [1.00, 6.00]	-0.17	1.57 (6.22)	1.75 (5.77)	-0.03
Number electrocardiograms received v2										- (- /	- (- /	
mean (sd)	1.56 (2.08)	1.54 (1.79)	0.01	1.77 (2.23)	1.72 (1.91)	0.02	1.82 (2.02)	1.80 (1.87)	0.01	1.78 (2.10)	1.75 (1.88)	0.02
median [IQR]	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0.00	1.00 [0.00, 2.00]	1.00 [0.00, 2.00]	0.00	1.00 [0.00, 2.00]	1.00 [1.00, 2.00]	0.00	0.79 (2.34)	0.79 (2.08)	0.00
Number of HbA1c tests ordered					,			,		,		
mean (sd)	0.39 (0.69)	0.39 (0.69)	0.00	0.14 (0.45)	0.15 (0.46)	-0.02	0.40 (0.71)	0.40 (0.70)	0.00	0.31 (0.63)	0.31 (0.62)	0.00
median [IQR]	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (0.66)	0.00 (0.66)	0.00
Number of glucose tests ordered	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 1.00]	0.00	0.00 (0.00)	0.00 (0.00)	0.00
mean (sd)	0.13 (0.58)	0.16 (0.96)	-0.04	0.10 (0.54)	0.11 (0.58)	-0.02	0.13 (0.61)	0.12 (0.48)	0.02	0.12 (0.58)	0.12 (0.56)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.63)	0.00 (0.62)	0.00
Number of lipid tests ordered	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.03)	0.00 (0.02)	0.00
mean (sd)	0.67 (0.86)	0.68 (0.84)	-0.01	0.25 (0.70)	0.24 (0.63)	0.02	0.68 (0.76)	0.68 (0.74)	0.00	0.53 (0.75)	0.52 (0.71)	0.01
median [IQR]	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-1.18	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	0.36 (0.81)	0.43 (0.77)	-0.09
Number of creatinine tests ordered	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	1.10	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	0.50 (0.01)	0.45 (0.77)	0.03
mean (sd)	0.07 (0.33)	0.07 (0.32)	0.00	0.05 (0.28)	0.05 (0.27)	0.00	0.10 (0.39)	0.09 (0.37)	0.03	0.08 (0.35)	0.07 (0.33)	0.03
median (IOR)	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.37)	0.00 (0.36)	0.00
Number of BUN tests ordered	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.57)	0.00 (0.50)	0.00
mean (sd)	0.04 (0.23)	0.05 (0.25)	-0.04	0.03 (0.22)	0.03 (0.22)	0.00	0.06 (0.30)	0.05 (0.28)	0.03	0.05 (0.27)	0.04 (0.26)	0.04
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.29)	0.00 (0.28)	0.00
Number of tests for microalbuminuria	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	5.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	5.00	3.30 (0.23)	3.00 (0.20)	0.00
mean (sd)	0.21 (0.70)	0.19 (0.64)	0.03	0.07 (0.37)	0.07 (0.37)	0.00	0.12 (0.41)	0.12 (0.39)	0.00	0.11 (0.42)	0.11 (0.41)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.46)	0.00 (0.44)	0.00
Total N distinct ICD9/ICD10 diagnoses at the 3rd	0.00 [0.00, 0.00]	5.00 [0.00, 0.00]	0.00	5.00 [0.00, 0.00]	3.00 [0.00, 0.00]	0.00	5.00 [0.00, 0.00]	3.00 [0.00, 0.00]	0.00	0.00 (0.40)	0.00 (0.44)	0.00
digit level Copy												
mean (sd)	3.02 (4.95)	3.04 (5.12)	0.00	2.23 (4.87)	2.21 (4.87)	0.00	4.18 (6.62)	4.08 (6.51)	0.02	3.40 (5.94)	3.34 (5.88)	0.01
median [IQR]	0.00 [0.00, 5.00]	0.00 [0.00, 5.00]	0.00	0.00 [0.00, 2.00]	0.00 [0.00, 2.00]	0.00	0.00 [0.00, 6.00]	0.00 [0.00, 6.00]	0.00	0.00 (6.35)	0.00 (6.30)	0.00
For PS												
Hemorrhagic stroke+Other cerebrovascular												
disease+Cerebrovascular procedure (for PS); n (%)	45 (1.6%)	52 (1.9%)	-0.02	297 (2.1%)	316 (2.3%)	-0.01	416 (1.9%)	398 (1.8%)	0.01	758 (1.9%)	766 (2.0%)	-0.01
Occurrence of creatinine tests ordered (for PS); n (%)	148 (5.3%)	154 (5.5%)	-0.01	495 (3.5%)	495 (3.5%)	0.00	1,648 (7.4%)	1,562 (7.0%)	0.02	2291 (5.9%)	2211 (5.7%)	0.01
Occurrence of BUN tests ordered (for PS); n (%)	95 (3.4%)	103 (3.7%)	-0.02	311 (2.2%)	333 (2.4%)	-0.01	1,063 (4.8%)	1,001 (4.5%)	0.01	1469 (3.8%)	1437 (3.7%)	0.01
Occurrence of chronic renal insufficiency w/o CKD												
(for PS) v2; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Chronic kidney disease Stage 1-2 (for PS); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0	0	#VALUE!	#VALUE!	#VALUE!	#VALUE!
Chronic kidney disease Stage 3-6 (for PS); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
	0 (0.0%) 35 (1.3%)	0 (0.0%) 35 (1.3%)	#DIV/0! 0.00		0 (0.0%) 229 (1.6%)	#DIV/0! -0.02	0 (0.0%) 283 (1.3%)	0 (0.0%) 274 (1.2%)	#DIV/0! 0.01	0 (0.0%) 509 (1.3%)	0 (0.0%) 538 (1.4%)	#DIV/0! -0.01
Chronic kidney disease Stage 3-6 (for PS); n (%)		- ()		0 (0.0%)			- ()					
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with	35 (1.3%)	35 (1.3%)	0.00	0 (0.0%) 191 (1.4%)	229 (1.6%)	-0.02	283 (1.3%)	274 (1.2%)	0.01	509 (1.3%)	538 (1.4%)	-0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%)		- ()		0 (0.0%)			- ()					
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or	35 (1.3%) 75 (2.7%)	35 (1.3%) 49 (1.8%)	0.00	0 (0.0%) 191 (1.4%) 285 (2.0%)	229 (1.6%) 269 (1.9%)	-0.02	283 (1.3%) 408 (1.8%)	274 (1.2%) 430 (1.9%)	-0.01	509 (1.3%) 768 (2.0%)	538 (1.4%) 748 (1.9%)	-0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%)	35 (1.3%)	35 (1.3%)	0.00	0 (0.0%) 191 (1.4%)	229 (1.6%)	-0.02	283 (1.3%)	274 (1.2%)	0.01	509 (1.3%)	538 (1.4%)	-0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic	35 (1.3%) 75 (2.7%)	35 (1.3%) 49 (1.8%)	0.00	0 (0.0%) 191 (1.4%) 285 (2.0%)	229 (1.6%) 269 (1.9%)	-0.02	283 (1.3%) 408 (1.8%)	274 (1.2%) 430 (1.9%)	-0.01	509 (1.3%) 768 (2.0%)	538 (1.4%) 748 (1.9%)	-0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous	35 (1.3%) 75 (2.7%)	35 (1.3%) 49 (1.8%)	0.00	0 (0.0%) 191 (1.4%) 285 (2.0%)	229 (1.6%) 269 (1.9%)	-0.02	283 (1.3%) 408 (1.8%)	274 (1.2%) 430 (1.9%)	-0.01	509 (1.3%) 768 (2.0%)	538 (1.4%) 748 (1.9%)	-0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation	35 (1.3%) 75 (2.7%) 0 (0.0%)	35 (1.3%) 49 (1.8%) 0 (0.0%)	0.00 0.06 #DIV/0!	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%)	-0.02 0.01 #DIV/0!	283 (1.3%) 408 (1.8%) 0 (0.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%)	-0.01 -0.01 #DIV/0!	509 (1.3%) 768 (2.0%) 0 (0.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%)	-0.01 0.01 #DIV/0!
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%)	35 (1.3%) 75 (2.7%)	35 (1.3%) 49 (1.8%)	0.00	0 (0.0%) 191 (1.4%) 285 (2.0%)	229 (1.6%) 269 (1.9%)	-0.02	283 (1.3%) 408 (1.8%)	274 (1.2%) 430 (1.9%)	-0.01	509 (1.3%) 768 (2.0%)	538 (1.4%) 748 (1.9%)	-0.01
Chronic kidney disease stage 3-6 (for PS); n (%) Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%)	35 (1.3%) 49 (1.8%) 0 (0.0%)	0.00 0.06 #DIV/0! 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%)	-0.02 0.01 #DIV/0!	283 (1.3%) 408 (1.8%) 0 (0.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%)	0.01 -0.01 #DIV/0! 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%)	-0.01 0.01 #DIV/0!
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosciensis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%)	35 (1.3%) 49 (1.8%) 0 (0.0%)	0.00 0.06 #DIV/0!	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%)	-0.02 0.01 #DIV/0!	283 (1.3%) 408 (1.8%) 0 (0.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%)	-0.01 -0.01 #DIV/0!	509 (1.3%) 768 (2.0%) 0 (0.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%)	-0.01 0.01 #DIV/0!
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) +	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%)	0.00 0.06 #DIV/0! 0.00 0.01	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%)	-0.02 0.01 #DIV/0! 0.03 0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%)	0.01 -0.01 #DIV/0! 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%)	-0.01 0.01 #DIV/0! 0.02 0.01
Chronic kidney disease stage 3-6 (for PS); n (%) Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-HGangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence-Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis-Kardiac conduction disorders-Other CVD (for PS) v2 (copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%)	35 (1.3%) 49 (1.8%) 0 (0.0%)	0.00 0.06 #DIV/0! 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%)	-0.02 0.01 #DIV/0!	283 (1.3%) 408 (1.8%) 0 (0.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%)	0.01 -0.01 #DIV/0! 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%)	-0.01 0.01 #DIV/0!
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Rectinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%)	0.00 0.06 #DIV/0! 0.00 0.01	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%)	0.01 #DIV/0! 0.03 0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%)	0.01 -0.01 #DIV/0! 0.01 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%)	-0.01 0.01 #DIV/0! 0.02 0.01 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy-Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%)	0.00 0.06 #DIV/01 0.00 0.01 0.02 -0.02	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%)	-0.02 0.01 #DIV/0! 0.03 0.01 0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%)	-0.01 0.01 #DIV/0! 0.02 0.01 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atheroscienosis+Cardiac conduction disorders+Other CVD (for PS) v3; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%)	0.01 #DIV/01 0.03 0.01 0.01 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 503 (1.3%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%)	-0.01 0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v3 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 0.02 0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%)	0.02 0.01 #DIV/0! 0.03 0.01 0.01 -0.01 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.01 0.01 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 503 (1.3%) 152 (0.4%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%)	-0.01 0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones-Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of AGIs (for PS); n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%)	0.01 #DIV/0! 0.03 0.01 0.01 -0.01 -0.01 -0.00 -0.03	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 225 (1.3%) 72 (0.3%) 18 (0.1%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v3; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of Meglitnides (for PS); n (%) Any use of Meglitnides (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%) 1 (0.0%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 #DIV/0!	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%)	-0.02 0.01 #DIV/0! 0.03 0.01 0.01 -0.01 -0.01 0.00 -0.03 #DIV/0!	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.01 0.00 #DIV/0!	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 503 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 5 9 (0.2%) 0 (0.0%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 -0.03 #DIV/0!
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v3 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of AGIs (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of thiazide; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 0 (0.0%) 332 (11.9%)	0.00 0.06 #DIV/01 0.00 0.01 0.02 -0.02 0.00 0.00 #DIV/01 -0.02	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 1,7 (0.1%) 0 (0.0%) 1,447 (10.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 2,7 (0.2%) 0 (0.0%) 1,514 (10.8%)	0.02 0.01 #DIV/0! 0.03 0.01 0.01 -0.01 -0.01 -0.03 #DIV/0!	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 2,867 (12.8%) 0 (0.0%) 2,867 (12.8%)	0.01 -0.01 #DIV/0! 0.01 -0.01 -0.00 -0.01 -0.00 -0.00 -0.00 #DIV/0! -0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 59 (0.2%) 0 (0.0%) 4713 (12.1%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0!
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Mcglitrinides (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dislysis (for PS); n (%) Use of thiazide; n (%) Use of the blockers; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 #DIV/0! -0.02 0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (68.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.03 #DIV/0! -0.01 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (55.3%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 4713 (12.1%) 25791 (66.0%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3, n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of Mcglitinides (for PS); n (%) Any use of Mcglitinides (for PS); n (%) Use of thiazide; n (%) Use of beta blockers; n (%) Use of beta blockers; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 -0.00 0.00 #DIV/0! -0.02 0.00 0.00 0.00 0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (68.0%) 5,367 (38.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%)	0.01 #DIV/01 0.03 0.01 0.01 -0.01 -0.01 -0.03 #DIV/01 -0.01 -0.01 -0.01 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (5.6%) 8,649 (38.8%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.01 0.01 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 533 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 4713 (12.1%) 25791 (66.0%) 15006 (38.4%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 -0.03 #DIV/0! 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thiazide; n (%) Use of beta blockers; n (%) All antidiabetic medications except insulin; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 #DIV/0! -0.02 0.00 0.00 0.00 0.00 0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 5,367 (38.4%) 2,704 (19.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%)	0.02 0.01 #DIV/0! 0.03 0.01 0.01 -0.01 -0.01 0.00 -0.03 #DIV/0! 0.01 0.01 0.01 0.00	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%) 4,497 (20.1%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.01 0.01 0.01 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 5 (0.0%) 0 (0.0%) 4713 (12.1%) 25791 (66.0%) 15006 (38.4%) 7772 (19.9%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.00 0.00 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atheroscienosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of AGIs (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of the ablockers; n (%) Use of the ablockers; n (%) Use of calcium channel blockers; n (%) All antidiabetic medications except insulin; n (%) DM Medications-Insulin (Opy; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 119 (4.3%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 #DIV/0! -0.02 0.00 0.00 -0.01 0.01	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 5,367 (38.4%) 2,704 (19.4%) 695 (5.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.00 -0.00 -0.00	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 #DIV/0! 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 6 (0.0%) 4713 (12.1%) 25791 (66.0%) 15006 (38.4%) 7772 (19.9%) 1654 (4.2%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Pyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of taiclum channel blockers; n (%) Use of beta blockers; n (%) All antidiabetic medications except insulin; n (%) Use of Low Intensity Statins; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 119 (4.3%) 925 (33.2%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 0.00 0.00 0.00 #DIV/0! 0.02 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 5,367 (38.4%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%) 4,638 (33.2%)	0.02 0.01 #DIV/0! 0.03 0.01 0.01 -0.01 -0.01 -0.03 #DIV/0! -0.01 0.00 -0.00 -0.00 -0.00 -0.01 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 4,497 (20.1%) 1,030 (4.6%) 7,780 (34.9%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (35.0%)	0.01 -0.01 #DIV/0! 0.01 -0.01 -0.00 -0.01 -0.00 -0.00 #DIV/0! -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 13175 (33.7%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 4713 (12.1%) 25791 (66.0%) 15006 (88.4%) 7772 (19.9%) 1654 (4.2%) 13367 (34.2%)	-0.01 #DIV/01 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders-Gangrene-Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thiadide; n (%) Use of beta blockers; n (%) Use of thaididebetic medications except Insulin; n (%) DM Medications - Insulin Copy; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 191 (4.3%) 925 (33.2%) 586 (21.0%)	0.00 0.05 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 0.00 9.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.03 -0.03	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 1,7 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 5,367 (88.4%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%) 3,170 (22.7%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%) 4,638 (33.2%) 2,9552 (21.1%)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.03 #DIV/0! -0.03 -0.01 -0.01 -0.00 -0.00 -0.01 -0.01 -0.00 -0.00 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,800 (34.9%) 4,999 (21.0%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (88.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (35.0%) 4,665 (20.9%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 1375 (33.7%) 8419 (21.5%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 15006 (38.4%) 1777 (19.9%) 1654 (4.2%) 8203 (21.0%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-Other CVD (for PS) v3 Copy; n (%) Previous cardiae procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of Meglitnindes (for PS); n (%) Any use of Meglitnindes (for PS); n (%) Use of the Ablockers; n (%) Use of the Ablockers; n (%) Use of calcium channel blockers; n (%) All antidiabetic medications except insulin; n (%) Use of Low intensity Statins; n (%) Use of High intensity Statins; n (%) Walligmant hypertension; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 119 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 40.01 -0.02 0.00 0.00 -0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%)	-0.02 0.01 #DIV/01 0.03 0.01 -0.01 -0.01 -0.03 #DIV/01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 1,4583 (6.5.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,800 (34.9%) 4,696 (21.0%) 3,405 (15.3%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (35.0%) 4,665 (20.9%) 3,554 (15.9%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 3175 (33.7%) 8419 (21.5%) 9657 (24.7%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 6 (0.0%) 4713 (12.1%) 7772 (19.9%) 1654 (4.2%) 13367 (24.2%) 8203 (21.0%) 9646 (24.7%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.02
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Pyeethyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) CXD stage 3-6 + dialysis (for PS); n (%) Use of thiazide; n (%) Use of totalcum channel blockers; n (%) All antidiabetic medications except insulin; n (%) DM Medications - Insulin Copy; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Gardiovascular strest test; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (39%) 6 (0.2%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 119 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%) 13 (0.5%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 0.00 0.00 0.00 #DIV/0! -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 0 (0.0%) 1,447 (10.4%) 9,487 (68.0%) 5,367 (38.4%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%) 96 (0.7%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%) 63 (0.5%)	-0.02 0.01 #DIV/0! 0.03 0.01 0.01 -0.01 -0.01 -0.00 -0.03 #DIV/0! -0.01 -0.01 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,800 (34.9%) 4,696 (21.0%) 3,405 (15.3%) 105 (0.5%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (45.0%) 4,665 (20.9%) 3,554 (15.9%) 85 (0.4%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 13175 (33.7%) 8419 (21.5%) 9657 (24.7%) 207 (0.5%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 59 (0.2%) 0 (0.0%) 4713 (12.1%) 25791 (66.0%) 15006 (88.4%) 7772 (19.9%) 1654 (4.2%) 8203 (21.0%) 9466 (24.7%) 161 (0.4%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.01 0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA for Stent) + History of CABG or PTCA (for PS) v3, n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of AGIs (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of the ablockers; n (%) Use of the ablockers; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%) Malignant hypertension; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 119 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 0.00 0.00 40.01 -0.02 0.00 0.00 -0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%)	-0.02 0.01 #DIV/01 0.03 0.01 -0.01 -0.01 -0.03 #DIV/01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 1,4583 (6.5.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,800 (34.9%) 4,696 (21.0%) 3,405 (15.3%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (35.0%) 4,665 (20.9%) 3,554 (15.9%)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 3175 (33.7%) 8419 (21.5%) 9657 (24.7%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 6 (0.0%) 4713 (12.1%) 7772 (19.9%) 1654 (4.2%) 13367 (24.2%) 8203 (21.0%) 9646 (24.7%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.02
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Rectinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiae procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Previous cardiae procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thiazide; n (%) Use of thiazide; n (%) Use of calcium channel blockers; n (%) Use of calcium channel blockers; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BMP tests	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%) 6 (0.2%) 655 (23.5%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 199 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%) 13 (0.5%) 781 (28.0%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 0.00 0.00 0.00 0.00 #DIV/0! 0.04 0.01 0.03 0.03 0.01 0.05 0.10	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (68.0%) 5,367 (38.4%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%) 96 (0.7%) 6,201 (44.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%) 63 (0.5%) 6,865 (49.2%)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.03 #DIV/0! -0.01 -0.03 -0.03 -0.04 -0.03 -0.04 -0.02 -0.03 -0.10	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 285 (1.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 4,497 (20.1%) 1,030 (4.6%) 7,800 (34.9%) 4,696 (21.0%) 3,405 (15.3%) 3,405 (15.3%) 105 (0.5%) 7,094 (31.8%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (88.8%) 4,460 (20.0%) 802 (3.6%) 4,665 (20.9%) 3,554 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%)	0.01 -0.01 #DIV/O! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/O! 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 533 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 31175 (33.7%) 8419 (21.5%) 9657 (24.7%) 207 (0.5%) 13950 (35.7%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 4713 (12.1%) 25791 (66.0%) 15006 (88.4%) 7772 (19.9%) 1654 (4.2%) 8203 (21.0%) 9646 (24.7%) 161 (0.4%) 15670 (40.1%)	-0.01 #DIV/01 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v3 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Pyerchyoridism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thiazide; n (%) Use of beta blockers; n (%) Use of thiazide; n (%) Use of thiazide; n (%) Use of thiazide; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BNP testsmean (sd)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%) 6 (0.2%) 655 (23.5%) 0.09 (0.43)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,731 (62.0%) 1919 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%) 13 (0.5%) 781 (28.0%) 0.09 (0.36)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 0.00 0.00 0.00 #DIV/0! -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -0.02 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 5,367 (38.4%) 2,704 (19.4%) 659 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%) 96 (0.7%) 6,201 (44.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 4,638 (33.2%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%) 63 (0.5%) 6,865 (49.2%) 0.07 (0.33)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.01 -0.00 -0.03 #DIV/0! -0.01 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.00 -0.00	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,200 (4.9%) 4,696 (21.0%) 3,405 (15.3%) 1,05 (0.5%) 7,094 (31.8%) 0.12 (0.40)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (15.9%) 4,665 (20.9%) 3,554 (15.9%) 85 (0.4%) 8,024 (35.9%) 0.13 (0.42)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.05 0.00 0.00 0.00 -0.02 0.01 -0.09	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 33175 (33.7%) 8419 (21.5%) 9657 (24.7%) 207 (0.5%) 13950 (35.7%) 0.10 (0.38)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 15006 (38.4%) 7772 (19.9%) 1654 (4.2%) 9464 (24.7%) 15670 (40.1%) 0.11 (0.39)	-0.01 #DIV/01 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/01 0.00 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Rectinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiae procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Previous cardiae procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thiazide; n (%) Use of thiazide; n (%) Use of calcium channel blockers; n (%) Use of calcium channel blockers; n (%) Use of Low Intensity Statins; n (%) Use of Low Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BMP tests	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 2 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%) 6 (0.2%) 655 (23.5%)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 199 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%) 13 (0.5%) 781 (28.0%)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 -0.00 -0.00 -0.00 -0.00 -0.01 -0.02 -0.02 -0.02 -0.00 -0.00 -0.00 -0.00 -0.00 -0.00 -0.01 -0.01 -0.03 -0.03 -0.03 -0.01 -0.05 -0.10	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (68.0%) 5,367 (38.4%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%) 96 (0.7%) 6,201 (44.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%) 63 (0.5%) 6,865 (49.2%)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.03 #DIV/0! -0.01 -0.03 -0.03 -0.04 -0.03 -0.04 -0.02 -0.03 -0.10	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 285 (1.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 4,497 (20.1%) 1,030 (4.6%) 7,800 (34.9%) 4,696 (21.0%) 3,405 (15.3%) 3,405 (15.3%) 105 (0.5%) 7,094 (31.8%)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (88.8%) 4,460 (20.0%) 802 (3.6%) 4,665 (20.9%) 3,554 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%) 8,549 (15.9%)	0.01 -0.01 #DIV/O! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/O! 0.01 0.01 0.00 0.00 0.00 0.00 0.01 0.01 0.01 0.01 0.01 0.00 0.00 0.00 0.00 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 533 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 31175 (33.7%) 8419 (21.5%) 9657 (24.7%) 207 (0.5%) 13950 (35.7%)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 4713 (12.1%) 25791 (66.0%) 15006 (88.4%) 7772 (19.9%) 1654 (4.2%) 8203 (21.0%) 9646 (24.7%) 161 (0.4%) 15670 (40.1%)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v3 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Pyerchyoridism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Delirium + Psychosis (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) Use of thiazide; n (%) Use of beta blockers; n (%) Use of thiazide; n (%) Use of thiazide; n (%) Use of thiazide; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BNP testsmean (sd)	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%) 6 (0.2%) 655 (23.5%) 0.09 (0.43) 0.00 (0.00, 0.00)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,731 (62.0%) 1919 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%) 13 (0.5%) 781 (28.0%) 0.09 (0.36)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 -0.00 -0.00 -0.00 -0.00 -0.01 -0.02 -0.02 -0.02 -0.02 -0.00 -0.00 -0.00 -0.00 -0.00 -0.01 -0.01 -0.03 -0.03 -0.03 -0.01 -0.05 -0.10	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 5,367 (38.4%) 2,704 (19.4%) 659 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%) 96 (0.7%) 6,201 (44.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 4,638 (33.2%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%) 63 (0.5%) 6,865 (49.2%) 0.07 (0.33)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.01 -0.00 -0.03 #DIV/0! -0.01 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.00 -0.00	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,200 (4.9%) 4,696 (21.0%) 3,405 (15.3%) 1,05 (0.5%) 7,094 (31.8%) 0.12 (0.40)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (15.9%) 4,665 (20.9%) 3,554 (15.9%) 85 (0.4%) 8,024 (35.9%) 0.13 (0.42)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.05 0.00 0.00 0.00 -0.02 0.01 -0.09	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 33175 (33.7%) 8419 (21.5%) 9657 (24.7%) 207 (0.5%) 13950 (35.7%) 0.10 (0.38)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 15006 (38.4%) 7772 (19.9%) 1654 (4.2%) 9464 (24.7%) 15670 (40.1%) 0.11 (0.39)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with (CD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations-Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders-Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Pyeethyoidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of Meglitinides (for PS); n (%) Any use of Meglitinides (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of thiazide; n (%) Use of blockers; n (%) Use of thiazide; n (%) Use of thiazide; n (%) Use of High Intensity Statins; n (%) Use of High Intensity Statins; n (%) Use of High Intensity Statins; n (%) Malignant hypertension; n (%) Cardiovascular stress test; n (%) Echocardiogram; n (%) Number of BNP testsmean (sd)median IQR	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%) 6 (0.2%) 655 (23.5%) 0.09 (0.43) 0.00 (0.00, 0.00)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 4 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,731 (62.0%) 1919 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%) 13 (0.5%) 781 (28.0%) 0.09 (0.36)	0.00 0.06 #DIV/0! 0.00 0.01 0.02 -0.02 -0.00 -0.00 -0.00 -0.00 -0.01 -0.02 -0.02 -0.02 -0.02 -0.00 -0.00 -0.00 -0.00 -0.00 -0.01 -0.01 -0.03 -0.03 -0.03 -0.01 -0.05 -0.10	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (88.0%) 5,367 (38.4%) 2,704 (19.4%) 659 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%) 96 (0.7%) 6,201 (44.4%)	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 207 (1.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 4,638 (33.2%) 4,638 (33.2%) 2,952 (21.1%) 5,989 (42.9%) 63 (0.5%) 6,865 (49.2%) 0.07 (0.33)	-0.02 0.01 #DIV/0! 0.03 0.01 -0.01 -0.01 -0.01 -0.00 -0.03 #DIV/0! -0.01 -0.00 -0.00 -0.01 -0.01 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.01 -0.00 -0.00 -0.00	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 14,583 (65.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,200 (4.9%) 4,696 (21.0%) 3,405 (15.3%) 1,05 (0.5%) 7,094 (31.8%) 0.12 (0.40)	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (15.9%) 4,665 (20.9%) 3,554 (15.9%) 85 (0.4%) 8,024 (35.9%) 0.13 (0.42)	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 #DIV/0! 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.00 0.05 0.00 0.00 0.00 -0.02 0.01 -0.09	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 530 (1.3%) 152 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 33175 (33.7%) 8419 (21.5%) 9657 (24.7%) 207 (0.5%) 13950 (35.7%) 0.10 (0.38)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 15006 (38.4%) 7772 (19.9%) 1654 (4.2%) 9464 (24.7%) 15670 (40.1%) 0.11 (0.39)	-0.01 #DIV/0! 0.02 0.01 0.00 0.00 0.00 0.02 -0.03 #DIV/0! 0.00 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00 0.01 0.00
Chronic kidney disease Stage 3-6 (for PS); n (%) Bladder stones+Kidney stones (for PS); n (%) Diabetes with peripheral circulatory disorders+Gangrene+Osteomyelitis(for PS) v3 with ICD10 Copy; n (%) Alcohol abuse or dependence+Drug abuse or dependence (for PS); n (%) Diabetes with other ophthalmic manifestations+Retinal detachment, vitreous hemorrhage, vitrectomy+Retinal laser coagulation therapy (for PS); n (%) Other atherosclerosis+Cardiac conduction disorders+Other CVD (for PS) v2 Copy; n (%) Previous cardiac procedure (CABG or PTCA or Stent) + History of CABG or PTCA (for PS) v3; n (%) Hyperthyroidism + Hypothyroidism + Other disorders of thyroid gland (for PS); n (%) Any use of AGIs (for PS); n (%) Any use of AGIs (for PS); n (%) CKD stage 3-6 + dialysis (for PS); n (%) Use of the blockers; n (%) Use of the lintensity Statins; n (%) Use of Histin Intensity Statins; n (%) Malignant hypertension; n (%) Echocardiogram; n (%) Echocardiogram; n (%) Number of BNP testsmean (sQ)median [IQR] Number of Cardiac biomarkers tests (tropnin, CK-MBs, M	35 (1.3%) 75 (2.7%) 0 (0.0%) 11 (0.4%) 515 (18.5%) 153 (5.5%) 430 (15.4%) 28 (1.0%) 4 (0.1%) 1 (0.0%) 319 (11.4%) 1,727 (61.9%) 1,068 (38.3%) 603 (21.6%) 126 (4.5%) 960 (34.4%) 553 (19.8%) 108 (3.9%) 6 (0.2%) 655 (23.5%) 0.09 (0.43) 0.00 (0.00, 0.00)	35 (1.3%) 49 (1.8%) 0 (0.0%) 11 (0.4%) 505 (18.1%) 141 (5.1%) 454 (16.3%) 27 (1.0%) 3 (0.1%) 0 (0.0%) 332 (11.9%) 1,731 (62.0%) 1,010 (36.2%) 585 (21.0%) 191 (4.3%) 925 (33.2%) 586 (21.0%) 103 (3.7%) 13 (0.5%) 781 (28.0%) 0.09 (0.36) 0.00 (0.00, 0.00)	0.00 0.05 #DIV/0! 0.00 0.01 0.02 -0.02 -0.00 0.00 0.00 0.00 -0.02 -0.02 -0.02 -0.02 -0.00 0.00	0 (0.0%) 191 (1.4%) 285 (2.0%) 0 (0.0%) 204 (1.5%) 4,706 (33.7%) 730 (5.2%) 1,697 (12.2%) 190 (1.4%) 76 (0.5%) 17 (0.1%) 0 (0.0%) 1,447 (10.4%) 9,487 (68.0%) 5,367 (38.4%) 2,704 (19.4%) 695 (5.0%) 4,415 (31.6%) 3,170 (22.7%) 6,144 (44.0%) 96 (0.7%) 6,201 (44.4%) 0.07 (0.32) 0.00 [0.00, 0.00]	229 (1.6%) 269 (1.9%) 0 (0.0%) 168 (1.2%) 4,661 (33.4%) 700 (5.0%) 1,748 (12.5%) 69 (0.5%) 27 (0.2%) 0 (0.0%) 1,514 (10.8%) 9,422 (67.5%) 5,347 (38.3%) 2,727 (19.5%) 733 (5.3%) 4,638 (33.2%) 2,9552 (21.1%) 5,989 (42.9%) 63 (0.5%) 6,865 (49.2%) 0.07 (0.33) 0.00 [0.00, 0.00]	-0.02 0.01 #DIV/01 0.03 0.01 -0.01 -0.01 -0.01 -0.03 #DIV/01 -0.01 0.00 -0.03 -0.01	283 (1.3%) 408 (1.8%) 0 (0.0%) 224 (1.0%) 3,619 (16.2%) 1,780 (8.0%) 3,078 (13.8%) 285 (1.3%) 72 (0.3%) 18 (0.1%) 0 (0.0%) 2,908 (13.0%) 1,4583 (65.3%) 8,746 (39.2%) 4,497 (20.1%) 1,030 (4.6%) 7,000 (3.4,9%) 4,696 (21.0%) 3,405 (15.3%) 105 (0.5%) 7,094 (31.8%) 0.12 (0.40) 0.00 (0.00, 0.00]	274 (1.2%) 430 (1.9%) 0 (0.0%) 191 (0.9%) 3,549 (15.9%) 1,772 (7.9%) 3,045 (13.6%) 264 (1.2%) 57 (0.3%) 28 (0.1%) 0 (0.0%) 2,867 (12.8%) 14,638 (65.6%) 8,649 (38.8%) 4,460 (20.0%) 802 (3.6%) 7,804 (35.0%) 4,665 (20.9%) 3,554 (15.9%) 8,024 (35.9%) 0,13 (0.42) 0.00 [0.00, 0.00]	0.01 -0.01 #DIV/0! 0.01 0.01 0.00 0.01 0.00 0.00 0.01 0.01 0.01 0.01 0.00	509 (1.3%) 768 (2.0%) 0 (0.0%) 439 (1.1%) 8840 (22.6%) 2663 (6.8%) 5205 (13.3%) 520 (0.4%) 37 (0.1%) 1 (0.0%) 4674 (12.0%) 25797 (66.0%) 15181 (38.9%) 7804 (20.0%) 1851 (4.7%) 237 (0.5%) 207 (0.5%) 207 (0.5%) 33950 (35.7%) 0.10 (0.38) 0.00 (0.40)	538 (1.4%) 748 (1.9%) 0 (0.0%) 370 (0.9%) 8715 (22.3%) 2613 (6.7%) 5247 (13.4%) 498 (1.3%) 129 (0.3%) 59 (0.2%) 0 (0.0%) 15006 (38.4%) 7772 (19.9%) 1654 (4.2%) 8203 (21.0%) 9646 (24.7%) 1510 (4.3%) 15670 (40.1%) 0.11 (0.39) 0.00 (0.42)	-0.01 #DIV/01 0.02 0.01 0.00

Number of Ambulatory Blood pressure monitoring tests												
mean (sd)	0.00 (0.02)	0.00 (0.02)	0.00	0.00 (0.03)	0.00 (0.04)	0.00	0.00 (0.02)	0.00 (0.03)	0.00	0.00 (0.02)	0.00 (0.03)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.03)	0.00 (0.04)	0.00
N of days on antihypertensive medications during baselin	e											
mean (sd)	131.24 (67.61)	130.11 (66.94)	0.02	132.77 (67.41)	132.32 (67.50)	0.01	137.09 (64.11)	136.78 (64.52)	0.00	135.13 (65.56)	134.71 (65.77)	0.00
	170.00 [94.75, 181.00]	169.00 [92.00, 181.00]	0.01	172.00 [97.00, 181.00]	171.00 [96.00, 181.00]	0.01	173.00 [118.00, 181.00]	173.00 [116.00, 181.00]	0.00	135.41 (72.60)	134.98 (72.81)	0.00
N of days in database anytime prior												
mean (sd)	1,737.28 (1,168.84)	1,752.47 (1,196.68)	-0.01	2,106.30 (1,213.13)	2,104.50 (1,207.54)	0.00	860.39 (497.95)	859.94 (468.49)	0.00	1368.18 (874.66)	1368.37 (865.24)	0.00
median [IQR]	1,578.00 [699.75, 2,481.50]	1,600.00 [708.75, 2,508.25]	-0.02)	8.50 [1,036.00, 3,090.75] \$	4.00 [1,017.00, 3,097.00]	-0.03 7	775.00 [499.00, 1,074.75] 7	775.00 [511.00, 1,085.00]	0.00	1142.98 (1039.21)	1157.24 (1029.89)	0.00
Mean Copay for per prescription cost (charges in U.S. \$) (1	ISO 1 day prior)											
mean (sd)	32.13 (39.93)	31.29 (40.47)	0.02	22.72 (21.47)	22.59 (23.48)	0.01	113.35 (101.72)	115.02 (120.71)	-0.01	75.17 (78.67)	76.01 (92.94)	0.00
median [IQR]	19.94 [8.75, 41.24]	20.38 [9.47, 39.44]	-0.01	18.19 [8.85, 30.64]	17.21 [8.61, 29.98]	0.01	90.00 [62.27, 132.46]	90.94 [63.10, 132.85]	-0.01	40.08 (79.30)	40.10 (93.57)	0.00
Missing; n (%)	56 (2.0%)	61 (2.2%)	-0.01	420 (3.0%)	422 (3.0%)	0.00	482 (2.2%)	502 (2.2%)	0.00	958 (2.5%)	985 (2.5%)	0.00
Colonoscopy; n (%)	96 (3.4%)	86 (3.1%)	0.02	468 (3.4%)	459 (3.3%)	0.01	621 (2.8%)	639 (2.9%)	-0.01	1185 (3.0%)	1184 (3.0%)	0.00
Fecal occult blood (FOB) test; n (%)	112 (4.0%)	111 (4.0%)	0.00	316 (2.3%)	303 (2.2%)	0.01	621 (2.8%)	603 (2.7%)	0.01	1049 (2.7%)	1017 (2.6%)	0.01
Flu vaccine; n (%)	525 (18.8%)	549 (19.7%)	-0.02	1,463 (10.5%)	1,461 (10.5%)	0.00	7,309 (32.7%)	7,390 (33.1%)	-0.01	9297 (23.8%)	9400 (24.1%)	-0.01
Mammogram; n (%)	227 (8.1%)	220 (7.9%)	0.01	782 (5.6%)	732 (5.2%)	0.02	1,723 (7.7%)	1,707 (7.6%)	0.00	2732 (7.0%)	2659 (6.8%)	0.01
Pap smear; n (%)	42 (1.5%)	41 (1.5%)	0.00	236 (1.7%)	221 (1.6%)	0.01	446 (2.0%)	438 (2.0%)	0.00	724 (1.9%)	700 (1.8%)	0.01
Pneumonia vaccine; n (%)	256 (9.2%)	263 (9.4%)	-0.01	419 (3.0%)	438 (3.1%)	-0.01	2,807 (12.6%)	2,800 (12.5%)	0.00	3482 (8.9%)	3501 (9.0%)	0.00
PSA test or Prostate exam for DRE; n (%)	483 (17.3%)	471 (16.9%)	0.01	1,011 (7.2%)	980 (7.0%)	0.01	3,880 (17.4%)	3,854 (17.3%)	0.00	5374 (13.8%)	5305 (13.6%)	0.01
Bone mineral density; n (%)	104 (3.7%)	103 (3.7%)	0.00	250 (1.8%)	257 (1.8%)	0.00	739 (3.3%)	724 (3.2%)	0.01	1093 (2.8%)	1084 (2.8%)	0.00
Use of Sympatomimetic agents; n (%)	10 (0.4%)	8 (0.3%)	0.02	70 (0.5%)	79 (0.6%)	-0.01	48 (0.2%)	53 (0.2%)	0.00	128 (0.3%)	140 (0.4%)	-0.02
Use of CNS stimulants; n (%)	4 (0.1%)	3 (0.1%)	0.00	78 (0.6%)	73 (0.5%)	0.01	28 (0.1%)	30 (0.1%)	0.00	110 (0.3%)	106 (0.3%)	0.00
Use of estrogens, progestins, androgens; n (%)	73 (2.6%)	78 (2.8%)	-0.01	625 (4.5%)	617 (4.4%)	0.00	657 (2.9%)	703 (3.1%)	-0.01	1355 (3.5%)	1398 (3.6%)	-0.01
Use of Angiogenesis inhibitors; n (%)	0 (0.0%)	1 (0.0%)	#DIV/0!	13 (0.1%)	4 (0.0%)	0.04	4 (0.0%)	10 (0.0%)	#DIV/0!	17 (0.0%)	15 (0.0%)	#DIV/0!
Use of Oral Immunosuppressants; n (%)	2 (0.1%)	1 (0.0%)	0.04	14 (0.1%)	7 (0.1%)	0.00	5 (0.0%)	3 (0.0%)	#DIV/0!	21 (0.1%)	11 (0.0%)	0.04
Use of fondaparinux or Bivalirudin; n (%)	0 (0.0%)	1 (0.0%)	#DIV/0!	12 (0.1%)	10 (0.1%)	0.00	2 (0.0%)	2 (0.0%)	#DIV/0!	14 (0.0%)	13 (0.0%)	#DIV/0!
Use of other direct thrombin inhibitors (lepirudin, des	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!	0 (0.0%)	0 (0.0%)	#DIV/0!
Use of Ticagrelor ON CED; n (%)	0 (0.0%)	1 (0.0%)	#DIV/0!	14 (0.1%)	12 (0.1%)	0.00	6 (0.0%)	6 (0.0%)	#DIV/0!	20 (0.1%)	19 (0.0%)	0.04
Use of Ticagrelor; n (%) Number of D-dimer tests	1 (0.0%)	2 (0.1%)	-0.04	19 (0.1%)	18 (0.1%)	0.00	43 (0.2%)	36 (0.2%)	0.00	63 (0.2%)	56 (0.1%)	0.03
mean (sd)	0.02 (0.14)	0.02 (0.14)	0.00	0.02 (0.15)	0.02 (0.15)	0.00	0.03 (0.18)	0.03 (0.18)	0.00	0.03 (0.17)	0.03 (0.17)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.17)	0.00 (0.17)	0.00
Numbe of CRP, high-sensitivity CRP tests	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.10)	0.00 (0.10)	0.00
mean (sd)	0.06 (0.33)	0.06 (0.32)	0.00	0.02 (0.20)	0.02 (0.19)	0.00	0.07 (0.36)	0.07 (0.34)	0.00	0.05 (0.31)	0.05 (0.29)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.32)	0.00 (0.31)	0.00
Number of PT or aPTTt tests												
mean (sd)	0.51 (1.32)	0.46 (1.53)	0.03	0.45 (1.36)	0.38 (1.44)	0.05	0.47 (1.25)	0.43 (1.37)	0.03	0.47 (1.30)	0.41 (1.41)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.44)	0.00 (1.56)	0.00
Number of Bleeding time tests												
mean (sd)	0.00 (0.00)	0.00 (0.00)	#DIV/0!	0.00 (0.02)	0.00 (0.01)	0.00	0.00 (0.01)	0.00 (0.02)	0.00	0.00 (0.01)	0.00 (0.02)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	#DIV/0!	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (0.02)	0.00 (0.02)	0.00
HAS-BLED Score (ICD-9 and ICD-10), 180 days	3.25 (0.70)	3.23 (0.67)	0.03	3.25 (0.74)	3.25 (0.74)	0.00	3.28 (0.63)	3.28 (0.62)	0.00	3.27 (0.68)	3.27 (0.67)	0.00
mean (sd) median (IOR)	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.03	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	2.36 (0.76)	2.36 (0.75)	0.00
N of Generic name drugs	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	3.00 [3.00, 4.00]	3.00 [3.00, 4.00]	0.00	2.30 (0.70)	2.50 (0.75)	0.00
mean (sd)	14.73 (11.91)	14.51 (12.77)	0.02	12.44 (8.50)	12.33 (9.55)	0.01	14.78 (10.66)	14.67 (11.77)	0.01	13.94 (10.04)	13.82 (11.11)	0.00
median [IQR]	12.00 [7.00, 19.00]	11.00 [6.00, 19.00]	0.08	11.00 [7.00, 16.00]	10.00 [6.00, 16.00]	0.11	12.00 [8.00, 19.00]	12.00 [7.00, 19.00]	0.00	9.07 (10.79)	8.65 (11.95)	0.00
N of Brand name drugs												
mean (sd)	4.80 (6.60)	4.49 (4.60)	0.05	5.59 (5.92)	5.53 (4.85)	0.01	4.64 (5.86)	4.56 (4.70)	0.02	4.99 (5.94)	4.90 (4.75)	0.00
median [IQR]	3.00 [0.00, 6.00]	3.00 [1.00, 6.00]	0.00	4.00 [2.00, 8.00]	4.00 [2.00, 7.00]	0.00	3.00 [1.00, 6.00]	3.00 [1.00, 6.00]	0.00	2.72 (6.54)	2.72 (5.25)	0.00
Use of clopidogrel ; n (%)	180 (6.5%)	177 (6.3%)	0.01	1,663 (11.9%)	1,623 (11.6%)	0.01	2,096 (9.4%)	2,122 (9.5%)	0.00	3939 (10.1%)	3922 (10.0%)	0.00
Systemic embolism; n (%)	13 (0.5%)	11 (0.4%)	0.01	50 (0.4%)	58 (0.4%)	0.00	77 (0.3%)	80 (0.4%)	-0.02	140 (0.4%)	149 (0.4%)	0.00
DVT; n (%)	35 (1.3%)	32 (1.1%)	0.02	207 (1.5%)	213 (1.5%)	0.00	245 (1.1%)	272 (1.2%)	-0.01	487 (1.2%)	517 (1.3%)	-0.01
PE; n (%)	5 (0.2%)	4 (0.1%)	0.03	92 (0.7%)	91 (0.7%)	0.00	84 (0.4%)	73 (0.3%)	0.02	181 (0.5%)	168 (0.4%)	0.01
Diabetes: 1 inpatient or 2 outpatient claims within 18	780 (28.0%)	749 (26.8%)	0.03	3,371 (24.1%)	3,331 (23.9%)	0.00	5,636 (25.3%)	5,630 (25.2%)	0.00	9787 (25.0%)	9710 (24.9%)	0.00
	0.40.0=**	4 (0.000)	ponte:	0.10.550	0/0.45	2.25	20 (0.45)	47/0 40*	2.22	20 (0.4%)	25 (0.45)	2.22
Intracranial or retroperitoneal hemorrhage: 1 inpatie	0 (0.0%) 203 (7.3%)	1 (0.0%)	#DIV/0!	9 (0.1%)	8 (0.1%) 844 (6.0%)	0.00	20 (0.1%)	17 (0.1%)	0.00	29 (0.1%)	26 (0.1%)	0.00 0.01
Peptic Ulcer Disease; n (%) Upper Gl bleed; n (%)	203 (7.3%)	208 (7.5%) 0 (0.0%)	-0.01 #DIV/0!	901 (6.5%) 5 (0.0%)	844 (6.0%) 4 (0.0%)	0.02 #DIV/0!	1,652 (7.4%) 0 (0.0%)	1,633 (7.3%) 1 (0.0%)	0.00 #DIV/0!	2756 (7.1%) 5 (0.0%)	2685 (6.9%) 5 (0.0%)	0.01 #DIV/0!
Lower/unspecified GI bleed: n (%)	21 (0.8%)	24 (0.9%)	#DIV/0! -0.01	104 (0.7%)	4 (0.0%) 98 (0.7%)	#DIV/U! 0.00	116 (0.5%)	1 (0.0%)	#DIV/0! -0.01	241 (0.6%)	254 (0.7%)	#DIV/U! -0.01
Urogenital bleed: n (%)	91 (3.3%)	24 (0.9%) 85 (3.0%)	0.01	441 (3.2%)	429 (3.1%)	0.00	671 (3.0%)	628 (2.8%)	0.01	1203 (3.1%)	1142 (2.9%)	0.01
Other bleeds; n (%)	29 (1.0%)	27 (1.0%)	0.02	167 (1.2%)	157 (1.1%)	0.01	229 (1.0%)	243 (1.1%)	-0.01	425 (1.1%)	427 (1.1%)	0.00
Prior cancer; n (%)	285 (10.2%)	289 (10.4%)	-0.01	1,288 (9.2%)	1,288 (9.2%)	0.00	2,427 (10.9%)	2,334 (10.5%)	0.01	4000 (10.2%)	3911 (10.0%)	0.01
Aspirin; n (%)	13 (0.5%)	11 (0.4%)	0.01	164 (1.2%)	161 (1.2%)	0.00	105 (0.5%)	97 (0.4%)	0.01	282 (0.7%)	269 (0.7%)	0.00
Aspirin/dipyridamole; n (%)	9 (0.3%)	9 (0.3%)	0.00	79 (0.6%)	71 (0.5%)	0.01	90 (0.4%)	84 (0.4%)	0.00	178 (0.5%)	164 (0.4%)	0.01
Other antiplatelet agents; n (%)	17 (0.6%)	13 (0.5%)	0.01	68 (0.5%)	77 (0.6%)	-0.01	134 (0.6%)	125 (0.6%)	0.00	219 (0.6%)	215 (0.6%)	0.00
PGP inhibitors; n (%)	1,098 (39.4%)	1,087 (39.0%)	0.01	6,825 (48.9%)	6,727 (48.2%)	0.01	9,742 (43.6%)	9,629 (43.1%)	0.01	17665 (45.2%)	17443 (44.6%)	0.01
Other gastroprotective agents; n (%)	19 (0.7%)	16 (0.6%)	0.01	131 (0.9%)	125 (0.9%)	0.00	165 (0.7%)	156 (0.7%)	0.00	315 (0.8%)	297 (0.8%)	0.00
Number of lipid tests ordered												
mean (sd)	0.67 (0.86)	0.68 (0.84)	-0.01	0.25 (0.70)	0.24 (0.63)	0.02	0.71 (0.86)	0.71 (0.81)	0.00	0.54 (0.81)	0.54 (0.75)	0.00

median [IQR]	0.00 [0.00, 1.00]	1.00 [0.00, 1.00]	-1.18	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	1.00 [0.00, 1.00]	1.00 [0.00, 1.00]	0.00	0.36 (0.87)	0.43 (0.81)	0.00
Proton pump inhibitor; n (%)	470 (16.8%)	440 (15.8%)	0.03	2,736 (19.6%)	2,724 (19.5%)	0.00	4,221 (18.9%)	4,253 (19.1%)	-0.01	7427 (19.0%)	7417 (19.0%)	0.00
H2 receptor antagonist; n (%)	91 (3.3%)	93 (3.3%)	0.00	384 (2.8%)	399 (2.9%)	-0.01	917 (4.1%)	890 (4.0%)	0.01	1392 (3.6%)	1382 (3.5%)	0.01
Vitamin K therapy; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	11 (0.1%)	8 (0.1%)	0.00	4 (0.0%)	4 (0.0%)	#DIV/0!	15 (0.0%)	12 (0.0%)	#DIV/0!
Number of neurologist visits												
mean (sd)	0.16 (0.98)	0.16 (0.97)	0.00	0.20 (1.18)	0.20 (1.00)	0.00	0.24 (1.44)	0.23 (1.23)	0.01	0.22 (1.32)	0.21 (1.14)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.43)	0.00 (1.23)	0.00
Number of INR (prothrombin) tests ordered												
mean (sd)	0.41 (1.13)	0.36 (1.33)	0.04	0.36 (1.18)	0.30 (1.28)	0.05	0.45 (1.21)	0.41 (1.34)	0.03	0.41 (1.19)	0.37 (1.32)	0.00
median [IQR]	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 0.00]	0.00 [0.00, 0.00]	0.00	0.00 [0.00, 1.00]	0.00 [0.00, 0.00]	0.00	0.00 (1.31)	0.00 (1.45)	0.00
Treating prescriber - Cardiologist; n (%)	1,281 (45.9%)	1,280 (45.9%)	0.00	7,610 (54.5%)	7,447 (53.3%)	0.02	12,337 (55.3%)	12,208 (54.7%)	0.01	21228 (54.3%)	20935 (53.6%)	0.01
Treating prescriber - Primary Care Physician; n (%)	1,575 (56.5%)	1,574 (56.4%)	0.00	4,213 (30.2%)	4,147 (29.7%)	0.01	5,306 (23.8%)	5,332 (23.9%)	0.00	11094 (28.4%)	11053 (28.3%)	0.00
Treating prescriber - Other; n (%)	1,997 (71.6%)	2,025 (72.6%)	-0.02	10,745 (77.0%)	10,635 (76.2%)	0.02	17,177 (77.0%)	17,046 (76.4%)	0.01	29919 (76.6%)	29706 (76.0%)	0.01
Alpha blockers; n (%)	400 (14.3%)	399 (14.3%)	0.00	1,835 (13.1%)	1,839 (13.2%)	0.00	3,188 (14.3%)	3,078 (13.8%)	0.01	5423 (13.9%)	5316 (13.6%)	0.01
CHADS2 score, 180 days, V												
mean (sd)	1.88 (1.05)	1.87 (1.00)	0.01	1.91 (1.09)	1.90 (1.07)	0.01	2.90 (1.27)	2.92 (1.26)	-0.02	2.47 (1.19)	2.48 (1.18)	0.00
median [IQR]	2.00 [1.00, 2.00]	2.00 [1.00, 2.00]	0.00	2.00 [1.00, 3.00]	2.00 [1.00, 2.00]	0.00	3.00 [2.00, 4.00]	3.00 [2.00, 4.00]	0.00	1.93 (1.30)	1.93 (1.28)	0.00
Use of Prasugrel; n (%)	5 (0.2%)	4 (0.1%)	0.03	56 (0.4%)	61 (0.4%)	0.00	1 (0.0%)	1 (0.0%)	#DIV/0!	62 (0.2%)	66 (0.2%)	0.00
Use of Loop Diuretics+other diuretics+other hyperten:	669 (24.0%)	668 (23.9%)	0.00	4,208 (30.1%)	4,198 (30.1%)	0.00	5,853 (26.2%)	5,880 (26.3%)	0.00	10730 (27.5%)	10746 (27.5%)	0.00
Commercial vs Medicare Advantage- Business Type Code - C	ORRECT ONE - OPTUM						0	0				
Commercial; n (%)	543 (19.5%)	550 (19.7%)	-0.01	11,890 (85.2%)	11,934 (85.5%)	-0.01			#VALUE!	12,433 (74.2%)	12,484 (74.5%)	-0.01
Medicare Advantage; n (%)	2,247 (80.5%)	2240 (80.3%)	0.01	2,070 (14.8%)	2,026 (14.5%)	0.01	-	-	#VALUE!	4,317 (25.8%)	4,266 (25.5%)	0.01
Commercial vs Medicare Advantage- Business Type Code												
COM = COMMERCIAL: n (%)	543 (19.5%)	550 (19.7%)	-0.01			#VALUE!			#VALUE!	543 (19.5%)	550 (19.7%)	-0.01
MCR = MEDICARE: n (%)	2,247 (80.5%)	2,240 (80,3%)	0.01			#VALUE!			#VALUE!	2,247 (80.5%)	2,240 (80.3%)	0.01
MCD = MEDICAID; n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	-		#VALUE!	-	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
NONE = NO BUSINESS LINE CODE (added in 2015); n (0 (0.0%)	0 (0.0%)	#DIV/0!			#VALUE!			#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
UNK = UNKNOWN (added in 2015); n (%)	0 (0.0%)	0 (0.0%)	#DIV/0!	•	•	#VALUE!	•	-	#VALUE!	0 (0.0%)	0 (0.0%)	#DIV/0!
Commercial vs Medicare Advantage- Data Type	0 (0.0%)	0 (0.0%)	#DIV/0:	n n	0	#VALUE:			#VALUE:	0 (0.0%)	0 (0.0%)	#DIV/0:
1 - Fee For Service: n (%)	•			1,842 (13.2%)	1,816 (13.0%)					1,842 (13.2%)	1,816 (13.0%)	0.00
2 - Encounter: n (%)	•			228 (1.6%)	210 (1.5%)					228 (1.6%)	210 (1.5%)	0.00
3 - Medicare; n (%)				11,016 (78.9%)	11,069 (79.3%)					11,016 (78.9%)	11,069 (79.3%)	0.00
4 - Medicare Encounter; n (%)	•	•		874 (6.3%)	865 (6.2%)		•	•		874 (6.3%)	865 (6.2%)	0.00
4 - Medicare Encounter; n (%)	-	•		874 (0.3%)	805 (0.2%)		•	-		874 (0.3%)	805 (0.2%)	0.00
Metropolitan Statistical Area - Urban (any MSA) vs Rural (no	on-MSA)									0	0	0.00
Urban; n (%)	-	-		11,038 (79.1%)	11,101 (79.5%)		-	-		11,038 (79.1%)	11,101 (79.5%)	0.00
Rural; n (%)	-	-		101 (0.7%)	111 (0.8%)		-	-		101 (0.7%)	111 (0.8%)	0.00
Unknown/Missing; n (%)	-	-		2,821 (20.2%)	2,748 (19.7%)		-	-		2,821 (20.2%)	2,748 (19.7%)	0.00